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In the United Kingdom (UK) there is easy access to a wide range of contraceptive 
methods, available at no cost. In addition, oral emergency contraception (EC) (1.5 mg 
levonorgestrel) is now widely available from the community pharmacy. In spite of this, 
unintended pregnancy is common. In 2014 in England and Wales, 184,571 induced abortions 
were performed, and in Scotland, the corresponding figure was 11,475.  
Long acting reversible methods such as contraceptive implants and intrauterine 
contraception, are amongst the most effective methods available and National Institute for 
Health and Care Excellence (NICE) recommends that increased uptake can lead to fewer 
unintended pregnancies. However, uptake of long acting reversible contraceptive (LARC) 
methods remains low. The majority of women who require to use EC do so following 
unprotected sex or an accident with a condom. Increasingly women in Great Britain prefer to 
attend a pharmacy for EC rather than a sexual and reproductive health (SRH) service or 
general practitioner (GP). Starting an effective on-going method of contraception after EC 
use is clearly important if women are to avoid unintended pregnancy. Community 
pharmacists in the UK and most other high income countries are usually unable to provide 
any on-going contraception except condoms. So we have created a situation where EC is 
provided almost solely from settings where other more effective methods of contraception 
cannot be immediately provided.  
Novel strategies are therefore required to facilitate both uptake and continuation of the most 
effective methods of contraception, in order to prevent unintended pregnancy for more 
women. This thesis presents a mixture of biomedical, clinical and health services research to 
evaluate a series of strategies aimed at improving uptake of the most effective methods of 
contraception. 
Two studies investigated patient knowledge and information provision relating to 
contraceptive methods. The first sought to determine if women held misconceptions about 
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intrauterine methods of contraception, and revealed that although myths persist in a small 
number of women, a lack of knowledge about these methods was also evident. The second 
study aimed to determine if the use of a digital video disc (DVD) to provide contraceptive 
information was acceptable and informative to women, and identified that it is, and could 
possibly enhance patient consultations. 
Studies three, four and five investigated strategies aimed at increasing the uptake of effective 
on-going contraception, following emergency contraception provided from a community 
pharmacy, and patient and health care provider attitudes to such approaches. They showed 
that simple interventions such as supplying one month of a progestogen only pill (POP), or 
offering rapid access to a family planning clinic (FPC), hold promise as strategies to increase 
the uptake of effective contraception after EC and that both women and clinicians were 
positive about such measures. Additionally, the problems encountered in conducting these 
studies provided valuable feedback to inform further development of research methods in the 
community pharmacy setting, and larger scale studies of such interventions. 
Community SRH services may be well placed to deliver more abortion care in the UK, and 
consequently this may result in greater uptake of contraception post abortion.  Study six 
aimed to determine the views of health professionals working in SRH regarding their 
attitudes towards providing more abortion services and also the views of staff within one 
community SRH centre in Scotland where a service providing early medical abortion was 
due to commence. It showed there is clear support amongst health professionals in 
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CHAPTER 1: Introduction 
 
Unintended pregnancy 
Worldwide, estimations of rates of unintended pregnancy are high. Approximately 85 
million unintended pregnancies occur annually and 33 million of them are thought to be in 
women using a contraceptive method. [1] A study of women attending for abortion or for 
ante-natal care, at a large hospital in Edinburgh in 2005, estimated that 90% of pregnancies 
amongst women requesting abortion were unintended, and almost one third of the 
pregnancies amongst the women who were attending for antenatal care had also been 
unintended. [2] Most could have been prevented by effective contraception. More recently, 
findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3), 
identified that in women with any pregnancy with a known outcome in the year preceding 
the survey, one in six were unplanned, with an annual prevalence estimate for unplanned 
pregnancy of 1.5%. [3] In the United States (US) it is estimated that 49% of all pregnancies 
are unintended. [4] In addition to the personal distress that some women may experience as a 
consequence of this, unintended pregnancy results in substantial costs to health services. 
[5,6]
 
In the US, it is estimated that there are 3.11 million unintended pregnancies annually, 
costing 4.6 billion dollars each year and that 53% of these costs were attributable to 
imperfect contraceptive adherence. [6] Whilst a large proportion of unintended pregnancies 
occur in those not using any method of contraception, a significant number result from 
incorrect or inconsistent use of a method. In almost half of all unintended pregnancies 
identified in a US study in 2001, a method of contraception was being used during the month 





    
Contraceptive efficacy 
Although many contraceptive options are available to women, long acting reversible 
methods are thought to be amongst the most effective, as they require minimal patient 
adherence following initiation. Reported rates of failure of contraception vary with perfect 
use and typical use, since methods that rely on user compliance are more likely to be used 
incorrectly or inconsistently. The percentage chance of a woman becoming pregnant within a 
year using either intrauterine contraception or a contraceptive implant, is the same with both 
perfect and imperfect use (0.2% and 0.05% chance of pregnancy, using Levonorgestrel 
intrauterine system (LNG-IUS) and the contraceptive implant respectively). [8] Conversely, 
with use of combined hormonal methods (pill, patch or ring), the chance of an unintended 
pregnancy is 30 times greater with typical use compared to perfect use (0.3% and 9% chance 
of pregnancy, within a year with perfect and typical use respectively). [8] Furthermore, a 
large systematic review of studies reporting contraceptive efficacy from 1990 onwards, 
concluded that long-acting hormonal contraceptives (LNG- IUS and implants) were as 
effective as female sterilisation and were closely followed in effectiveness by copper 
intrauterine devices with ≥300mm
2
 surface area. [9] The term ‘Long Acting Reversible 
Contraception’, commonly referred to as LARC, has been defined in a UK National 
Guideline as ‘contraceptive methods that require administration less than once per cycle or 
month’. [10] In the UK, LARC is taken to include; copper intrauterine devices (IUD), 
progestogen-only intrauterine systems (IUS), progestogen-only injectable contraceptives, 
progestogen-only subdermal implants and combined vaginal rings. [10] Another term that 
has been used less commonly, to describe methods of contraception that don’t require any 
active intervention before three years of use, is ‘forgettable contraception’. However, this 
additionally includes non-reversible sterilisation and excludes both progestogen-only 
injectables and the contraceptive vaginal ring. [11] In the United States, LARC methods are 
described as those with a long duration of action and no need for active adherence following 
initiation. This takes into account both intrauterine devices and contraceptive implants. [12] 
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Rates of uptake of effective contraception 
Comparison of rates of use of specific contraceptive methods between countries can be 
difficult, as a result of differences in design, methods and implementation of the population 
surveys used to obtain such data. [13] Furthermore, some countries have data available that 
is more up to date than others. Nevertheless, uptake of LARC can be seen to vary across the 
world. In the UK, the most recent national data available from the Office for National 
Statistics sexual health survey, in 2008/2009, indicated that 75% of women aged 16-49 yrs. 
were currently using a method of contraception. However, in this survey the proportion of 
women using LARC methods were low, with 6% using an IUD or IUS, 3% using the 
progestogen-only injectable and only 1% using an implant. [14] Estimations from the US, 
from a population survey in 2006/2008, are similarly low. Whilst 78.6% of women are using 
contraception, just 5.3% use an IUD or IUS, 1.4% use a contraceptive injectable and only 
0.7% use an implant. [13] Conversely, reported rates of use of intrauterine contraception are 
as high as 40.6% in China (data from a 2006 population survey), 36.1% in Egypt (data from 
2008) and 22.7% in France (data from 2004/2005) of women aged 16-49 years of age, who 
are either married or in a union. [13] Likewise, in some countries the use of the contraceptive 
injectable is far higher at 28.4% in South Africa (data from 2003/2004) and 31.8% in 
Indonesia (data from 2007). [13] Across the world, reported use of the contraceptive implant 
remains low, with Norway reporting the greatest use, at 3.3% of women aged 16-49 who are 
married or in a union (data from 2005). [13] Although many of the most recently available 
population surveys reporting contraceptive use are now over 5 years old, some over 10 years, 
and uptake of LARC methods may have increased in these countries since their publication, 






    
Patient’s knowledge and attitudes towards LARC   
There are several possible explanations for the low uptake of LARC methods in some 
countries. It has been shown that women lack accurate knowledge about the individual types 
of LARC and often hold negative attitudes towards them. [15-17] Qualitative research from 
the UK identified a common theme of women having little accurate knowledge about 
individual methods, instead relying on information relayed to them by friends and family. 
[15] In this study conducted in Scotland in 2007 the views of 55 women of varying ages, 
were sought during focus group discussions with regard to the acceptability of LARC 
(injectable/ IUD / IUS / Implant). In addition to limited knowledge, it was apparent that 
women were also concerned about the potential side effects of these methods, and in many 
cases these concerns were based upon the past negative experiences of friends. Even after 
providing women with accurate information, concerns remained and only a minority (25%) 
expressed any interest in using LARC in the future. [15] Similarly, in a separate qualitative 
study, a lack of knowledge and fear of possible side effects, were amongst the common 
themes identified during interviews with ten women specifically about intrauterine 
contraception. [16] Further concerns were anxiety about fitting of an IUD and of the risk of 
infection with an IUD. Additionally, this study highlighted that women felt that lack of 
personal control of intrauterine contraception was a drawback. [16] Whilst many doctors 
may perceive that a method of contraception that can be fitted and forgotten about, such as 
both intrauterine methods and contraceptive implants, is beneficial, some women disagree. 
Women described feeling a loss of control of their contraception as they required it to be 
both fitted and removed by a health professional, and furthermore they expressed concerns 
that it felt less reliable as they could not see it once fitted. [16] A survey undertaken in the 
US, specifically targeted adolescent and young women to determine their attitudes towards 
intrauterine contraception (IUC). [17] In response to advice from the American College of 
Obstetrics and Gynecology (ACOG) to consider IUC as first-line contraception in 
adolescents, the investigators sought to study the views of women aged 14-27 years to 
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identify how realistic this might be. Of the 252 women surveyed, 98% had previously had 
sex, although none of them had previously used an IUD/IUS. Less than half (45%) had heard 
of an IUD/IUS, and following a brief description of an IUD/IUS, only 26% expressed some 
degree of interest in using it in future. Similar negative perceptions were evident again, 
including fear of pain at insertion and the requirement for a health professional to fit and 
remove the device. [17]
 
Health professionals have the opportunity to educate women, and 
dispel myths where they do exist, about both IUD/IUS and other LARC methods.  
 
Health professionals’ knowledge and attitudes towards LARC 
Although health professionals may well have the opportunity to educate potential users of 
LARC about its benefits, it is also clear that lack of accurate knowledge and the skills 
required to provide these methods also exists among health professionals themselves. [18-
21] Following a recommendation by the National Institute of Clinical Health and Excellence 
(NICE) in the UK, that increased use of LARC methods could decrease unintended 
pregnancy rates, the views of doctors and nurses working in general practice (main providers 
of contraception in the UK) were sought with regard to LARC. [18] Respondents to this 
survey regarded LARC methods as safe, easy to use and rated them highly for efficacy 
compared to non-LARC methods. However, they ranked LARC lower than the combined 
pill, for acceptability. Misconceptions were prevalent in both doctors and nurses about side 
effects of these methods, with a significant proportion of respondents incorrectly believing 
that the contraceptive implant could cause weight gain and a delay in return to fertility. Over 
half of male (58%) and a third (35%) of female doctors stated they would not consider a 
contraceptive implant as a first line method for women in any age group, and 46% of male 
and female doctors would not consider the injectable as first line. This may in part be related 
to the high proportion of doctors in the survey (81% of male and 45% of female doctors) 
who felt they saw too few patients to maintain the skills to insert implants. [18] If the health 
professionals most commonly discussing contraception with women, possess inaccurate 
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knowledge, or lack the skills to counsel women about or administer LARC methods, then 
clearly an opportunity to increase their uptake via patient education is lost. A further survey 
of general practitioners in London, UK, concerning their knowledge and attitudes about the 
LNG-IUS, highlighted again that misconceptions about this method are prevalent. [19] In 
this survey, 17% of the 71 surveyed, incorrectly agreed the LNG-IUS would increase the risk 
of pelvic inflammatory disease (PID), whilst 23% believed it to increase the risk of an 
ectopic pregnancy. When asked regarding their first line choice of contraception for a young 
(<25yrs age) nulliparous women only 8% stated a LARC method, none opted for LNG-IUS 
and the majority (92%) chose the pill. [19] Amongst the Canadian counterpart to UK GPs, 
Family Physicians (FPs), it was also clear that many incorrectly believed misconceptions 
about IUDs. [20] Over 60% of respondents incorrectly felt ectopic pregnancy and PID were 
major risks of using an IUD. Once again, the majority (>70%) would not recommend use of 
an IUD to nulliparous women. [20]    
There is also evidence that gynaecologists may hold misconceptions about intrauterine 
contraception. [21,22] A 2002 survey of Fellows of American College of Obstetricians and 
Gynecologists, regarding knowledge of and attitudes towards IUD, identified that nearly a 
third (29%) believed that the  IUD increased the risk of PID by 10% or more. [21] It was 
also suggested that US gynaecologists feared litigation from such grossly exaggerated beliefs 
about risks with use of an IUD, which in turn presented a barrier to uptake of the IUD. [21] 
A more recent survey showed that such misconceptions about the IUD still prevailed among 
gynaecologists in the US from 2008. [22] Negative attitudes towards the IUD and other 
methods of LARC, might mean that health professionals are unlikely to promote these 
methods and may even perpetuate incorrect negative views of intrauterine contraception in 
patients.  Beliefs that LARC methods such as the IUS/IUS are not suitable for young or 
nulliparous women are particularly worrisome, since these women are arguably at greatest 
risk of unintended pregnancy and would benefit from the most effective method. It is 
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possible therefore, that better training and knowledge about these methods among health 
professionals could increase uptake of LARC in women.  
 
Accessibility and cost of LARC 
There are national practice recommendations, advising health professionals to provide 
counselling to all women about all contraceptive methods including LARC, in the UK and 
the US. [10,23] Additionally, World Health Organisation (WHO) policy aims to eliminate 
systemic barriers to contraceptive services and increase access to modern contraception. [24]
 
However, the uptake of LARC remains limited in some areas and in certain groups of 
women, as a result of difficultly accessing it and high costs. In the UK, contraception has 
been provided free of prescription charges as part of the National Health Service (NHS) 
since the 1970s. Furthermore, women do not require to pay any consultation fees to receive 
contraception, and have the option of attending a range of providers, including their general 
practitioner or community sexual health clinics. [10] In contrast, in the US and other parts of 
the world, women may be faced with high upfront costs for LARC methods. [23] The ability 
to provide these methods and the actual cost women may require to pay can depend upon the 
level of health insurance she has, if any, and the LARC methods available to her at the clinic 
she opts to attend. Some free or low-cost clinics may not be able to fund and therefore 
provide these methods to all women. [25,26] There is evidence in the US that women of low-
income status, (implied by virtue of receiving public health insurance), are significantly 
more likely to undergo sterilisation following a pregnancy rather than use LARC. [27] This 
may not simply reflect higher upfront costs with LARC, but may also reflect other barriers to 
access that potentially affect low income groups, such as difficulty in travelling to a 
contraceptive provider, particularly for women who may live in remote or rural areas. 
[27,28]  Difficulty with access to services or the requirement to travel a distance to attend, is 
a particular barrier to the use of the injectable method of contraception since it requires to be 
administered by a health professional every ten (norethisterone enanthate, NET-EN) or 
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twelve (depot medroxyprogesterone acetate, DMPA) weeks. Even for those women where 
access to services is not a particular problem, they may be less inclined to use it if they 
perceive regular 3 monthly visits to be an inconvenience. There is some evidence that the 
potential ability to self -administer the injectable method could increase its acceptability and 
possibly uptake of this method. [29] In a survey of women attending a family planning clinic 
in Scotland, 61% of women surveyed stated they would prefer to attend a clinic less often for 
contraceptive supplies. [29] Two-thirds of the women who were current users of the 
injectable, expressed a theoretical preference to use a preparation that they could self-inject 
at home. In the same survey, a significant proportion of ex-users and never users of the 
method stated they would consider using it again, if it were available for self-administration. 
[29]  
Contraceptive  services  in remote and/ or rural areas (even in developed nations) may also 
have difficulty in providing  LARC to women, due to having fewer providers or lacking the 
provider training that is more easily available in urban areas. [28] In a survey of both urban 
and rural family planning providers at Title X clinics (those providing free contraceptive 
services) in Texas, US, providers in urban areas were more likely to report that they were 
well trained in LARC methods (75%) compared to rural providers (57%). [28] 
  
Provision of contraception after emergency contraception 
The availability of EC provides women with a second chance to prevent an unintended 
pregnancy. The majority of women who require to use EC do so following unprotected sex 
or an accident with a condom. [30,31] A smaller proportion of women may have had a 
mishap with a hormonal method of contraception (e.g. missed pills). [30,31] Increasingly 
women in Great Britain prefer to attend a pharmacy for EC rather than an SRH service or a 
GP. [32] Levonorgestrel emergency contraception (LNG-EC) has been available free of 
charge without a prescription from pharmacies since 2008 in Scotland, [33] and since 2011 
in Wales. [34] In a recent trial comparing two oral emergency contraceptives fewer than 3 % 
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of women fell pregnant, and so the vast majority of women remain at risk of pregnancy after 
they have used EC. [35] A few women get pregnant in the same cycle from sexual 
intercourse after taking EC. In a meta-analysis which included 11 trials of just under 5000 
women who had sexual intercourse after using EC but before return of menses (i.e. in the 
same cycle), the relative risk of pregnancy was 2.67 (2.11-3.39) when compared with women 
who did not have sex after using EC. [36] Starting an effective on-going method of 
contraception after EC use is clearly important if women are to avoid unintended pregnancy. 
UK guidelines recommend that women using EC should be provided with an effective 
contraceptive to start either with the onset of their next period, or immediately if they will 
not abstain from sex. [37] This may be an interim ‘bridging’ method that women can use 
until they can initiate their chosen contraceptive. [37]
 
Community pharmacists in the UK and 
most other industrialised countries are usually unable to provide any on-going contraception 
except condoms which are available for purchase. Two mystery shopper studies have shown 
that while pharmacists are good at adhering to protocols for providing EC, only a minority of 
them give women advice about on-going contraception. [38,39] In an audit of almost 500 
women attending a specialist family planning clinic (FPC) for EC in 2007/08, only 24% 
were provided with effective contraception (excluding condoms) to start immediately. [30] 
This figure may be even lower when EC is obtained from non-specialist services. So while in 
the UK EC is much easier to obtain, and by making it free of charge in pharmacies use has 
almost certainly increased, [39] we have created a situation where EC is provided almost 







    
Strategies to increase the uptake of effective contraception 
Improve patient knowledge by provision of accurate information 
It is evident that barriers exist which may hinder efforts to increase the uptake of the most 
effective forms of contraception, although there are various approaches which could be taken 
to try to overcome them. Strategies to improve women’s knowledge of LARC methods may 
result in a more positive attitude towards LARC. This was demonstrated in a study 
conducted in the US in 2006, where a team of investigators devised a three minute 
educational intervention about the IUD for women attending general obstetric and 
gynaecology clinics. [40,41] The intervention consisted of  brief oral information about 
intrauterine contraception, including; its effectiveness, risks, benefits, effects on fertility and 
menstruation, length of use and difference between the two different types and use of a 
plastic model IUD to explain the insertion procedure. The investigators showed that 
following the intervention, over half of all participants (54%) had a positive attitude towards 
IUDs compared to 15% before the intervention. Furthermore, even in women who had prior 
knowledge of the IUD, the proportion with a positive attitude towards them rose 
significantly from 38% to 64%. [41] The authors concluded that all sexually active young 
women could benefit from brief education about the IUD. [41] Previous qualitative research  
has identified that some of the factors  that women take into account when choosing their 
method of contraception include; their perception of safety, efficacy, reliability, ease of use, 
side effects and reversibility. [15] Therefore the provision of accurate information about 
LARC, including reassurance of the safety, reliability, ease of use and reversibility of these 
methods, in addition to a clear explanation of side effects that are common and those that are 
not, may result in increased interest in these methods.  
Unlike other medical treatments (antihypertensive drugs, antibiotics) it is the individual user 
who chooses the method. The choice is likely to be based on information from friends, 
family, or the media, just as much as from health professionals. [42] Effectiveness of a 
contraceptive method depends upon correct and continued use, and this depends vitally on its 
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acceptability to the user. It seems logical that giving people good quality information about a 
contraceptive and what to expect during use should improve both correct use and 
continuation rates, however there is little evidence for this and none from the UK. [43] 
Providing detailed information about a contraceptive method takes time to do well, but for 
many health care providers consultation times are short. Health care providers have different 
levels of training and education and may place emphasis on different aspects of a 
contraceptive method. Furthermore, the content of the consultation may vary depending 
upon organisational factors such as whether the patient is the first or last to be seen that day. 
Consequently, the quality of information women receive about a contraceptive may be of 
variable quality, sometimes inaccurate and may reflect the bias of the provider. In NHS 
Lothian, the SRH service has used DVDs (digital video discs) in the clinic for several years 
to provide information about vasectomy, intrauterine contraception and abortion. This 
ensures that patients get accurate and standardised information in an audio-visual format. In 
a questionnaire survey of women requesting abortion who received information by DVD, 
women rated highly the content of the DVD and the acceptability of receiving information 
this way. [44] 
 
Improve healthcare providers’ knowledge 
However, improving knowledge and attitudes amongst patients will remain difficult if poor 
knowledge or negative attitudes prevail amongst the health professionals who provide 
contraception. National practice guidelines, which recommend the use of LARC in women 
of all ages, and provide a clear guide for health professionals to refer to when considering 
their use, aim to eliminate the misconceptions that exist amongst health professionals. 
[10,45] Furthermore, in the US, the ACOGs ‘LARC program’ works to ensure health 
professionals have access to the most up to date information and resources through provision 
of training and training materials and an E-newsletter. [46] The ‘LARC program’ is a 
national strategy of the ACOG, and in addition to providing information and guidance on 
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LARC methods to health providers via the college website, it involves various activities 
nationally which aim to promote and increase the uptake of LARC. [46] 
 
Improve access to the most effective methods 
A large prospective cohort study undertaken in St Louis in the US, known as CHOICE, 
which has now been the subject of several publications, involved several measures with the 
aim of promoting the use and increasing the uptake of LARC (which included intrauterine 
contraception and the contraceptive implant). [25,35,36,47-49] The Contraceptive CHOICE 
Project aimed to recruit a cohort of 10000 women aged 14-45 yrs., of age, and provide them 
with any reversible contraceptive method of contraception that the woman chose at no cost 
for a three year period. In addition to obtaining the method free of charge, all participants 
read information about the safety and effectiveness of LARC and underwent in-depth, 
evidence based, contraceptive counselling by trained contraceptive providers before they 
chose their method. In addition to removing the barrier of cost and providing education about 
LARC to all women at enrolment, LARC was made more accessible to many women as the 
CHOICE project was widely available in many outpatient facilities throughout the region. 
All participants were followed up by telephone at three months, six months and then six 
monthly intervals until three years. [47] Over a four year period from 2007-2011, over 9000 
women were recruited, with a mean age of 25 yrs. One third had only high school education 
or less, almost half were nulliparous and almost two thirds reported a previous unintended 
pregnancy. [48] The authors suggested that the demographics of this cohort of women 
indicated they were at high risk of unintended pregnancy. The majority (75%) of participants 
recruited opted for an IUD/IUS or implant as their choice of contraception (46% chose LNG-
IUS, 12% chose Cu-IUD, 17% chose contraceptive implant). If those choosing DMPA were 
included in this total (7%), then 82% of participants chose LARC as defined in this review. 
[48] This level of uptake for methods of LARC is significantly higher than both the most 
recent nationally reported US uptake rates, and reported uptake in many other parts of the 
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world. [13] This strongly suggests that when you remove potential barriers to these methods, 
uptake will increase. Of course, emulating this rise in use of LARC would obviously be more 
difficult in practice when it is not part of a large, regional, well organised and well-funded 
research study. The CHOICE study also analysed 12 months of follow-up data in over 5000 
participants, to estimate continuation rates and satisfaction with intrauterine contraception 
and implants. It has been noted in previous research that some health professionals may have 
concerns about high discontinuation rates with these methods. [18]
 
However, in this analysis, 
discontinuation rates were significantly higher among women not using a long acting method 
than in those using an IUD/IUS or implant (45% vs. 14% in IUD/IUS or implant users). 
Furthermore, those using LARC were significantly more likely to be satisfied with their 
method at 12 months (84% satisfied vs. 53% satisfied on non-LARC users). [49]
 
This may 
help to alleviate the concerns some health professionals may have about user dissatisfaction 
or discontinuation of LARC, and thus they may be more inclined to promote LARC use.  
The development of a subcutaneous form of Depo-Provera as an injectable method of 
contraception, lends the possibility of self-administration, so removing the barrier of access 
for some women to this method. [29,50-52] Three studies have investigated the feasibility of 
self-administration of subcutaneous DMPA. [51-53] Continuation rates at 1 year at 12 
months were high (74% US and 88% UK studies) and most women found the injections to 
be convenient (95%), easy (87%) and would recommend them to others (94%). The third 
study showed that self-administration of this subcutaneous injectable was feasible even in 
teenagers after brief training. [53] The possibility to self-administer may not only be 
attractive to women but could potentially help to prevent unintended pregnancies for some 
women who might otherwise miss an injection because they unable to get to a scheduled 
clinic appointment. A further benefit of a subcutaneous form of Depo-Provera, aside from 
the option of self-administration, is the potential for it to be administered by a range of health 
professionals including community pharmacists. [54] This was shown to be feasible in a 
pilot study in the US, whereby 50 women were randomised following an initial dose in 
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clinic, to receive two subsequent doses of subcutaneous Depo-Provera at either the same 
clinic or at a community pharmacy. Continuation rates with the second and third injections 
were similar in both settings and follow-up surveys showed no significant differences in 
patient satisfaction with location, convenience, privacy and respect from providers. [54] For 
those women who are not keen to self-administer, attendance at a pharmacy in a location 
suitable for them would offer another option.  
 
Target vulnerable groups 
Although women aged 20-34yrs. account for the largest number of unplanned pregnancies, 
proportionally more occur in teenagers (16-19 yrs.), with just under half of all pregnancies in 
this age group being unplanned. [3] Specific measures to improve access to, increase 
awareness of and increase interest in LARC within this age group are therefore important. As 
already discussed, national guidelines and recommendations which reassure health 
professionals of the safety, benefits and acceptability of LARC in adolescents and young 
adults, go one step towards this. [10,23,45] Provision of youth friendly services may go one 
step further. The WHO defines youth friendly services as being equitable, accessible, 
acceptable, appropriate and effective for young people. [55] Strategies to make services 
youth friendly include convenient locations and opening hours, age appropriate educational 
materials and specific training of health professionals working within these services in 
adolescents and young adults. A team of investigators in the US aimed to identify youth 
friendly services within publicly funded facilities, and the relationship of LARC-related 
services in these settings versus non youth friendly services. [56] Out of just over 600 
services that were surveyed, 78% were deemed as youth friendly sites. Respondents from 
these sites, were significantly more likely to indicate that LARC methods were typically 
discussed during a contraceptive visit with teens/young adults, and additionally that LARC 
provision had increased in their services, compared to sites that were not deemed as ‘youth 
friendly’. [56] This study thus highlights that it is important to take account of the specific 
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needs of teenagers and young adults when designing contraceptive services as increased 
interest in and attendance at youth friendly services, will result in greater opportunities to 
educate them about LARC, and consequently increased uptake of LARC.          
 
The use of LARC following abortion  
Provision of counselling regarding contraceptive methods and access to a wide range of 
contraception immediately following an abortion, is an important component of abortion 
care. [1] Increasing evidence has emerged in recent years that immediate uptake of LARC 
following an abortion, reduces the incidence of repeat abortions. [57-60] In one such study, 
of just under 1000 women attending for abortion in Scotland in 2008,  the chance of a further 
abortion in the subsequent two years was 20 times less with the use of intrauterine 
contraception post abortion, compared to the oral contraceptive pill. The risk of further 
abortion was 16 times less with use of the contraceptive implant compared to the pill. [57] 
Therefore, strategies to increase the uptake of LARC immediately following abortion care 
important. Furthermore, this is a time when women may be more motivated to use such 
methods and may welcome the opportunity to discuss LARC. [61] For a small number of 
women, who may only attend health services on very few occasions, it may be the only 
opportunity to educate them about the benefits of LARC and dispel any misconceptions. In a 
survey of women requesting abortion in the US about their views on receiving contraceptive 
advice, two thirds of those surveyed expressed a desire to leave the abortion facility with a 
contraceptive method or supplies. [61] Additionally, over 60% of women expressed an 
interest in using a LARC (IUD/IUS/Implant) method in the future. [61] In a study from the 
UK, of provision of specialist contraceptive advice to women at the time of abortion 
compared to standard care, enhanced advice and provision was associated with an increase in 
the uptake of LARC at this time. [62] Similarly, in New Zealand, an intervention that 
involved updating medical staff about LARC, promoting these methods to women and then 
providing them free of charge, significantly increased the uptake of LARC post-abortion 
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Insertion of intrauterine contraception is feasible at the time of 
surgical abortion. However, it is not standard practice for insertion to occur at the time of 
medical abortion; particularly if the woman leaves the abortion facility after medication has 
been administered, going home to pass products of conception. In these circumstances, 
arrangements therefore require to be made for her to return for insertion of intrauterine 
contraception at a later date, if she opts for this. However, it has been shown that many 
women will not return for such appointments. [64] One review of over 200 women referred 
following medical abortion, over a two and a half year period, indicated only 53% attended. 
[64]
 
Aiming for early insertion at one week post abortion, as opposed to delayed insertion, is 
one potential strategy to increase the proportion of women who will attend. Insertion of 
intrauterine contraception at one week post medical abortion has been shown to be as safe as 
delayed insertion. [65,66] Moreover, in two separate studies where women were randomised 
to either early (1 week) or delayed (3-4 weeks) insertion following medical abortion, 
significantly more women returned for insertion in the early group. [65,66] Therefore, 
arranging for women to return for insertion of an IUD/IUS post medical abortion, sooner 
rather than later, is likely to have a greater impact on increasing uptake.  
 
The use of LARC post-partum 
It has been estimated that around 40% of women will have resumed vaginal sex by 6 weeks 
post-partum, and there is some evidence that this figure may be even higher amongst teenage 
mothers. [67,68] The post-partum period is therefore an important time to initiate 
contraception and may be another opportunity within which the uptake of LARC could be 
increased. Guidance is available for health professionals regarding the timing of initiation of 
LARC postnatally, and to reassure them of their safety and benefits. [10,45]
  
A recent survey 
of 800 postpartum women in North Carolina, US, showed that a high proportion of mothers 
(38%) were intending to use either an implant or an intrauterine device as contraception; [69] 
a figure that is much higher than most recent estimates of use of LARC nationally in the US. 
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[13] Factors associated with intention to use LARC were if the index pregnancy had 
originally been unintended and if they had no desire for another baby within two years.  
Clearly however, there is no guarantee that intent to use these methods actually translates 
into increased use of them. One retrospective review of postpartum contraception in 
California, US, highlighted this. Although over 40% of women intended to use a highly 
effective method of contraception postpartum, of this group, only just over a third had 
actually established a LARC method by 8 weeks postpartum. [70] Potential barriers to 
LARC uptake in the postpartum period include the same barriers as at other times, namely; 
lack of patient or provider knowledge, cost and access. In addition, significant change to a 
woman’s home life with the birth of a baby and possibly medical issues such as post-
operative wound care, establishing breastfeeding and infant health concerns, may also 
supersede concerns about contraception at this time. [71] If health professionals bear these 
additional problems in mind when discussing postpartum contraception with women, and 
service providers take these factors into account when organising their care, we may be more 
successful in initiating highly effective contraception in a group of women who would gain 
great benefit from it. Immediate insertion of contraceptive implants or intrauterine 
contraception postpartum may avoid the problem of women failing to return for insertion in 
the weeks following delivery. In a study of adolescent mothers from the US, those who 
chose to have a progestogen only implant inserted soon after childbirth were shown to have 
good continuation rates with this method, and were significantly less likely to become 
pregnant again within 12 months compared to counterparts using other methods. [71] A 
Cochrane Database Review, of nine randomised controlled trials of immediate postpartum 
insertion of IUDs, found this to be safe and effective. [72] Although expulsion rates may be 
slightly higher than with interval insertion, the added advantages of immediate insertion 
include; highly motivated women at this point in time, assurance the women is not pregnant 
and convenience. [72] 
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In Summary 
Long acting reversible methods of contraception are amongst the most effective methods 
available to women, yet uptake rates are low. Aside from cost issues, improving knowledge 
and dispelling misconceptions about LARC in women will be important to increase demand 
for these methods. However, improved education and training for health providers regarding 
LARC is also necessary to ensure this occurs. Providing women with information promoting 
the benefits of LARC through social marketing can empower women to choose the most 
effective methods for themselves. Taking measures to ensure services meet the needs of 
specific groups, such as the provision of LARC in a youth friendly setting, may further 
enhance uptake. Similarly, offering LARC methods immediately or shortly following 
abortion and postpartum, targets women who may be highly motivated to use LARC at that 
point in time. Better uptake and continuation rates of LARC could lead to fewer unintended 
pregnancies and the associated distress for affected women and cost to health services they 
bring.  
In the following chapters I will address both potential barriers to the uptake of effective 
contraception, and possible strategies to overcome these, with the aim of preventing 
unintended pregnancy. In chapter two I will address patients’ knowledge and attitudes 
towards the use of intrauterine methods of contraception. Chapter three examines the use of 
DVD, as a means of providing accurate information about a contraceptive method. In 
chapters four through six, potential strategies to increase the uptake of effective 
contraception following emergency contraception will be considered. Chapter seven 
considers the potential increase in uptake of effective contraception following abortion 
through provision of abortion services in a community sexual health setting. 
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CHAPTER 2: Myths and misconceptions about intrauterine 
contraception among women seeking abortion. 
 
Introduction 
The use of intrauterine contraception, either as an intrauterine device (IUD) or hormone-
releasing intrauterine system (IUS), varies significantly across the world. Worldwide use was 
most recently estimated to be 14% although this rises in some countries with rates as high as 
37% in Eastern Asia. [1,2] The UK however has much lower rates of use of intrauterine 
contraception, (6% using an IUD and 2% using an IUS in 2010). [3] Intrauterine 
contraception is considerably less popular in the UK than either oral contraception or 
condoms. [3] A systematic review of literature regarding contraceptive efficacy, found the 
IUS to be as effective as female sterilisation, and the IUD was rated second to the IUS for 
effectiveness. [4]  
In 2011, the rate of abortion per 1000 women aged 15-44 yrs was 12.0 in Scotland and 17.5 
in England and Wales. [5,6] National guidance from the UK recommends that increasing 
uptake of intrauterine contraception has the potential to reduce the number of abortions. [7] 
There is also global evidence that immediate initiation of intrauterine contraception at the 
time of abortion is associated with a significant reduction in the likelihood of subsequent 
abortion. [8-10] In 2011, 29% of women having an abortion in Scotland and 35% in England 
and Wales had at least one previous abortion. [5,6] Increased uptake of intrauterine 
contraception amongst women having an abortion could therefore play an important role 
reducing this repeat abortion rate. Unfortunately, myths and misconceptions about may 
account for the low uptake of this method in the UK. [11,12]  
In order to determine what proportion of women seeking an abortion hold misconceptions 
about the IUD/IUS, we conducted a survey amongst women requesting abortion at a hospital 
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abortion service at the Royal Infirmary of Edinburgh, Scotland. The Royal Infirmary of 
Edinburgh (RIE) is the main provider (80%) of abortion services in Lothian (Edinburgh and 
surrounding area). In 2011, 2416 induced abortions were conducted in Lothian. [5] The 
purpose of the study was to provide information to help guide health professionals in 
developing effective educational strategies that may increase positive attitudes towards 
intrauterine contraception, so that more women may consider this as a method of ongoing 
contraception after an abortion.  
 
Methods 
In order to help to develop a short questionnaire for women to complete regarding their 
beliefs about intrauterine contraception, two separate sources were used to identify common 
misconceptions women may have.  Firstly, statements about intrauterine contraceptives were 
taken from unpublished transcripts of interviews undertaken with young people aged 13-21 
years during 2000-2004 as part of an evaluation of a national teenage pregnancy strategy. 
[13] Secondly, we extracted negative statements about the IUD/IUS from an online social 
networking  and micro-blogging service (Twitter), by conducting two searches 10 days apart 
in December 2011. The search terms used were; ‘IUD’, ‘intrauterine device’, ‘IUS’, 
‘mirena’, ‘coil’ and ‘paragard’. Statements were identified that discussed the IUD, although 
those that used the term in an unrelated meaning were not included. By reviewing these 
sources common themes were identified regarding women’s views towards, and concerns 
about the IUD and IUS. This allowed us to create a questionnaire (appendix 1) that consisted 
of a short introductory paragraph followed by 12 negative statements regarding the IUD/IUS. 
During January and
 
February 2012, a sample of 125 women attending the RIE clinics 
requesting an abortion were given the questionnaire by one of the clinic nurses and invited to 
complete it and place it in an opaque sealed envelope in a collection box. The questionnaires 
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were completed by women prior to either ultrasound scan or consultation with medical staff 
in the clinic, and they therefore were not aware of what method of abortion they could have 
(if at all), and had not discussed contraception with any medical staff in the clinic at that 
point.  The questionnaire was anonymous and self-completed and required a response to 
each statement on a 5 point Likert scale from ‘strongly agree’ to ‘strongly disagree’. Further 
questions sought demographic information including, age, postcode area of residence (used 
to obtain a Carstairs deprivation category score [14]) and previous and intended 
contraceptive use.  
 
Statistics 
All data were coded and entered onto a database using Microsoft Excel. Data were entered to 
the database by a research nurse and data were checked and coded by L Michie. Responses 
to each statement were combined such that ‘strongly agree’ and ‘somewhat agree’ were 
grouped as ‘agree’ whilst ‘strongly disagree’ and ‘somewhat disagree’ were grouped as 
‘disagree’. The remaining group of responses were ‘neither agree nor disagree’. Data 
analysis was performed using IBM Statistical Package for Social Sciences (SPSS) software 
Version 18 (SPSS Inc. Chicago, Il, USA). Demographic data was obtained including means 
and standard deviations (SD). To allow statistical comparison between age groups, 4 age 
groups were defined; 0-19 years, 20-24 years, 25-34 years and 35 years and over. 
Comparisons were made using Fisher’s exact test as counts within the individual cells of the 
contingency table fell below 5.  Statistical significance was deemed to be p<0.05.  
Ethical Approval 
The questionnaire was reviewed by the chair of a local research ethics committee who 
confirmed that ethical approval was not required. 
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Results 
A total of 106 completed questionnaires were obtained from 125 distributed (85% response 
rate). Age of respondents ranged from 15-42 years. Demographics are shown in table 1.   
 
Table 1 Demographics of respondents 
 
a
Deprivation Category is a marker of deprivation in Scotland based upon postcode area of 
residence [14] 
Age  Years 





  N[%] 
1-2 Affluent 15[14.2] 
3-5 Moderate 77[72.6] 
6-7 Deprived 14[13.2] 
  
Parity  N[%] 
Nulliparous 57[53.8] 
Parous 49[46.2] 
Previous Abortion  36[34] 
  
Previous methods of contraception ever used  N[%] 
Condom 98[92] 
Oral contraceptive pill 74[74] 
Progestogen only implant 16[15] 
Progestogen only injectable 12[11] 
IUD/IUS 8[8] 
Combined hormonal patch 5[3] 
None 4[4] 
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78% of women (n=83) had used more than one method of contraception previously, 8 
women (8%) had previously used an IUD or IUS in the past (Table 1). Regarding future 
planned use of contraception, three women (3%) intended to use no contraception and two 
(2%) were uncertain. Of those respondents (n =101) who were intending to use 
contraception, the methods planned included; oral contraceptive pill (33[31%]), IUD or IUS 
(27[25%]), progestogen only implant (26[24%]), barrier methods (26[24%]), progestogen 
only injectable (13[12%]), combined hormonal contraceptive patch (3[3%]) and sterilisation 
(2[2%]). Parous women were significantly more likely to indicate that they planned to use an 
IUD/IUS for future contraception compared to nulliparous women (p=0.009). Women who 
had previously had an abortion were also significantly more likely to choose IUD/IUS as 
future method when compared to women with no history of abortion (p=0.039). Women who 
had used an IUD/IUS as a contraceptive method previously were significantly more likely to 
choose this as future contraception (p=0.003).  














    
Table 2 Response to negative statements about intrauterine contraception 
                                     N[%]   
                              Agree               Neither   Disagree 
Statements                     Agree/nor disagree  
        
1. It is painful to have inserted.   36[34]  59[56]  11[10] 
 
2. It is only suitable for women who   8[7.5]  40[37.7] 58[54.7] 
have had children. 
 
3. It is not suitable if you have had  3[2.8]  53[50]  50[47.2] 
more than 3 children. 
 
4. Can only be used in older women.  4[3.8]  38[35.8] 64[60.4] 
 
5. There is a good chance it can make  3[2.8]  45[42.5] 58[54.7] 
you infertile. 
 
6. There is a good chance it can damage   17[16]  36[34]  53[50] 
the womb. 
  
7. There is a good chance it can damage   6[5.7]  44[41.5] 56[52.8] 
the ovaries.  
 
8. It can rust inside you.    8[7.5]  36[34]  62[58.5] 
 
9. It can move around inside your body.  25[23.6] 28[26.4] 53[50] 
 
10. There is a high chance it might fall out. 16[15.1] 40[37.7] 50[47.2] 
 
11. It can get stuck on the babies head  6[5.6]  36[34]  64[60.4] 
if you become pregnant. 
 
12. It is a breeding ground for infection.   17[16]  47[44.4] 42[39.6] 
 
Agreement with negative statements ranged from 2.8% to 34%. The range in percentage of 
women who neither agreed/nor disagreed with each negative statement was 26.4% to 56%. 
The statements that most women agreed with were that ‘it is painful to have inserted’ (34%) 
and that ‘it can move around inside your body’ (23.6%). Responses were compared between 
women who had previously used an IUD or IUS and those who had never used these 
methods. Women who had used previously used an intrauterine contraceptive were 
significantly more likely to disagree with statement 5 (‘There is a good chance it can make 
you infertile’) than those who had not (p=0.03). There was no significant difference in 
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responses between these groups for all other statements.  Women aged 19 years and under 
(n= 24) were significantly more likely to agree with statement 1 (‘It is painful to have 
inserted’) compared to women in any other age group (p=0.037). There were no significant 
associations between any demographic factors tested (age group, deprivation category score, 
reproductive history) and agreement with any other statements. 
 
Discussion  
Our study showed that only a small percentage of women requesting an abortion agreed with 
the negative statements about intrauterine contraception, suggesting that only a minority of 
these women held major misconceptions about this method. Our study did however show 
that approximately one third of women ‘neither agreed nor disagreed’ with the statements, 
which may suggest a lack of knowledge about intrauterine contraception amongst this group. 
Thus the abortion consultation does offer a good opportunity to provide information about 
this most effective method of contraception that has been shown to reduce the risk of a 
subsequent abortion. [8-10] Some health professionals may worry that women requesting an 
abortion may not wish to discuss contraception at this time, or that they may feel under 
pressure to accept contraception in order to obtain agreement to have an abortion. However, 
there is good evidence that women value the opportunity to discuss contraception at this visit 
and do not feel coerced into accepting a method of contraception. [15] Although the 
consultations to discuss abortion may be lengthy and the time available to discuss 
contraception is short, there is evidence from the US that even brief (3 mins) oral educational 
interventions about the IUD/IUS,  can improve knowledge and positivity about this method. 
[16-18] Furthermore, women seeking an abortion find that information about contraception 
imparted from viewing a digital video disk (DVD) rather than a face-to face consultation 
with a health professional, to be highly acceptable at this time. [15]
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In our study the most common misconceptions about intrauterine contraception that women 
agreed with were that the IUD/IUS is painful to have inserted and that it can move around 
inside your body. This may indicate that health professionals need to concentrate on 
providing accurate information and reassurance to women about these issues. In particular, 
oral analgesia or local anaesthesia for insertion can be discussed with women, as is 
recommended by the faculty of sexual and reproductive health guidance, UK. [19]
 
Women 
can also be reassured that the likelihood of an IUD/IUS perforating the uterus is rare. [19]  
The demographic characteristics of women participating in our survey were similar to that of 
previous studies of women attending for abortion in our region. [10] In addition, our finding 
of 8% of women having previously used an IUD/IUS is in keeping with rates of uptake of 
intrauterine contraception in the UK.
 
[3] More surprising was the finding that 25% of 
respondents were considering using an IUD/IUS following the abortion. A study of ongoing 
contraception post abortion from our service in 2008, showed that 9.5% of women had an 
IUD/IUS inserted immediately following the abortion. [10] It is possible that this apparent 
increase in ‘interest’ in intrauterine contraception in our current study may reflect the impact 
of a Scottish Government sexual health strategy, using social marketing  to promote 
awareness of the most effective long acting methods of contraception. [20] Our surveys were 
anonymous, so it is unlikely that women felt compelled to indicate interest in this method of 
contraception. It does however suggest that the consultation prior to an abortion is a good 
opportunity for health professionals to provide accurate information to women about the 
IUD/IUS, since motivation to use this method may be high and its uptake may protect 
women from a subsequent abortion. There are limitations to our study. The sample size was 
small, and the inclusion of only negative statements regarding the IUD/IUS may have 
introduced the possibility of bias. Respondents may have been likely to simply agree with 
statements, and if positive statements had also been included this may have minimised such 
bias. However, the findings add weight to the importance of abortion care providers being 
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trained and funded to be able to provide the IUD/IUS to women at the time of abortion, if 
they wish this and if it is appropriate to do so. [10] 
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CHAPTER 3: Giving information about methods of 
contraception using a DVD: is it acceptable and informative? 
A pilot randomised study. 
 
Introduction 
Unintended pregnancy is common. In Scotland in 2013 there were 11,777 therapeutic 
abortions [1] and around 30% of pregnancies are unplanned. [2] Most could have been 
prevented by effective contraception. Unlike other medical treatments (antihypertensive 
drugs, antibiotics) it is the individual user who chooses the method. The choice is likely to be 
based on information from friends, family, or the media, just as much as from health 
professionals. [3] Effectiveness of a contraceptive method depends upon correct and 
continued use, and this depends vitally on its acceptability to the user. It seems logical that 
giving people good quality information about a contraceptive and what to expect during use 
should improve both correct use and continuation rates, however there is little evidence for 
this and none from the UK. [4] 
Providing detailed information about a contraceptive method takes time to do well, but for 
many health care providers consultation times are short. Health care providers have different 
levels of training and education and may place emphasis on different aspects of a 
contraceptive method. Furthermore, the content of the consultation may vary depending 
upon organisational factors such as whether the patient is the first or last to be seen that day. 
Consequently, the quality of information women receive about a contraceptive may be of 
variable quality, sometimes inaccurate and may reflect the bias of the provider.    
In NHS Lothian, the sexual and reproductive health service (SRH) has used DVDs (digital 
video discs) in the clinic for several years to provide information about vasectomy, 
intrauterine contraception and abortion. This ensures that patients get accurate and 
standardised information in an audio-visual format.  In a questionnaire survey of women 
requesting abortion who received information by DVD, women rated highly the content of 
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the DVD and the acceptability of receiving information this way. [5] However, the 
effectiveness of a DVD for information giving, nor how it compares to a traditional face-to-
face consultation for providing information, has not been formally evaluated.
 
To provide standardised, quality information about the contraceptive implant (Nexplanon
®
), 
a DVD was developed for use at Chalmers Centre, SRH service, NHS Lothian. The 
information included was taken from the Faculty of Sexual and Reproductive Healthcare 
Clinical Effectiveness Unit Guidance on contraceptive implants, [6] and covered mode of 
action, insertion, removal, contra-indications, risks and side effects. The content of the DVD 
was agreed by clinicians working in the service and the DVD made with technical help from 
the Medical Photographic Department, NHS Lothian. The DVD was piloted among 
stakeholders and minor modifications made. The final version lasted 9 minutes. We 
conducted a pilot study with the primary aim of determining whether women found receiving 
information about Nexplanon
® 
via a DVD acceptable and informative. We also wished to 
ascertain how the amount and accuracy of information recalled after watching a DVD 
compared to that following face-to-face consultation with a clinician, and if the information 
given by either modality matched women’s experience of Nexplanon
® 




All women aged ≥16 years, attending Chalmers from January to June 2013 for medical 
abortion, and considering using Nexplanon®, were invited to participate. Following a routine 
consultation and after arrangements had been made for the abortion procedure, the clinician 
determined eligibility for Nexplanon®, according to UK Medical Eligibility Criteria for 
contraceptive use. [7] Exclusion criteria included previous use of contraceptive implant and 
the need for an interpreter during the consultation.  A member of the research team provided 
further written and verbal information about the study before written consent was obtained 
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from women agreeing to participate. 50 women considering starting Nexplanon® for the first 
time were recruited.  
 
Interventions and randomisation 
Participants were randomised to be given information about Nexplanon®, either by DVD 
(35 women) or in a traditional one to one face-to-face consultation (15 women) by either a 
doctor or nurse (control group). Because this was a pilot study, a randomisation scheme 
allocating more participants to intervention than control was chosen to improve power in the 
intervention group without seriously affecting the power for between-group comparisons. A 
clinician gave women in the control group information about Nexplanon® according to their 
routine practice. Women randomised to the DVD, watched it in the consultation room. When 
the DVD had finished, the clinician returned to the consulting room, providing an 
opportunity for women to ask any questions, and women wishing to have insertion of the 
method were scheduled for this following the abortion.  Randomisation was made at time of 
recruitment using sequentially numbered opaque sealed envelopes produced by computer-
generated randomisation sequence. Due to the nature of the intervention, it was not possible 
to blind either the research team or the participant, to the allocated intervention. Women 




In order to determine both acceptability of method of information provision, and knowledge 
recalled, immediately following the consultation all women underwent a structured interview 
with a single researcher. A standard proforma (appendix 2) was used to record demographic 
information and previous contraceptive use. Four set multiple choice questions were used to 
determine what information the subject had taken from the consultation and its accuracy. 
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Overall acceptability of the consultation was determined using a Lickert [8] scale to quantify 
descriptors including ‘helpful’, ‘easy to understand’ and ‘confusing’.  
Three months following the initial consultation, all women were contacted for a short 
standardised telephone interview (appendix 3), lasting ≤5 minutes, by the same member of 
the research team (LM). Three attempts at contact were made to the given telephone 
numbers, at varying times of day. Women were asked which contraceptive method they had 
chosen following the consultation. Women who had Nexplanon® inserted were asked if the 
implant (particularly with respect to side effects and bleeding patterns) matched their 
expectations. All were asked about their experience of taking part in a randomised trial, and 




At the time of telephone interview all women were invited to attend for a further in-depth 
interview with a member of the research team, designed to explore in more detail their 
feelings about participation in a research study and the use of a DVD for information giving 
compared with traditional consultations. Four women who watched the DVD and four who 
did not watch the DVD agreed to attend. A topic guide was used, based on the key areas 
described above, to structure each interview. Women were offered a £20 voucher if they 
attended for in-depth interview. Interviews occurred between May and August 2013 in 
Chalmers Sexual Health Centre, and lasted approximately 30 minutes. Interviews were 
audio-recorded and transcribed verbatim. Data was organised by cross sectional indexing. 
After all interviews were conducted the data was analysed using thematic analysis. [9] 
   
Statistics 
A sample size of 35 subjects was allocated to the DVD group to allow estimation of 
percentage rates of acceptability and knowledge recall to within a standard error of around 
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8%. The power for the randomised comparison to 15 controls is low, but sufficient to give a 
high chance of detecting a statistically significant major difference in either acceptability or 
knowledge recall between the two groups, of the order of 40%. The allocation of unequal 
numbers to the two groups was to improve the power for estimation within the DVD group 
without greatly decreasing the power for the between-group comparisons. All data, including 
demographic data recorded at recruitment and at telephone follow-up, were coded and 
entered onto a Microsoft Excel database. Descriptive statistics were obtained including 
means and standard deviations (SDs). Rates of acceptability and knowledge recall in both 
groups were calculated. Comparisons were made using chi-squared tests or Fisher’s exact 
test where appropriate counts within individual cells of the contingency table fell below 5. 
Statistical significance was deemed to be p<0.05. 
 
Ethical Approval 
The Scotland A Research Ethics Committee (12/SS/0075) approved the study in May 2012. 
 
Results 
Only eight of 58 women asked to participate declined, giving a recruitment rate of 86%. 
Seven women had no time to participate, whilst one declined as she did not wish to be 
randomised to watch the DVD. The mean age of participants was 24 years (SD, 5.5). 35 
women were recruited to the DVD arm of the study, 15 to the control arm. There were no 












    
Table 3 Demographics of women recruited 
 
                                                         DVD  
       N=35  
                  Control  
                     N=15 
 
Age (yrs.)    mean (SD) 
Range 
 
      24 (5.3) 
      16-36 
 
                  23 (5.9) 




        1-2(Affluent) 
    N(%)       3-5 (Moderate) 
                     6-7 (Deprived) 
 
 
      3 (9) 
      25 (71) 
      7 (20) 
 
                 1 (7) 
                 13 (87) 
                 1 (7) 
 
Smoker        No                         
    N(%)      Current 
                    Ex 
 
 
     19 (54)                                                    
     13 (37)                          
     3 (9)                                       






Previous birth         N (%) 
 
     12 (34) 
 
                 5 (33) 
 
 
Previous abortion   N (%) 
 
     11 (31) 
 
                 3 (20)  
   
 
Previous contraception use       
             none 
  N (%) condoms 
            combined (pills/patch) 
            progestogen only pill 
            contraceptive injection 
            intrauterine method 
           
 
   
     2 (6) 
     32 (91) 
     26 (74) 
     11 (31) 
     3 (9) 
     2 (6)  
 
 
                0  
                14 (93) 
                14 (93) 
                0 
                1 (7) 
                1 (7)  
*
DepCat Score is a marker of deprivation in Scotland based upon postcode area of residence scoring 
from 1 least deprived, to 7 most deprived. [15] 
 
Immediately following either the DVD or face-to-face consultation all women were asked 
four multiple choice questions to test information recall. Recall was similar in both groups in 
response to three of the questions (Table 4), however respondents in the control group 
incorrectly expected mood and/or skin changes as common side effects with Nexplanon® 





    
Table 4 Responses to questions relating to recall of information given 
                                                                                  DVD Group     Control Group  p value 
Question (correct answer in bold)                              N (%)                 N (%)           
Question 1.  
Length of licence limit of implant? 
                  1 year 
                    3 years                            
                  5 years    
 
 
         0 
         33 (94) 
         2 (6) 
 
 
     0 
    15 (100) 






Question 2.  
The implant works by inhibiting ovulation? 
                   Yes                               
                  No  
                  Uncertain 
 
 
        28 (80) 
        1 (3) 
        6 (17) 
 
 
    11 (73) 
    0 






Question 3.  
Common side effects to expect with implant?
* 
                   Weight gain 
                     Irregular bleeding        
                   Amenorrhoea 
                   Mood or skin changes 
 
 
        6 (17) 
       29 (83) 
       28 (80) 
       2 (6) 
 
 
     5 (33) 
     15 (100) 
     14 (93) 











Question 4.  
There can be a delay in return to fertility? 
                   Yes 
                     No                                
                   Uncertain 
 
 
       14 (40)       
       15 (43) 
       6 (17)  
 
 
      2 (13) 
     10 (67) 







respondents allowed multiple responses to question 3, so total number of responses for question 
exceed group total  
a
overall p values calculated from 3x3 contingency tables, comparing DVD to control for each 
question 
b
individual p values calculated from 2x2 contingency tables for each possible response, comparing 
DVD to control 
 
All participants were asked if they intended to proceed to implant insertion after the abortion 
procedure, 43 (86%) women stated they did (30 (86%) and 13 (87%) in DVD and control 
groups respectively). The remainder were uncertain, no woman definitely decided not to 
have Nexplanon® inserted. DVD participants were asked to respond to a series of statements 
relating to the DVD itself. 31 (89%) women agreed it was helpful, 33 (94%) agreed it was 
easy to understand and 24 (69%) felt it an acceptable way to receive information compared 
to a face-to-face consultation. 34 (97%) women disagreed that the DVD was confusing, only 
one felt neutral. Asked to rate the usefulness of the information they received via the DVD 
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on a scale from 0 (least useful) to 10 (most useful), responses ranged from 5 to 10, with a 
mean of 9 out of 10.   
38 (76%) women were successfully contacted and interviewed three months later, 27 (77%) 
from the DVD group and 11 (73%) from the control group. There were no statistically 
significant demographic differences, between women interviewed and those not. Of those 
with no completed follow-up at three months, one no longer lived in the UK, two had an 
incorrect number documented on their contact sheet, two answered but declined to proceed 
with interview and seven did not answer after three attempts at contact. The mean time to 
telephone interview from recruitment was 92 days (SD 3.9) (13 weeks), range 88-104. Of 
those women completing telephone follow-up, 34 (89%) of them had an implant inserted, 25 
(93%) and 9 (82%) in the DVD and control groups respectively. A further two women in the 
DVD group stated they still intended to get it fitted at a later date, and two in the control 
group stated they had changed their mind, due to concerns about using a ‘foreign object’ 
(n=1) or concern about possible bleeding patterns (n=2). Of those women who had an 
implant fitted (n=34), 9 (26%)  remained happy with their implant, 10 (29%) were uncertain 













    
Table 5 Experience of implant at 3 months follow-up in those who had one fitted 
                                                                       DVD Group    Control Group  p value 
                                                                           (N=25)               (N=9)               
Happy with implant  
                                                           N (%) 
 
         6 (24) 
 





    0.31
a 
Uncertain about implant 
                                                           N (%) 
 
         6 (24) 
 
          4 (44) 
Having some problems with implant 
                                                           N (%) 
 
         6 (24) 
 
          2 (22) 
Not happy at all with implant        
                                                           N (%) 
 
         7 (28) 
 
          0 
If side effects experienced, do they meet 
expectations from information provided? 
N= number indicating side effects present 
(N=0 in respondents happy with implant)                                             
N (%)    Yes 
              Not to the extent I have experienced 
             No, not at all 
 
       (N = 19)  
 
          
         7 (37) 
         9 (47) 
         3 (16) 
 
        (N=6) 
 
           
          5 (83) 
          0 




   
 
   0.09
b 
a
comparison of experience of implant between DVD and control groups 
b
comparison of expectation of side effects between DVD and control groups 
 
 
All women who stated they were not happy with their implant described side effects 
experienced. They were asked if the information received had led them to expect these side 
effects. Over 60% of those experiencing side effects in the DVD group stated they did not 
expect them to this extent, whilst the majority (83%) in the control group did, although this 
difference did not reach statistical significance (Table 5). Side effects described included; 
bleeding problems (15), mood changes (8), concern about amenorrhoea (1), pain/irritation 
(2) at site of implant, and skin changes (1). By three months follow-up, five (20%) women in 
the DVD group who had Nexplanon® fitted had already had it removed, whilst all nine 
women in the control group continued to use Nexplanon®. This difference was not 
statistically significant (p=0.29). Women in the DVD group were again asked about their 
experience, 27 (93%) agreed the DVD was informative and that that they would be happy to 




    
In-depth interviews 
One of the four women in the control group, failed to attend. Therefore three in-depth 
interviews were conducted in the control group, four in the intervention group. All seven 
respondents still had Nexplanon® in-situ at time of interview.  
The respondents in both groups generally viewed the information provided to them, either by 
DVD or face-to-face consultation as sufficient. All four respondents who watched the DVD 
thought it was useful and helpful as a means of information provision (Figure 1). 
 







However, there also seemed to be a consensus that a DVD could not entirely replace the 
traditional consultation, as women also valued the opportunity to ask questions from 
someone face-to-face (Figure 2). 
  







“I think it covered everything and it was good because it mentioned loads of 
other things.” 
 
“I was happy with the DVD. I would say it covered everything so I am quite 











“I thought it was quite good. I have to say I don’t think I was taking it all in. Some 
information to take away would be ideal; something to think about later if you had 
questions because the DVD doesn’t give you the opportunity to ask questions there 
and then.” (DVD group) 
 








    
Some suggestions were made to improve the DVD; including the use of endorsements from 
women who have already used an implant and the use of graphics to demonstrate insertion 
and mechanism of action. All respondents felt that having the DVD available to watch on a 
website would be useful (Figure 3). 
 










All respondents expressed positive views about participating in clinical research and all 
would agree to do so again if asked. Respondents appeared to have no concerns with the 
concept of being randomised and understood the purpose of it.  
 
Discussion 
This pilot study demonstrates that using a DVD to provide information about the 
contraceptive implant is both acceptable and informative. The majority of participants who 
watched it felt the DVD was both helpful and easy to understand, and rated it highly with a 
mean of nine out of ten points for usefulness. Although recall of information was similar 
between both DVD and control groups, more women in the control group incorrectly thought 
side effects of mood/skin changes were common. This highlights the variation in counselling 
“Maybe getting some other peoples comments instead of just showing the 
demonstration and talking about it. To get some different ages of women and 
girls commenting on how it’s affected them personally and how it’s benefited 
them.” (DVD group) 
 
“I think it would be a great idea. It would make it really accessible and people 
could go back time and time again if they had something else they wanted to 
know or if they wanted to double check something.” (DVD group) – regarding 






    
that can occur in face-to-face consultations. The majority of respondents in the DVD group, 
when asked at follow-up three months later, stated they would be happy to watch a DVD for 
information provision again. Participants from both groups who returned for in-depth 
interview were happy with the quality of information provided to them at their initial 
consultation, and those who watched the DVD felt it was useful and helpful. Previous 
research about the use of a DVD to provide information about abortion to women, found 
similarly, that women rated receiving information via DVD highly. [5] Some sexual health 
services have adopted the use of DVD’s routinely, and have reported that men find it 
preferable to attending an outpatient appointment for vasectomy pre-op counselling. [10]   
Whilst research relating to the use of a DVD in contraceptive counselling is limited, the use 
of ‘apps’ providing information about contraception, including long acting reversible 
contraceptives (LARC), that patients can access on a smartphone or tablet computer prior to 
a consultation, have proved acceptable for providing information, and may increase 
knowledge and interest in effective forms of contraception. [11,12]
 
Likewise a computer 
based contraceptive assessment module, with the use of additional specifically tailored 
health materials, may positively influence contraceptive choices and potentially improve 
contraceptive continuation and adherence. [13,14]   
Our qualitative research revealed some possible suggestions to consider in production of 
DVDs for patient information. The use of endorsements from women who have previously 
used the method may help aid decision making. The use of case studies showing other 
patients’ experiences was well liked by men using a DVD for vasectomy counselling. [10] 
The use of animated graphics demonstrating mode of action of contraceptive methods, and 
where relevant, insertion and removal procedures, may also be helpful (but expensive to 
produce). It was clear that women appreciate having the opportunity to ask questions of 
health professionals, and to have information provided to them to take away to read, or 
possibly watch later. It is not our intention that DVDs should replace face-to-face 
consultations completely, rather they could enhance it. A health provider will always be 
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required to issue the chosen method of contraception allowing questions to be asked, but 
after watching a DVD or similar technology the questions should be better informed and 
more focused. The concept of having DVDs available to watch on a relevant website, either 
before or after a consultation was welcomed by women in our study. 
There are limitations to our pilot study, namely the select population we recruited from and 
the small number of participants. The results may therefore not be applicable to the general 
population. We chose to recruit women attending a clinic for abortion, as this is a time when 
counselling about contraceptive use, and particularly encouraging the use of LARC methods, 
is vitally important. Although the sample was small, we did achieve a high recruitment rate 
and our aim in this small pilot study was determine if using a DVD was feasible and 
acceptable, with a view to considering a larger multicentre study following this. Neither the 
research team, nor participants, were blinded to the intervention to which they were 
randomised. Women requiring an interpreter were excluded, eliminating a segment of the 
population. In any further larger scale studies it would be important to consider producing 
DVDs in other languages, although this would be expensive.  
This pilot study has shown that the use of audio-visual DVDs to provide patient information 
on the contraceptive implant is acceptable and informative, and can be used to enhance 
patient consultations rather than replace them altogether.  A large scale randomised 
controlled trial is now needed to determine if provision of quality standardised information 
via DVD can improve uptake or continuation rates of long acting reversible methods of 
contraception and save time during consultations, something which we did not evaluate. 
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CHAPTER 4: Contraceptive use among women presenting to 




The majority of women who require to use emergency contraception (EC) do so following 
unprotected sex or an accident with a condom. [1,2]  A smaller proportion of women may 
have had a mishap with a hormonal method of contraception (e.g. missed pills). [1,2] 
Increasingly women in Great Britain prefer to attend a pharmacy for EC rather than a sexual 
and reproductive health service or general practitioner (GP). [3] Levonorgestrel emergency 
contraception (LNG-EC) has been available free of charge without a prescription from 
pharmacies since 2008 in Scotland [4], and since 2011 in Wales [5]. In a recent trial 
comparing two oral emergency contraceptives fewer than 3% of women fell pregnant, and so 
the vast majority of women remain at risk of pregnancy after they have used EC. [6] A few 
women get pregnant in the same cycle from sexual intercourse after taking EC. In a meta-
analysis which included 11 trials of just under 5000 women who had sexual intercourse after 
using EC but before return of menses (i.e. in the same cycle), the relative risk of pregnancy 
was 2.67 (2.11-3.39) when compared with women who did not have sex after using EC. [7] 
Starting an effective on-going method of contraception after EC use is clearly important if 
women are to avoid unintended pregnancy. Community pharmacists in the UK and most 
other industrialised countries are usually unable to provide any on-going contraception 
except condoms which are available for purchase. Two mystery shopper studies have shown 
that while pharmacists are good at adhering to protocols for providing EC, only a minority of 
them give women advice about on-going contraception. [8,9]  
Little is known about the views of women who present for EC towards the use of regular 
effective methods of contraception. In order to determine such views, and estimate the 
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proportion of women using EC that may wish to start a method of effective contraception, 
we designed a questionnaire for women to complete when they attended a pharmacy for EC. 
We also sought to determine the views of both women attending for EC, and clinicians in 
sexual and reproductive healthcare (SRH), towards the possibility of a pharmacist being able 
to provide women with a limited supply of progestogen only oral contraceptives at the time 
of EC, allowing them time to arrange an appointment to obtain a long term method.   
 
Methods 
Two separate one-page, self-completed questionnaires were designed; (1) a questionnaire 
offered to women presenting to any of nine community pharmacies with a request for EC in 
January 2013 (appendix 4), and (2) a questionnaire distributed to delegates (clinicians in 
SRH) at the Faculty of Sexual and Reproductive Healthcare, UK scientific meeting in May 
2011. A short introductory paragraph explained the purpose and anonymous nature of both 
questionnaires.  
Chapter five describes a study designed to determine the feasibility of simple pharmacy 
based interventions to increase the uptake of effective contraception after EC from the 
pharmacy. For the purpose of this study and that described in chapter five, pharmacists who 
had previous experience of undertaking research [10, 11] or dispensed ten or more courses of 
EC monthly, were invited to participate and attend a meeting with the study team. Nine 
pharmacists agreed to participate in this questionnaire Pharmacists in Scotland can prescribe 
and dispense EC to women free of charge under a pre-approved patient group directive 
(PGD), although they require to complete additional training related to sexual health and 
contraception to enable them to do so. [12] Women were offered the questionnaire by the 
pharmacist at the time of EC consultation and once completed placed it in a sealed collection 
box before leaving the pharmacy. All questionnaires were numbered, to enable us to identify 
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those that were handed out and not completed or returned, therefore allowing us determine 
the response rate. At the scientific meeting, questionnaires were distributed during a plenary 
session and collected from delegates at the end of the session. Both questionnaires, which 
included limited demographic data, required simple tick box responses, however additional 
space was provided for free text comments in response to some questions. Delegates were 
asked to indicate how they felt about a limited supply of a progestogen-only oral 
contraceptive pill (POP) being offered to women presenting for EC. Responses included; 
extremely positive, positive, neutral, negative and extremely negative. Extremely positive 
and positive results were combined, and similarly for negative. 
 
Statistics 
All data were coded and entered onto two separate databases using Microsoft Excel. Data 
analysis was performed using IBM Statistical Package for Social Sciences (SPSS) software 
Version 18 (SPSS Inc. Chicago, Il, USA). Demographic data was obtained including means 
and standard deviations (SD) where appropriate. To allow statistical comparison between 
age groups in the questionnaire conducted in the pharmacy, four age groups were defined; 
14-19 years, 20-24 years, 25-34 years and 35 years and over. Comparisons were made using 
Chi square test or Fisher’s exact test where appropriate, if counts within the individual cells 
of the contingency table fell below 5.  Statistical significance was deemed to be p<0.05.  
 
Ethical Approval 
The questionnaire for women attending for EC in the pharmacy was reviewed by the 
scientific officer of the local research ethics committee, who confirmed that ethical approval 
was not required as the questionnaire was an opinion survey seeking views of patients on a 
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Pharmacy questionnaire  
A total of 211 completed questionnaires were obtained from 232 distributed to women 
attending pharmacies for EC (91% response rate). The mean age of respondents was 23 years 
(range 14-48yrs, SD 5.6). For 59 women (28%) this was the first time they had taken EC; 
151 (72%) had used it before and one person (0.5%) did not answer the question. 
Significantly more women aged 14-19 years were using EC for the first time compared to 
women aged 35 years and over (Table 6). The mean number of episodes of ever-use of EC 















    
Table 6 Previous use of emergency contraception (EC) 
Age 
(years) 
N (%) First ever use                        
N (%) 
 
Yes           No          Missing 
Use in past 12 months     
N (%) 
 
Yes           No          Missing    
14-19 59 (28) 27 (46)*  32 (54)      0 24 (41)    32 (54)    3 (5) 
20-24 83 (39) 20 (24)    62 (75)      1(1) 23 (28)    50 (60)    10 (12) 
25-34 58 (27) 11 (19)    47 (81)       0 20 (34)    33 (57)     5 (9) 
≥35 11 (5) 1 (9)*      10 (91)       0 3 (27)      8 (73)        0 
Total 211 (99) 60 (28)    151 (72)     1(0.5) 70 (33)    123 (58)   18 (9) 
* p= 0.006 
 
The majority (n=140; 66%) of women were using condoms as their contraceptive method at 
time of requesting EC, whilst 45 (21%) were using a hormonal method and 26 (12%) were 











    













Would they like to start using a  











The majority of women (n=163; 77%) stated they were currently in a sexual relationship at 
the time of using EC. Almost a third of women (n=66; 31%) required to use EC on this 
N=211 
No hormonal method 
N=166 (79%) 
 Condoms N=140 
 None N=26 
Hormonal method 
N=45 (21%) 
 Pill N=41 
 Ring N=1 
 Patch N=1 
 Injection N=1 






Already have supply at 
home, not yet started 
                     N=9 (5%) 
 
Uncertain   N=24 (14%) 
 




Prefer to use 
condoms and EC 
when required 
N=47 (28%) 
Prefer to use no 




    
occasion because they had had unprotected sex, whilst almost half (n=99; 47%) of them 
reported a condom failure (Table 7).  
 
Table 7 Relationship status and reason for EC use 
Age (years) N (%) In a sexual relationship
*
                        
N (%) 
Yes           No          Unsure 
Reason for EC use                                        
N (%) 
Unprotected   Condom     Forgot  Missing   
   sex                  failure     regular   data 
                                           method 
14-19 59 (28) 43 (73)   11 (19)        5 (8) 23 (39)              25 (42)     11 (19)    0 
20-24 83 (39) 64 (77)    17 (20)       2(2) 26 (31)              37 (45)     19 (23)    1 (1) 
25-34 58 (27) 48 (83)     7 (12)        3 (5) 15 (26)              29 (50)     13 (22)    1 (2) 
≥35 11 (5) 8 (73)       2 (18)        1 (9) 2 (18)                 8 (73)        1 (9)       0  
Total 211 (99) 163 (77)   37 (18)    11 (5) 66 (31)              99 (47)     44 (21)     2 (1) 
*
Women responded to question ‘Are you in an ongoing sexual relationship?’ 
 
There were no significant associations between women’s’ age and method of contraception 
used, reason for use of EC or relationship status. 
All women were asked if they would like to start using a regular method of contraception 
other than condoms, and if so from where they would choose to obtain it. Of the 166 women 
who were not already using a hormonal method of contraception at time of EC, 73 (44%) 
women would like to do so. (Figure 7) Most commonly women would choose to obtain 
contraception from their general practitioner (GP, family doctor) (n=80; 48%), while 12 
(7%) would attend a family planning clinic (FPC); 4 (2%) did not state a preference; 7 (4%) 
would attend a sexual health service for young people and 7 (4%) were unsure where they 
would go. A third of women (n=52; 31%) chose not to answer this question. Three women 
stated they would choose to obtain contraception from a pharmacy, whilst one woman stated 
she wished to go ‘somewhere no one knows her’ to obtain contraception.  
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Women were asked if it would have been helpful for the pharmacist to provide a one month 
supply of the progestogen-only contraceptive pill (POP), to allow them time to attend 
elsewhere for on-going contraception. The majority (n=135; 64%) agreed this would have 
been helpful, 25 (12%) women felt it would not be, 38 (18%) were unsure and 13 (6%) did 
not respond. Significantly more young women (age 14-19 years) felt a supply of POP would 
have been helpful, compared to women aged 35 years and over (80% vs. 18%, p=0.002). 
There were 15 women who added free text comments to their response to this question. Five 
women made positive comments stating that this was a good idea and three women 
commented that it would be helpful as it was difficult to obtain an appointment with their GP 
to discuss contraception. The reasons given by the seven women who stated that it may not 
be helpful included; problems using the POP in the past (n=2); a wish to avoid hormones 
(n=1), concern about possible side effects (n=2), a preference to discuss contraceptive 
methods with a doctor (n=1) and concern that a medical condition they had may 
contraindicate the use of the POP (n=1).   
 
Scientific meeting questionnaire 
A total of 110 questionnaires were completed from 150 distributed at the scientific meeting 
(73% response rate). The majority of respondents were female (88%) and 90% were doctors 






    
Table 8 Demographics of respondents at scientific meeting 
 N (%) 




Male 13 (12) 




  31-40 16 (15) 
 41-50  49 (45) 
 >50 42 (38) 




Nurse 10 (9) 
Other 1 (1) 
 
When asked how they felt about the concept of a pharmacist being able to provide a 28 day 
supply of a POP at the time of EC the majority (n=101; 92%) felt positively about this, 
whilst 6 (5%) were neutral and 3 (3%) were negative. There were no statistically significant 
differences in views towards this concept between gender, age group and work roles. 
Respondents were invited to provide additional free comments about this concept. Six made 
comments re-affirming their view that this is a good idea with benefits to women. Concerns 
expressed included that this may lead to a decrease in the use of long acting reversible 
methods of contraception (LARC) (n=2) or an increase in the use of EC (n=2), and two 
delegates stated that they would still prefer women to be reviewed by a medical professional 
to discuss all methods of contraception and have testing for sexually transmitted infections 
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where appropriate. Concern was also expressed that pharmacists would require adequate 
training to enable them to dispense POP and advise women correctly (n=4).   
 
Discussion  
Our study confirmed previous findings that the majority of women presenting for EC do so 
either following unprotected sexual intercourse or as a result of a condom failure. [1,2]  
Given the small number of women using effective contraception at time of EC and the fact 
that over three quarters of respondents to our survey determined themselves to be in an 
ongoing sexual relationship, we can assume that the majority of them remained at risk of 
unintended pregnancy. Reassuringly however, our study did identify that almost half of 
women not already doing so, would wish to use an ongoing method of contraception, 
suggesting that there is potential to target this large group of women to increase 
contraceptive use after EC. Our results suggest that significantly more young women (<20 
years of age) were using EC for the first time compared to older women (>35 years of age), 
and that significantly more welcomed the option of a supply of POP at the time of EC. 
Although the number aged 35 years or over was small and there is the possibility this may 
have resulted by chance, it suggests these that younger and potentially more vulnerable 
women may be receptive to simple interventions to increase contraceptive uptake. 
Research has shown that pharmacists are good at supplying EC, and that women rate 
community pharmacy EC services highly. [9,13] However, it has also identified that 
pharmacists are not particularly good at providing advice about on-going contraception, and 
some women have expressed concerns about receiving advice in the pharmacy about future 
contraception. [9,13,14] A recent study in London, UK, concluded that when pharmacists 
were trained to provide oral contraception by an approved PGD, they were competent in 
doing so and women were satisfied with this additional service. [15] Simple interventions 
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within the pharmacy that may encourage and help women to start effective contraception 
after EC and have also been the subject of recent research. [16] We considered the 
possibility of a pharmacist providing a limited supply of a POP, allowing women time to 
arrange an appointment with a healthcare professional to discuss contraception further. We 
suggested offering a POP rather than a supply of the combined oral contraceptive pill (COC), 
since the list of contraindications to the POP is very small,  making it more suitable for 
pharmacy provision. [17] The concept was welcomed by both the majority of women 
presenting for EC and healthcare professionals working within the field of sexual health. 
Women commented on the difficulty in obtaining an appointment with their GP, and this 
could act as interim measure in such situations.  
Obviously, not all women who use EC wish to start a regular method of contraception. A 
proportion of women will inevitably make an informed choice to use condoms or no 
contraception, and interventions like this are unlikely to impact on this group of women. 
[1,16,18] As with other studies, some women had concerns about obtaining a limited supply 
of the pill from the pharmacist. [13] However, providing reassurance to women may allay 
some of these. Women can be reassured of the very small daily dose of progestogen in a 
POP compared to the dose in EC, and its safety compared with the COC. A small number of 
health professionals expressed concern that such interventions may decrease the use of the 
most effective LARC methods and preferred that women attended a clinic to discuss such 
methods. However, we know that a large number of women now seek EC from community 
pharmacies [3] and that they rate such services highly. [13] Moreover even when women 
attend specialist services for EC almost three quarters of them leave without effective 
contraception let alone a long acting method. [1] Therefore, we require to establish ways in 
which we can help women access on-going contraception after obtaining EC from a 
pharmacy. 
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There are limitations to our study.  There is lack of demographic data available from both of 
our study populations. Short anonymous questionnaires were used in order to encourage a 
high response rate and we chose to limit the amount of demographic data sought. However, 
the survey was conducted in several large pharmacies across a large city, with a response 
rate close to 100%, so we would hope our study population is close to being representative of 
most women presenting for EC in Scotland. Additionally, there is the possibility of bias 
resulting from the method of distribution of both questionnaires. As the pharmacists 
distributing the questionnaires had participated in research before, or had shown an interest 
in doing so, the response rate in this group may be artificially higher. The delegates 
responding to the questionnaire distributed at the conference may not be typical of all 
clinicians working in this field. The vast majority were doctors, with only a minority of 
nurses. Furthermore, it is likely those that did respond would be more likely to do so in a 
positive manner.  
Encouragingly, many women presenting for EC would wish to use effective on-going 
contraception if they do not already do so, and would welcome a simple intervention in the 
pharmacy to help them do so. Clinicians in SRH, who are experts in contraception, are also 
positive about such an intervention. By facilitating women to obtain on-going methods of 
effective contraception at time of using EC, we may succeed in preventing more unintended 
pregnancies for more women.  
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CHAPTER 5: Pharmacy based interventions for initiating 
effective contraception following the use of emergency 
contraception: a pilot study. 
 
Introduction 
Since hormonal emergency contraception (EC) became available without prescription from 
UK pharmacies, increasingly women prefer to attend a pharmacy for EC rather than a doctor. 
[1] From late 2008, levonorgestrel-EC (LNG-EC) became available from pharmacies 
throughout Scotland free of charge. [2] Fewer than 5 % of women get pregnant after EC so 
the vast majority remain at risk [3] In a meta-analysis of 11 trials among almost 5000 women 
having sexual intercourse after using EC but in the same cycle, the relative risk of pregnancy 
was approaching three times that of women who abstained from sex. [4] UK guidelines 
recommend that women using EC should be provided with an effective contraceptive to start 
either with the onset of their next period, or immediately if they will not abstain from sex. [5] 
This may be an interim ‘bridging’ method that women can use until they can initiate their 
chosen contraceptive. [5] In an audit of almost 500 women attending a specialist family 
planning clinic (FPC) for EC in 2007/08, only 24% were provided with effective 
contraception (excluding condoms) to start immediately. [6] This figure may be even lower 
when EC is obtained from non-specialist services. Community pharmacists in the UK (as 
elsewhere in the industrialised world) are unable to provide any on-going contraception 
(except condoms, which can be purchased). Two mystery shopper studies show that while 
UK pharmacists provide EC appropriately, only a minority give women advice about on-
going contraception which mostly comprises advising them to consult a doctor. [7,8] So 
while in the UK EC is much easier to obtain, and by making it free of charge in pharmacies 
use has almost certainly increased, [8] we have created a situation where EC is provided 
almost solely from settings where other more effective methods of contraception cannot be 
immediately provided. We need urgently to explore ways to ensure that women attending 
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pharmacies for EC have easy and rapid access to an on-going contraceptive method which 
they start as soon as possible. 
Within the Edinburgh region community pharmacists dispense an average of 1300 courses of 
EC every month. We wished to test two interventions designed to increase the uptake of 
effective on-going contraception (all methods other than barrier methods) after use of EC 
obtained from a pharmacy. As a pilot study, the primary outcome was to determine the 
feasibility of a larger study, investigating whether either intervention resulted in an increased 
proportion of women self-reporting use of effective on-going contraception at 6-8 weeks 
after EC use, compared to standard care.  
 
Materials and Methods  
Pharmacist and subject recruitment 
Pharmacists who had previous experience of undertaking research [9, 10] or dispensed ten or 
more courses of EC monthly, were invited to participate and attend a meeting with the study 
team. Eleven pharmacists from 11 different pharmacies, agreed to participate (appendix 5). 
A small incentive (£10 per subject recruited) was offered. Four pharmacies were randomised 
to the POP intervention arm of the study, four to the rapid access arm and three to standard 
care. 
At the start of the study, a pharmacist randomised to the POP arm of the study was relocated 
out of Edinburgh, so this pharmacy was removed from the study and the remaining three 
pharmacies in the POP arm were each allocated a greater recruitment target. Four months 
into the study, a participating pharmacist in the standard care arm, retired so the pharmacy 
was replaced by another pharmacy. All participating pharmacists underwent pre-study 
training with two members of the research team. This consisted of a detailed explanation of 
the study and their allocated study arm, inclusion and exclusion criteria, the requirements to 
complete study paperwork (including demographic information from participants) and 
consent forms.  
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Between 23
rd
 April 2012 and 21
st
 December 2012, the 11 study pharmacies were asked to 
invite all women aged 16 years and over, presenting for EC, who had been using either no 
contraception or a barrier method, to participate. Further eligibility criteria included; woman 
eligible for EC according to the PGD criteria with no medical contraindications, resident in 
the United Kingdom and not requiring language interpreting services. Contraindications 
which prevent a pharmacist from dispensing LNG-EC via a PGD include; unexplained 
vaginal bleeding, pregnancy, severe hepatic dysfunction, severe malabsorption syndrome, 
previous unprotected sexual intercourse in the same menstrual cycle or unprotected sex over 
72 hours earlier. Although women were excluded if they were already using a hormonal 
method of contraception, it became apparent later that a small number of such women were 
recruited and they were subsequently excluded from statistical analysis of the primary 
outcome.   
After EC was dispensed by the pharmacist a short verbal description of the study and a 
written patient information leaflet were provided to eligible women, and written consent was 
obtained by the pharmacist. Demographic data including date of birth, postcode area of 
residence, and contact details (mobile/landline telephone numbers and email addresses) were 
also recorded. Pharmacists were asked to record to number of women declining to participate 
and the number of eligible women not invited to participate (e.g. when the pharmacy was 
particularly busy, or when the pharmacist consulting was unfamiliar with the study i.e. 
locum / relief staff).  
 
Randomisation 
A cluster randomised design was chosen since it was deemed impractical to randomise 
individual women in pharmacies. Each pharmacy (cluster) agreeing to participate was 
randomised to provide one of the interventions or standard care. Restricted randomisation 
was used to ensure balance between study arms with respect to EC dispensing figures and 
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the deprivation category [11] that is based on deprivation category scores derived from 
postcode area in which the pharmacy is situated. 
 
Interventions 
Intervention 1:  
A packet of 35 progestogen-only pills (POP - 35 mcg levonorgestrel; Norgeston®, Bayer 
UK) was provided by the pharmacist (using a locally approved Patient Group Directive 
(PGD)) at no cost to women as a bridging method of contraception, giving them one month 
to attend their usual healthcare provider for on-going contraception. A PGD allows 
pharmacists to dispense certain approved medications without a prescription. Out with this 
study, pharmacists in Scotland are not currently able to dispense the POP without a 
prescription. Pharmacists were not specifically trained to provide information regarding 
where to attend for further ongoing contraception, although could provide their usual verbal / 
written information similar to those pharmacists in standard care groups. The very few 
absolute contraindications to the POP [12] make it easier to argue the case for pharmacy 
provision compared with the combined oral contraceptive pill. Pharmacists were trained in 
POP counselling and provision before the study started and given nationally available 
written information leaflets about the POP to issue with the supply of pills. Women were 
advised to start the POP immediately or within 24 hours of EC use and to abstain from 
sexual intercourse or use condoms for 48 hours, before relying upon the POP for 
contraceptive protection.  
Intervention 2:   
Participants in the ‘rapid access’ arm, were instructed by the pharmacist to take their empty 
packet of EC to the local specialist FPC (a single large clinic in Edinburgh city centre) to 
discuss contraception, as soon as possible. Women attending the FPC were seen on the day 
that they presented as a drop-in client, without requiring a booked appointment, and were 
offered all methods of contraception, including long acting reversible methods of 
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contraception (LARC) to start immediately. This differed from standard practice, as women 
not participating in the study who present as a drop-in for ongoing regular contraception may 
be asked to return on another day, if the clinic is already at capacity. The EC boxes were 
clearly labelled, alerting FPC staff to study participants. The boxes were returned to the 
study coordinator. Pharmacists provided written information about the location and opening 
hours of the FPC.  
Standard care 
Pharmacists dispensed EC in the usual manner, which included the option to provide their 
usual verbal and /or written information (if available) regarding the importance of 
establishing an effective on-going method of contraception. All pharmacies within the region 
have leaflets detailing the location and services available at local FPCs, should they wish to 
use them.  
Participants were advised that they would be contacted 6-8 weeks later to complete a short 
telephone interview. At interview completion a £10 voucher to redeem in the pharmacy was 
mailed to participants. 
  
Telephone follow-up to determine use of contraception after EC 
Two members of the research team conducted all follow-up, which consisted of a short 
telephone interview lasting approximately 5 minutes at 6-8 weeks after attendance for EC 
when women who had received a packet of POP should have finished it. In an attempt to 
maximise follow-up rates at least three attempts at contact were made to both landline and 
mobile telephone numbers, at varying times of the day. Furthermore, if no telephone contact 
was possible, for those participants who had provided an e-mail address, an e-mail was sent 
to them to ensure the telephone contact number documented was correct, and to identify if 
there was a more suitable time to call the participant. Women were asked what method of 
contraception they were currently using, about their experience of obtaining EC from the 
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pharmacy and of the care that they received. All women were asked if they felt that a small 
supply of POP had been, or would in theory have been, ‘helpful’. 
 
Statistical Analysis 
No published data were available on which to base a sample size. There are no data on how 
many women who use EC then visit their GP or FPC for on-going contraception. Less than 
50% of pharmacists providing EC around Edinburgh [8] give advice about contraception 
after EC use. We assumed that the proportion of women starting on-going contraception 
following EC from a pharmacy would be far less than that in the specialist FPC clinic (24%). 
[6] For this pilot study we aimed to recruit 180 women (60 to each arm of the study) from 
10-12 pharmacies, as we considered this to be a reasonable number of women to recruit 
within our eight month timescale, whilst still providing an adequate number for follow-up. 
Based on previous research in sexual health, amongst reproductive age women, [10] we 
estimated that 50% of women attending for EC would agree to participate and we anticipated 
loss to follow-up of at most 50%. From these assumptions we calculated that pharmacists 
would need to see 360 women for EC, in order to recruit 180 and collect follow-up data on at 
least 90 women. 
All data, including demographic data recorded at recruitment and at telephone follow-up, 
were coded and entered onto a Microsoft excel database and checked. Analysis was 
performed using IBM Statistical Package for Social Sciences (SPSS) software Version 18 
(SPSS Inc. Chicago, Il, USA). Descriptive statistics were obtained including means and 
standard deviations (SD). To take account of the cluster randomisation, it was necessary to 
carry out an analysis at cluster rather than individual subject level, and the proportions in 
each cluster using effective contraception were compared between groups by two-sample t-
tests, [13] weighted by the different number of patients in each cluster. This approach was 
preferred to random-effects modelling, including variation at both individual and cluster 
level, because of the small number of clusters, since it explicitly recognises this through the 
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degrees of freedom rather than requiring a normal approximation to generate P-values. 
Confidence limits for relative probabilities were derived from t-tests based on the logarithms 
of the effective proportions. Statistical significance was deemed to be p<0.05.  
 
Ethical Approval 
The South East Scotland Research Ethics Committee 03 (11/ss/0045) approved the study in 
September 2011.  
 
Results 
During the eight month recruitment period, a total of 168 subjects were recruited, with a 
mean age of 23 years (SD 5.2), to the POP (n=56), rapid access (n=58) and standard care 
(N=54) groups respectively. The commonest reason for requesting EC was a condom 
accident (n=62 (61%)). Of those recruited, 132 (78%) were subsequently contactable by 
telephone 6-8 weeks later. Of those contacted, 102 women (61% of all subjects recruited) 
completed the telephone interview; the remaining 30 women withdrew consent to continue 
in the study. (Figure 5)  
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The demographics of those women completing telephone follow-up in each of the three 
study arms are shown in table 9.  
 
 
Table 9 Demographics of women completing telephone interview 
 
   POP  
N=39  
Rapid access  
N=28 
 Standard care 
 N=35 
 
Age (yrs.)  mean (SD) 
Range 
 
 22 (5.2) 
 16-44 
 
 25 (5.6) 
 18-40 
 






        1-2(Affluent) 
    N(%)         3-5 (Moderate) 
                     6-7 (Deprived) 
 
 
 4 (10%) 
 33 (90%) 
 0 
 
 9 (32%) 
 18 (64%) 
 1 (4%) 
 
 3 (9%) 
 31 (89%) 
 0 
 
Previous birth         N (%) 
 
 2 (5%) 
 
 1 (4%) 
 
 1 (3%) 
 
Previous abortion   N (%) 
 
 4 (10%) 
 
 3 (11%)  
 
 3 (9%) 
 
Contraception at time of EC      
                  none 
  N (%)       condoms 
                  other (e.g. cocp)           
 
 13 (33%) 
 26 (67%) 
 
 
 8 (28%) 
 17 (61%) 
 3 (11%) 
 
 
 12 (34%) 
 19 (54%) 
 4 (12%) 
*
DepCat Score is a marker of deprivation in Scotland based upon postcode area of residence 
scoring from 1 least deprived, to 7 most deprived. [11] 
 
 
For subjects who were not contactable, only data on age was available, and there was no 
significant difference in age between women contacted and those not contacted (mean age of 
23 yrs. (SD 5.2), and 22 yrs. (SD 4.9) respectively). 
In the POP arm, 35/ 39 (90%) women reported using the pills provided. Two women chose 
not to use the pills as they were ‘not currently sexually active’, one woman stated ‘she did 
not get round to using it’ and one was concerned about side effects. Most women, 26/ 35 
(74%), who took the pill reported completing the packet; five used between seven and 14 
pills; three delayed starting and had not finished the packet at the time of interview; the 
information was not documented for one woman. Three of the five women who stopped 
taking the pills did so because of side effects and two stated they had difficulty remembering 
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to take it. Asked if they felt that the option of a one month supply of POP being available 
from the pharmacy following EC was helpful; 33 (84%) agreed that it was, three (8%) felt it 
was not and three (8%) were unsure. 
In the rapid access arm, 9/ 28 (32%) women attended the FPC, three on the day they 
obtained EC and six, two days to one month later. Attendance at the FPC after EC use was 
confirmed by collection of the marked EC boxes. The commonest reason given for not 
attending for rapid access contraception was ‘pressure of time’ (n=10 (53%)). Additional 
reasons included ‘prefer to see GP’ (n=1), ‘still considering contraceptive options’ (n=1), 
‘FPC too far away’ (n=1), ‘forgot’ (n=1), ‘not sexually active’ (n=2) and two women stated 
that ‘the option was not clearly explained to them’. A one month supply of POP being 
available from the pharmacy following EC would have been helpful to 15 women (54%) 
however 10 (36%) felt it would not help and three women (10%) were unsure. 
Women in the standard care arm were asked if they had received information from the 
pharmacists about the range of methods of contraception available, or where they could 
obtain contraception. Eight (23%) women stated they received no information about methods 
available and six (17%) had not received any information about where they could get 
contraception. A one month supply of POP from the pharmacy following EC would have 
been helpful to 16 women (46%) but 13 (37%) felt it would not have helped and six (17%) 
women were unsure. 
 
Effective method of contraception use at 6-8 weeks post EC 
Seven women were excluded from further analysis as they were using hormonal 
contraception at the time of presenting for EC and continued to use it at follow-up, (three in 
the rapid access and four in the standard care arms of the study). Only 16% of women 
receiving standard care reported using an effective method of contraception 6-8 weeks after 
EC.  When compared to standard care, the relative probability of a woman using an effective 
method of contraception vs. barrier method / no method, after use of EC was 3.13 (95% C.I. 
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1.90-5.13) in the POP group and 2.57 (95% C.I. 1.55-4.27) in the rapid access group. 
Compared to standard care, the use of a LARC 6-8 weeks after EC was significantly greater 
in the rapid access group (20% vs. 0% p=0.004). (Table 10) 
 
 
Table 10 Method of contraception used at 6-8 weeks post EC 
 
 














Contraception                      
 
     All 
  effective 
  methods                   










    LARC 
methods 





















Effective =all contraceptive methods aside barrier or natural methods  
LARC=long acting reversible method of contraception (Intrauterine method, contraceptive 
implant, contraceptive injection) 
 
Statistical comparisons of interventions to standard care;  




Rapid access p=0.006 








This pilot study demonstrates that a simple intervention may increase the uptake of effective 
contraception after the use of EC obtained from pharmacies. The relative probability of using 
an effective method of contraception 6-8 weeks after using EC was three times (among 
women in the POP group) and more than twice (among women in the rapid access group) 
that among women in the standard care group. This was a pilot study and loss to follow-up 
(including lack of willingness to be interviewed after successful contact) was relatively high. 
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However, even if we assume that all the women who did not complete telephone follow-up 
in each arm of the study, were not using an effective method of contraception, there would 
still be a significant increase in the use of an effective method in the intervention (POP group 
39% vs. 9% (p=0.005); rapid access groups 22% vs. 9% (p=0.043)). 
Both interventions are simple and cheap to provide, although any rapid access arrangement 
would need to be agreed with local services. While this may be more difficult in places 
without large specialist FPC services it should not be impossible for GPs to agree that 
women who have used EC should be seen urgently. There is only one other study of a 
pharmacy based intervention after EC that we know of. [14] In this Jamaican study women 
were offered a voucher for a discount on the cost of oral contraceptive pills. This study did 
not increase the uptake of effective contraception after EC, and at follow-up six months later, 
most women continued to use condoms or no method.  
For the endpoint of this feasibility study we chose contraceptive use after EC at a time when 
women receiving the POP should have finished the packet. Increasing the uptake of effective 
contraception after EC is not a surrogate for reducing unintended pregnancies or abortions 
and discontinuation rates of oral contraceptives are high. [15] Moreover both oral and 
injectable contraceptives have proven no better than condoms in preventing repeat abortion. 
[16,17] However, the rapid access intervention also resulted in a statistically significant 
increase in the uptake of LARC which has been shown to decrease both repeat abortion and 
teenage pregnancy. [18] Not all women attending for EC will want to start effective 
contraception. In an anonymous questionnaire of women attending for EC conducted in the 
same pharmacies in Edinburgh, 53% wished to continue using condoms. [19]   
There are inevitably limitations to our study. Contraceptive use 6-8 weeks after EC was self-
reported. It is unlikely that inaccurate reporting alone could account for the significant 
differences in use of effective contraception between both intervention groups and standard 
care. We also lack robust data on those women who were not recruited to the study and 
cannot rule out selective recruitment. Pharmacists said they either did not have time to 
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document these demographics during busy working periods, or they simply forgot. This 
illustrates the difficulties encountered when conducting clinical research in pharmacy 
settings. [20] Finally, as described in methods, we were unable to undertake power 
calculations to determine an accurate sample size and we fell short recruiting the intended 
target sample size during the eight month recruitment period. Furthermore, completed 
telephone follow-up occurred in only 61% of subjects and we were therefore unable to 
determine contraceptive use in the remaining 40%. Prior to conducting a larger scale study, 
further qualitative research with both pharmacists and EC users may help determine what 
incentives they feel might enhance both recruitment and  study continuation and follow-up. 
These results should also be able to guide power calculations to determine sample sizes for 
any such larger studies. 
This pilot study has shown that whilst conducting research within a pharmacy setting poses 
certain challenges, it is feasible. Despite the small number of participants, the results suggest 
that the use of simple pharmacy based interventions may increase the uptake of effective 
contraception after EC. More robust evidence from a larger study is required to demonstrate 
that the interventions really do increase use of effective contraception and that this leads to 
reductions in unintended pregnancies. Frequently interventions which look promising at a 
pilot stage are shown to be ineffective when scaled-up in a larger study or rolled out to 
routine care. [21, 22] 
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CHAPTER 6: Provision of contraception after emergency 
contraception from the pharmacy: evaluating the 
acceptability of pharmacy for providing sexual and 




Community pharmacies in the UK are well placed to provide sexual health services, with 
many already providing emergency contraception (EC). Women rate these services highly, 
perceived benefits including anonymity and ease of access. [1,2] Although a small number of 
pharmacies currently provide enhanced sexual health services, such as provision of oral 
contraception, there is scope for more to do so and for even greater development. [3,4] 
Research exploring pharmacy based provision of such services is important to determine 
whether it really is advantageous for patients. An evaluation of community pharmacy 
provision of oral contraception demonstrated that pharmacists were competent to provide the 
service and clients were satisfied with it. [5] Several studies have sought the views of 
pharmacists regarding the provision of chlamydia screening in the pharmacy. While 
pharmacists are willing to provide screening there are difficulties, such as pharmacists 
feeling uneasy about offering screening to all women in all circumstances and tending to 
select groups for screening, such as those presenting for EC, or those under 16 years of age. 
[6-8] 
As sexual health services develop within the pharmacy setting, there are increased 
opportunities to undertake sexual health research within the setting. Studies regarding the 
views of community pharmacists towards participation in research are limited. One study of 
the views of UK pharmacists in a pharmacy research network suggested the majority were 
‘interested in research’, [9] and in a questionnaire survey, two thirds of Australian 
pharmacists responding stated they were interested in participating in research to some 
extent. [10] Whilst sexual health research, including a pilot of expedited partner therapy for 
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chlamydia, has previously been conducted effectively from the pharmacy setting, [11] 
research undertaken in this setting is not without challenges. Some of the challenges 
documented by previous sexual health researchers in the pharmacy included; difficulty in 
calculating a response rate as no record of those declining participation in the study was 
kept; slow recruitment; and problems ensuring patient confidentiality. [12]  
UK guidelines recommend that women using EC should be provided with an effective 
contraceptive to start either with the onset of their next period, or immediately if they will 
not abstain from sex. [13] In a meta-analysis of 11 trials among almost 5000 women having 
sexual intercourse after using EC but in the same cycle, the relative risk of pregnancy was 
more than two times that of women who abstained from sex.[14] We conducted a pilot study 
of pharmacy based interventions for initiating effective contraception after EC, in 
community pharmacies in Edinburgh, UK in 2012.[15] Pharmacies were cluster randomized 
to provide either standard care or one of two interventions: (a) one packet of progestogen-
only pills (POPs), giving women 1 month to arrange ongoing contraception; (b) invitation to 
present the empty EC packet to a family planning clinic (FPC) for contraceptive advice 
(rapid access (RA). Pharmacists who had previous experience of undertaking research 
[11,16] or who dispensed at least ten courses of EC monthly, were invited to participate. 
Eleven pharmacists from eleven different pharmacies agreed to take part. Four pharmacies 
were randomised to the POP intervention arm of the study, four to the rapid access arm and 
three to standard care. All participating pharmacists underwent pre-study training with two 
members of the research team. 
Between 23rd April 2012 and 21st December 2012, the 11 study pharmacies were asked to 
invite all women aged 16 years and over, presenting for EC, who had been using either no 
contraception or a barrier method, to participate. After EC was dispensed by the pharmacist a 
short verbal description of the study and a written patient information leaflet were provided 
to eligible women, and written consent obtained by the pharmacist. Demographic data and 
contact details (mobile/landline telephone numbers and email addresses) were recorded. [15] 
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Pharmacists were asked to note the number of women declining to participate and the 
number of eligible women who were not invited to participate (e.g. when the pharmacy was 
particularly busy). Women were contacted 6-8 weeks later for a telephone interview, during 
which they were asked what method of contraception they were using, and about their 
experience of obtaining EC from the pharmacy. The aim of the study was to determine the 
feasibility of a larger study to ascertain if pharmacy based interventions can increase the 
uptake of effective contraception after EC.[15] Recruitment to and follow-up of participants 
in that study, and the methodology of this study is described fully in chapter five. In this 
chapter the views of both the women and the pharmacists regarding the provision of these 
interventions from the pharmacy setting are described. Using these findings our primary aim 
was to identify possible barriers and facilitators to providing such interventions from the 
pharmacy in practice. In addition, during the study we documented any operational problems 
that arose with research in the pharmacies, to help inform the development of larger scale 
studies of such interventions from the pharmacy. 
 
Methods  
Semi-structured interviews with women 
In the pilot study, women were contacted for a telephone interview at 6-8 weeks post EC, to 
determine contraceptive use at that time. A purposive sample of 12 women (4 from each 
study arm), were recruited at time of telephone follow-up to undergo a face to face interview 
to allow further evaluation of the intervention (or lack of it in standard care arm). The face-
to-face interviews were semi-structured and conducted by a qualitative researcher at a time/ 
venue chosen by the women. The interviews were carried out between August and 
November 2012.  
Given that this is a novel intervention, a semi-structured interview using a standardised topic 
guide was chosen as a flexible research method. This was to facilitate the generation of data 
that could be easily compared and thematically analysed, whilst also enabling women to 
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raise issues that are important to them and could inform future development of the research 
and clinical implementation of interventions. Women were asked to briefly recount their 
contraceptive history and describe the circumstances leading to the index episode of 
obtaining EC from the pharmacy. They were also asked to share their experience of 
obtaining EC from the pharmacist and being invited to participate in the study. Women were 
asked to reflect on their experience of the intervention (if assigned POP or RA appointments) 
and also their thoughts about these interventions being offered as routine practice. Finally, 
women were asked about their motivation to participate in the research and whether 
providing a financial incentive influenced their decision to participate. Interviews were 
audio-recorded and transcribed verbatim. Data was organised by cross sectional indexing 
and thematically analysed and presented.[17]
 
 
Structured interviews with pharmacists 
All study pharmacists agree to participate in a telephone interview before and after the study. 
These interviews were conducted by telephone and were arranged at a time of day 
convenient for the pharmacists in order to minimise disruption to working practice.  Nine 
pharmacists were interviewed pre-study and ten post-study (some remained unavailable). 
None of the pharmacists simply declined to undergo the interview. The structured telephone 
interviews were conducted by two public health practitioners who had prior experience with 
this approach and methodology. A standardised topic questionnaire was used to enable 
comparability of data collected. In the pre-study interviews pharmacists were asked; whether 
they anticipated any barriers or issues to arise, any specific training required, and their views 
on the provision of vouchers as incentive for the women. In the post-study interviews they 
were asked to highlight any problems experienced with the process of the research or the 




    
 
Observations from the research team 
Throughout the study, a research log was utilised by the research team to record any 
operational issues arising as a result of conducting a research study from this setting.  
 
Ethical Approval 
Ethical approval was sought and approved for the original pilot study, [15] which included 
approval to conduct the qualitative interviews reported in this article. The South East 




Semi-structured interviews with respondents 
49 women were asked to participate in a further interview and 26 agreed (53%). Once the 
desired sample of 12 women had successfully attended for interview, no further women were 
asked to participate, hence only 49 women asked.12 women were interviewed; all chose to 
be interviewed  at the  city centre SRH service, rather than their home or another venue. 
The interviews each lasted about one hour and covered all the questions prepared in the topic 
guide. The demographics of women interviewed (n=12), compared to those of all women 
who were successfully contacted for telephone interview (n=102) in the pilot study, are 










    
Table 11. Comparison of demographics of women completing telephone interview 
(in pilot study) and attending for face to face interview 
 
  Telephone interview 
N=102 
Face to face interview 
N=12 
 











        1-2(Affluent) 
   N(%)         3-5 (Moderate) 
                     6-7 (Deprived) 
 




















DepCat Score is a marker of deprivation in Scotland based upon postcode area of residence scoring 
from 1 least deprived, to 7 most deprived.[18]
 
 
The three key themes that were discussed during the interview include accessing effective 
contraception, provision of POP or Rapid Access (RA) appointments, and recruitment at the 
pharmacy and participation in the study.  
Accessing effective contraception 
Women’s description of their experience highlighted challenges they faced in accessing 
effective contraception which had led to their need for EC. Most women were using 
condoms as their regular contraceptive method with EC used as a ‘back up’ when they felt 
they had put themselves at risk of pregnancy. All of the women interviewed indicated that 
they did not view EC as a routine method of contraception and all expressed the wish to be 
using effective, ongoing contraception.  
Difficulties getting an appointment to discuss contraception with their General Practitioner 
(GP) or at family planning services were noted by women. The limited availability of 
appointments after work coupled with having to be ‘organised and plan ahead’ weeks in 
advance had been suggested as reasons for putting off accessing more contraception. A 
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couple of respondents said they felt contraception would not be a priority for the GP service, 
hence their reluctance to raise it with their GP.  
 
“I am very busy and work irregular hours which makes it very difficult for me 
to get appointments with my current GP. I don’t want to trouble my GP for 
minor health concerns so I prefer to self-medicate or go to the pharmacy across 
from where I live where they operate a drop-in system to suits me better.” 
(standard care group)  
 
Provision of POP or Rapid Access (RA) appointments 
All women interviewed welcomed both interventions noting that it would be good to have 
different options available to support women in accessing effective contraception.  
Provision of a month supply of POP  
The women had mixed views on being offered the POP when presenting for EC at the 
pharmacy. Discussions centred around two themes: the amount of POP provided and the 
setting of the provision (at the pharmacy, when presenting for EC). While some women said 
that a month supply was enough for a woman to make a follow up appointment to access 
further supply or to discuss other methods, several women felt that one month supply could 
be a ‘waste of time’ or put women off using hormonal methods altogether.  
 
“I think it will be useful for other women… but for myself and other women, it 
will take a while for the pill to settle, so a month supply may not be worth it as 
it may not be able to give a good indication of the side effects on the body. 
This might put some women off thinking it is not working for them.” (standard 
care group) 
 
Some women felt that being offered the POP at the pharmacy was a good alternative to 
accessing it only at the GPs or the FPCs.  
 
“It is quite good to do this because some people can be quite hesitant going on 
it and asking about it from their GP. So if they are offered, they can try it. It is 
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easier to ask GP for more rather than to start on it. A month supply should be 
enough to make an appointment with their GP.” (POP group) 
 
However, others had reservations about starting a woman on a new hormonal method at the 
time of presenting for EC. A few women questioned whether it was the role of the 
pharmacist to undertake contraception consultations. One woman who attended her GP to 
discuss contraception said that her GP was shocked that she was offered the POP.  
 
“I think for women like me who have never tried hormones before, it is not a 
good idea. I want to speak to someone about different options and the health 
implications of hormones before I take them. My GP was surprised when I 
mentioned that I was given the pills at the pharmacy, it was not a good method 
for me.” (POP group) 
 
All four women from the POP arm of the study recalled being provided with information by 
the pharmacist and given the opportunity to ask questions about the POP. However three 
women said they felt they went away having questions about POP which they did not feel 
able to ask at the time.  
Provision of a Rapid Access (RA) appointment 
All women welcomed the idea of a woman presenting for EC to be provided with a RA 
appointment, as it enabled quicker access to consultations and potentially more specialist 
support that can help match women to suitable and effective methods of contraception.  
 
“Getting the emergency contraception can kick start your brain to think about 
wanting to get on the pill or something… having an appointment to see 
someone quickly to discuss more will be really helpful.” (standard care group) 
 
Moreover, a few respondents suggested that an appointment several days after presenting at 
the pharmacy for EC could give a woman time to reflect on her experience and seek 
appropriate clinical as well as emotional support during follow up.   
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“For women getting the morning after pill, it can be quite a stressful time for 
them. With the appointment, they can speak to someone about what happened 
especially if it had been a bad situation. The appointment will give them a little 
bit longer to think things through and then they have someone to confide in. If 
it’s within a week that is not too long to wait.” (POP group) 
 
There was some discussion about the option of services where the RA appointment can be 
accessed. A few women noted that being offered a RA appointment at a FPC would be 
welcomed especially by younger women who may not feel comfortable using their own GP 
for EC and contraception. A few women said they would like the RA appointment to be 
available from their own GPs. These women mentioned that they would be unlikely to use a 
RA appointment if it were available only from the FPC as they preferred to see their own GP 
with whom they already have a good relationship and who knows about their medical 
histories.   
 
“I have a good relationship with my GP who knows me well and my problems with 
finding a suitable method. I am aware that they have specialist here in the centre but 
I really don’t want to go through my history again with another person. I rather go 
back to my own GP.” (RA Group) 
 
Recruitment at the pharmacy and participation in the study 
Discussions with women about their experience at the pharmacy suggested that they felt the 
information given to them by the pharmacist about contraception and the study was clear.  
When asked whether they felt it was appropriate to recruit women when they presented for 
EC at the pharmacy most women replied that it was as they were able to make an informed 
choice and did not feel pressured into participating.  
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“The pharmacist was very nice, it was all very relaxed and very human. It 
didn’t feel like I was being sold anything… I didn’t feel any pressure to be 
involved. I think women just need to be assured there is not a lot involved and 
that they can help other women, feel like they are part of something useful.” 
(standard care group) 
 
A couple of women noted however, even though they were happy to participate, they were 
keen to be ‘in and out’ of the pharmacy as soon as possible and would have liked to be able 
to directly contact the research team to discuss being involved rather than having to decide 
whilst at the pharmacy.  
 
“I’m not entirely sure I knew exactly what she was talking about although I 
was given the information to take away. I think the pharmacist could have 
asked me a bit more question. But to be honest, I didn’t ask her much because 
I just wanted to get out of there.” (POP group) 
 
After prompting, one woman revealed that she had felt ‘obliged’ to agree to participate 
despite being assured by the pharmacist that participation was voluntary and would have no 
impact on the service she would receive. When asked about their motivation to participate in 
the study, most women said they wanted to ‘help other women’ through the study and to 
‘give back’ to the excellent services they received. When asked if the incentive voucher (£10 
value to spend in the pharmacy) was a motivation, most women said it helped to remunerate 
the time they had given to take part, although they would have participated without the 
voucher.  
 
Pre and post study interviews with pharmacists  
Pre-study interviews 
Interviews were conducted with nine pharmacists. The majority perceived no potential 
problems with the study although two expressed concern that the time taken to recruit 
women, within a busy commercial setting, may potentially present a problem. The small 
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incentives offered to pharmacies to recruit women (£10 per woman recruited) and those 
offered to women to participate (£10 voucher to spend in pharmacy) were seen as helpful. 
They felt the option of rapid access to a FPC was a good idea to help build on the women’s 
motivation to use ongoing contraception at presentation for EC.  
Post-study interviews 
Post study telephone interviews were conducted with 10 pharmacists. All were positive 
about their involvement and felt that pharmacies could offer a wider range of sexual and 
reproductive health services. Concerns were expressed by some that recruitment had been 
slower than they expected. They felt that pressure on consultation time had not been a 
significant issue, although there were some occasions when the pharmacy was too busy to 
allow recruitment. 
 
Methodological issues identified from research team observations 
Operational issues were documented throughout the study and reviewed, with the following 
key themes identified: 
Retention/continuity of pharmacist 
There was the difficulty in retaining within the study the pharmacists who had agreed to 
participate and underwent pre-study training. One pharmacist randomised to the POP arm 
was relocated to another pharmacy out of Edinburgh, so this pharmacy was removed from 
the study and the remaining three pharmacies in the POP arm were each allocated a greater 
recruitment target. Four months into the study, a pharmacist participating in the standard care 
arm retired without informing the research team, and the replacement did not wish to 
participate. Recruitment within this pharmacy therefore stopped and was replaced by another 
pharmacy. 
Recruitment of women 
Recruitment of women to the study, within all of the pharmacies, slowed towards the end of 
the study. In one of the larger pharmacies, which is a branch of a large pharmacy 
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conglomerate within the UK, recruitment slowed over the months of June and July, as the 
travel vaccination service offered by the pharmacy became the priority. The number of 
women recruited overall during the study fell short of intended recruitment numbers of 180 
by 12.   
Adherence to study protocol  
There were problems related to pharmacists adhering to guidance given to them during pre-
study training about inclusion and exclusion criteria for recruitment, maintaining records of 
the numbers of eligible women who were dispensed EC but not recruited, and documenting 
the reasons for this. Exclusion criteria included women who were already using a hormonal 
method of contraception at time of recruitment. However, seven women were recruited 
whilst already using a hormonal method. They were subsequently excluded from statistical 
analysis of the primary outcome of the study. All pharmacists failed to keep accurate records 
of the numbers of women to whom EC was dispensed and who would have been eligible to 
participate, but either declined or were not approached to by the pharmacist. Thus there was 
no way to determine an accurate response rate, or to ascertain the reasons the pharmacists 
chose not to recruit, or why women decided not to participate.   
A further concern was the occasional difficulty the pharmacists had in maintaining accurate 
documentation. On two occasions the form documenting consent to participate was not 
signed by the woman, and without consent they could not be contacted for follow up. Some 
pharmacists did not document women’s date of birth on every occasion resulting in time 
spent trying to determine this information from pharmacy records. Additionally, the contact 
information recorded at time of recruitment was inaccurate for 14 women providing no way 
of conducting follow-up with them. 
 
Discussion 
Enhanced sexual health services provided in pharmacies have been shown to be effective and 
viewed favourably by women. [1,2,5,11] Our pilot study demonstrated that the provision of 
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simple interventions from the pharmacy after EC may increase the uptake of contraception. 
[15] Overall, women welcomed both interventions and felt they offered solutions to the 
barriers they faced in obtaining regular contraception, leading to the use of EC, in terms of 
making appointments and being supported to find acceptable and effective contraception. 
Some concerns were highlighted relating to ‘easy access’ to hormonal methods at 
pharmacies and the preference some women have for visiting their own GP rather than a 
family planning clinic.  Reassuring women about the safety of POPs, and provision of 
information to General Practitioners (GP’s) about a service providing POP after EC, may 
help alleviate some of the concerns we identified from women in our study. Consideration 
could also be given to extending the provision of rapid access to contraception to GP’s, 
rather than FPC’s alone.  
A barrier to rolling out such findings from a pilot study into clinical practice is the ability to 
conduct high quality research in this setting. The difficulties we encountered in conducting 
the study may impinge on the quality of evidence obtained and therefore the ability to 
translate it to clinical practice. Although limited evidence would suggest pharmacists are 
interested in participating in research, [9,10] we had some problems in retention of 
pharmacists during the study. Whilst pharmacists felt recruitment to the study and provision 
of interventions did not significantly affect their consultation time, recruitment slowed in all 
pharmacies at points throughout the study. Community pharmacies, which are commercial 
businesses, may have to prioritise more lucrative services above clinical research at certain 
times. Reassuringly women found the notion of being recruited to clinical research within a 
pharmacy acceptable. However, as with recruitment to research in any setting, care should be 
taken (by pharmacist and research team) to ensure women do not feel obliged to participate 
at a time when they may be feeling anxious and vulnerable.  
Although the depth of detail provided from face to face interviews, and similar responses 
from women across the groups, provides strength to the methodology and suggests reliability 
of results, there are obvious limitations in this study. This was a small study, with a small 
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sample of women from a single urban site, as the interviews were intended to explore 
possible facilitators and barriers. The results may not be applicable in other settings, such as 
rural pharmacies. 
Conducting a pilot study and undertaking the follow-up interviews with women, provided an 
opportunity to gain valuable feedback. Women welcomed both participation in research and 
the interventions offered. Pharmacists viewed their participation in the study positively. The 
problems encountered provide valuable feedback to inform further development of research 
methods in the pharmacy setting, and larger scale studies of such interventions. 
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CHAPTER 7: Abortion care services delivered from a 




Delivery of abortion care services throughout the UK is changing.  In England and Wales in 
2011, 61% of all abortions were carried out in the independent sector, funded by the NHS, 
whilst 35% were carried out in NHS hospitals. [1] In contrast, in Scotland 98% are provided 
through the NHS and most of these are delivered from hospital-based departments of 
obstetrics and gynaecology. [2]  A key component of the care of women requesting an 
abortion, as directed in UK guidelines, is the provision of comprehensive counselling and 
immediate access following abortion to all available forms of contraception, in particular the 
long-acting reversible methods. [3] Indeed there is growing evidence that uptake of  these 
effective methods of contraception, notably the intrauterine device (IUD) and system (IUS) 
and the progestogen-only implant, is associated with a significantly reduced risk of  repeat 
abortion. [4-8] In some hospital settings, the care of women requesting an abortion may be 
delegated to the more junior members of the medical staff, who often lack knowledge about 
contraception and the training to insert implants or intrauterine methods.  Whilst there is a 
lack of recent evidence regarding the attitudes of UK obstetrics and gynaecology trainees 
towards provision of abortion care, there are anecdotal reports that increasing numbers of 
them are choosing to opt out of abortion care for reasons of personal belief or because they 
find the work repetitive.  A questionnaire of a proportion of both consultants and trainees in 
obstetrics and gynaecology in the UK in 1998 acknowledged similar concerns.  The results 
identified that around a third of trainees in obstetrics and gynaecology had not had any 
training in abortion procedures, a similar number stated a conscientious objection to abortion 
and a number of consultants expressed views that some trainees also opted out of abortion 
for other reasons. [9]  
96 
    
It has been suggested that abortion services would be better placed in the community sexual 
and reproductive health (SRH) setting, since staff working within this area may be better 
placed to provide for women’s ongoing contraceptive needs and have expertise in insertion 
of intrauterine devices and contraceptive implants. [4] Additionally, SRH services may well 
be better placed for screening and testing for sexually transmitted infections and may have 
more robust systems for partner notification. Increasing numbers of women in Great Britain 
are having early abortion, 78% of abortions in England and Wales having been performed at 
under 10 weeks gestation and 65.5% in Scotland under 9 weeks in 2011 [1,2] and increasing 
numbers of this group  are opting for  the medical method and choosing to go home soon 
after treatment to pass the pregnancy at home. [10,11]  There is good evidence that early 
medical abortion is highly amenable to delivery from a community setting and highly 
acceptable to women. [12] 
The attitude of general practitioners, gynaecologists and medical students in the United 
Kingdom, towards their involvement in provision of abortion has been the subject of 
previous research. [13-16] However, no previous studies have focused on the views of those 
working within the field of SRH.  In this study we aimed to determine the views of health 
professionals working in SRH regarding their attitudes towards a future role for specialists in 
SRH providing more abortion care services by surveying delegates at the annual scientific 
meeting of the Faculty of Sexual and Reproductive Healthcare in the UK.  In addition, we 
wished to determine the views of staff working within a community SRH centre in 
Edinburgh, Scotland, about the planned provision within the following six months of early 




To obtain the views and attitudes of a large number of healthcare workers, either working 
within or with an interest in SRH, we designed a questionnaire to distribute to all attendees at 
a large UK SRH scientific meeting (Faculty of Sexual and Reproductive Healthcare) in April 
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2012 (appendix 6).  An introductory paragraph on the questionnaire explained its purpose 
and anonymity. Completed questionnaires were placed in sealed collection boxes.  The 
questionnaire collected demographic data of the respondents including gender, age, current 
working role and geographical region of work, information on their current practice of and 
attitude to abortion, and their views on location of abortion care services.  Responses in the 
sections relating to views on abortion and attitude and willingness to participate in, and 
location of, abortion care services, were recorded by the participants on 5 point Likert scales, 
the options ranging from strongly disagree to strongly agree. [17]  
For the survey of staff within the community SRH service in Edinburgh, an anonymous 
internet questionnaire was distributed to all staff named on an up to date staff mailing list 
between January and March 2012 (appendix 7).  The questionnaire sought demographics 
including gender and role within the service in addition to views regarding the planned 
introduction of the early medical abortion service and willingness to participate in it.  
Responses consisted mostly of drop-down list options with additional free-text responses to 
selected questions.  
 
Statistics 
Data from both questionnaires were coded and entered onto separate databases using 
Microsoft Excel.  In the questionnaire of attendees at the sexual health scientific meeting, 
responses relating to views on abortion, willingness to participate and location of services, 
were combined such that ‘strongly agree’ and ‘somewhat agree’ were grouped as ‘agree’ 
whilst ‘strongly disagree’ and ‘somewhat disagree’ were grouped as ‘disagree’.  The 
remaining group of responses was ‘neither agree nor disagree’.  Data analysis was performed 
using IBM Statistical Package for Social Sciences (SPSS) software Version 18 (SPSS Inc. 
Chicago, Il, USA).  Groups were compared by Chi squared test or Fisher’s exact test where 
counts within any individual cell of the contingency table fell below five. Statistical 
significance was deemed to be p<0.05.  
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Ethical Approval 
Both questionnaires were reviewed by the chair of a local research ethics committee who 
confirmed that ethical approval was not required as they constituted health services research. 
 
Results 
165 questionnaires were returned out of 200 distributed at the UK SRH scientific meeting 
(82% response rate).  Almost all respondents were female (88%) and over two thirds (73%) 
were aged between 41 and 60 years.  Over half of respondents worked in England (54%) and 





































    
Table 12 Demographics of Respondents to questionnaire 1 
 
    
Gender N(%)  
Female 146(88) 
Male 18(11) 
Missing data 1(1) 
    






    




England and Wales 1(1) 
Northern Ireland 2(1) 
Ireland 1(1) 
Channel Islands 3(2) 
    
Working role N(%)   
Consultant 35(21) 
General Practitioner 51(31) 
Staff Grade / Associate Specialist Grade Doctor 53(32) 
Trainee Doctor 16(10) 
Unspecified Doctor 2(1) 
Nurse 6(3) 
No longer working 1(1) 





Regarding any current involvement in abortion, only 5 (3%) stated they had no involvement 
in any aspect of abortion care; 129 (78%) currently referred women for abortion; 106 (64%) 
counselled and assessed women for consideration for abortion and 103 (62%) signed the 
required legal paperwork for abortion.  Only 24 (14%) respondents stated that they either 
performed surgical abortion or administered the medications required for medical abortion. 
Most respondents, 149 (90%), considered themselves to be ‘broadly pro-choice’; 6 (4%) 
were undecided and 10 (6%) stated they were broadly anti-abortion.  There was no 
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statistically significant difference between gender, age groups, region of work or current 
working role and personal view of abortion.  
Statements were put forward to respondents regarding their view on location of abortion 
services, their willingness to participate, and views as to whether there is a role within SRH 
for abortion care. The responses are shown in table 13. 
   
 
Table 13 Views on location of and participation in abortion services 
               N(%) 
 
                   Neither          
Statement                    Agree         Agree/Disagree  Disagree   Missing      
 
1. Abortion services would be best suited  
to community clinics as opposed to hospital    128(78)   24(14)         12(7)             1(1) 
      setting.  
  
2. Abortion services are best provided                
within a hospital based setting in                      31(19)          44(27)        88(55)             2(1) 
gynaecology.  
 
3. Abortion services are best provided by 




4. Abortion services should be divided  
across these services.                                        83(50)          49(30)        29(18)             4(2) 
 
5. I would be willing to participate in abortion  
care for women, including relevant paperwork  
or administering medication / undertaking        115(70)         13(8)          35(21)             2(1)  
procedure where appropriate. 
 
6. I do not feel my role within sexual and  
reproductive health should have any                11(7)             8(5)           143(87)           3(4) 




The majority of respondents, 128 ( 78%), attending the UK SRH scientific meeting felt that 
abortion services were best suited to community clinics rather than hospital services.  83 
(50%) felt that services should be divided across community, hospital and non-NHS 
charitable and private organisations.  Respondents working in England were statistically 
more likely to agree that abortion services were best suited to non-NHS charitable and 
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private organisations compared to  respondents working in other regions (p = 0.001).  In 
addition, female respondents were statistically more likely to agree that abortion services 
were best suited to non-NHS charitable and private organisations compared to men (p = 
0.017).  There were no other statistically significant differences in responses to statements 
regarding location of services between gender, age groups, region of work or working role.  
115 (70%) agreed that they would be willing in the future to participate in abortion services; 
35 (21%) disagreed whilst 13 (8%) were undecided.  The majority, 143 (87%), disagreed that 
there was no role in SRH for abortion services; 8 (5%) neither agreed nor disagreed and 11 
(7%) agreed there was no role.  Significantly more women disagreed with this statement than 
males (p = 0.006).  Respondents who considered themselves to be broadly anti-abortion were 
statistically more likely to disagree to participate in abortion services (p = 0.001) and 
statistically more likely to agree that there is no role in SRH for abortion services (p = 
0.004). 
The questionnaire of staff working within an SRH service in Edinburgh was distributed to 90 
people. 62 responded (69% response rate).  The majority (56; 90%) of respondents were 
female.  24 (39%) responders were nursing staff, 22 (35%) doctors and 16 (26%) 
administrative and clerical staff.  
All were asked ‘How do you feel about the plan for early medical abortion to take place in 
your service?’  44 (71%) stated they felt this was a natural extension to the services already 
offered, 4 (6%) were neutral and 9 (15%) were uncertain.  Only 5 (8%) felt it was not an 
appropriate setting.  There was no significant difference in responses to this question with 
gender and different working roles.  In response to the question, ‘Would you be happy to be 
involved in such a clinic?’ 44 (71%) stated yes, 7 (11%) stated ‘no’ due to conscientious 
objection to abortion and 11 (18%) were either uncertain or stated that this would not be of 
interest to them.   Neither gender nor working role was associated with response to this 
question.  
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Respondents were asked, from a list of potential advantages, to select those which they felt 
would apply to women as a result of providing an early medical abortion service within the 
service.  Responses are shown in table 14. 
 
Table 14 Possible advantages for women of an abortion service located in Chalmers 
Sexual Health Centre.   
 
Possible Advantages N(%)  
(multiple advantages could be selected by each 
respondent) 
  
Better provision of contraception post procedure 44(71) 
More holistic approach to patient care  42(68) 
Opportunity to better manage STIs 33(53) 
More readily accessible site for patients 32(52) 




A third of responders, 21 (34%), felt all were possible advantages to women.  
Respondents were asked, ‘Do you feel there will be any potential disadvantages to women 
seeking an abortion, in having their care delivered from the community SRH setting?’ and 
were invited to specify what they considered the disadvantages to be.  32 (52%) felt there 
would be no disadvantages, 14 (22%) thought there would and 16 (26%) were uncertain. A 
total of 8 possible disadvantages suggested by the responders were: possible lack of 
anonymity within the community setting (n=4), concern that the new abortion service would 
place undue additional workload on the existing services (n=2), concern that some women 
may not wish to attend an SRH clinic for abortion due to possible stigma associated with 
sexual health clinics (n=1), and that women may not wish to return to the SRH service in the 




    
 
Discussion  
This study showed that most of the health professionals in SRH who were surveyed were 
generally supportive of providing abortion services from a community SRH setting. This is 
reassuring for future workforce provision of abortion services in the UK.  Currently, those 
abortion services that are provided from hospital departments of obstetrics and gynaecology 
often compete for staffing with acute areas such as labour ward, with the result that staffing 
of the abortion clinic may be delegated to junior, inexperienced members of the team. There 
is also evidence that trainees in obstetrics and gynaecology may lack interest in abortion 
management since a survey of senior trainees in 2008 showed that only 2.8% had opted to 
undertake the advanced training module in abortion care. [18] Our study confirms that 
doctors working within community SRH may be more willing to participate in abortion 
services.  Additionally, abortion care is included as a mandatory module within the new 
training curriculum for UK specialist trainees in community SRH, ensuring that all doctors 
training in this new specialty gain knowledge and exposure of this integral part of SRH. [19]  
Increasing numbers of women in Great Britain who request an abortion are at early gestation 
(≤ 9 weeks), and increasing numbers are choosing to have an early medical method that 
enables them to leave the abortion service soon after treatment to pass the pregnancy at 
home. [10,11]  There is evidence that this method is highly amenable to provision in a 
community setting and that it is safe to do so and furthermore it is acceptable to women. [12] 
Our results show that the overwhelming majority of delegates at the scientific meeting in 
SRH agreed that abortion services would be suited to a community SRH setting.  
Additionally, the majority of staff working in a community SRH clinic where abortion 
services were about to be introduced felt that this was a natural extension to the services 
already offered. 
 
There are other reasons why it may be advantageous for more abortion care to be provided 
from community SRH clinics.  First, it is possible that uptake of the most effective long 
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acting reversible methods of contraception  (LARC) would be greater in a specialist 
contraceptive setting  compared to  a hospital setting, where hospital staff may lack specialist 
contraceptive knowledge or the ability to insert intrauterine contraception  or progestogen-
only implants.  In our study, 7 out of 10 staff surveyed at the community SRH clinic agreed 
that better contraceptive provision would be an advantage of providing abortion care through 
the SRH clinic.  Immediate postabortal provision of LARC is important as there is increasing 
evidence that insertion of an IUD/IUS or an implant is associated with a significantly 
reduced risk of  having a further abortion. [4-8] In a Scottish study of a hospital-based 
abortion service, women who chose to have an IUD/IUS fitted were almost 18 times less 
likely, and women who chose to have a contraceptive implant inserted were 16 times less 
likely, to return for another abortion within the next 2 years, compared to those choosing to 
use an oral contraceptive pill. [4]  
It would also seem only logical that an integrated community SRH service would also be 
better placed to manage sexually transmitted infections (STIs) in women requesting abortion.  
Indeed over half of respondents (53%) working within the community SRH clinic agreed 
that better management of STIs would be an advantage to offering abortion care within their 
setting.  It has previously been shown that women who test positive for Chlamydia 
trachomatis at a hospital abortion service have poorer partner treatment rates than their 
counterparts who test positive at either a genitourinary medicine clinic or family planning 
clinics. [20] This suggests that management of STIs amongst women requesting abortion 
may be particularly challenging for hospital services. 
Of course it is possible that there may be some disadvantages to providing abortion care 
services from a community setting. Only a small number of staff from the SRH clinic 
reported possible   disadvantages and these tended to be related to perceived increasing 
workload for themselves, or concerns that women may have less anonymity than in a 
hospital clinic.  Clearly any abortion service must be able to provide guarantees of privacy 
and anonymity for women and sexual health services are surely particularly sensitive to 
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users' needs in this respect.  A concern that was expressed by a minority of staff was that 
women might be reluctant to attend an SRH setting due to perceived stigma attached to 
sexual health service.  However, currently many women actually choose to attend SRH 
clinics to request a referral for abortion.  Clearly, future qualitative research on the views and 
experiences of women attending abortion services in both hospital and community settings 
will be important to determine the location of services that women would consider most 
convenient and acceptable.  
Although more than three quarters of respondents from the scientific meeting felt that 
abortion services were suited to a community SRH setting, half also agreed that services 
should be divided across community, hospital and non-NHS organisations.  Currently in 
England and Wales, abortion services are delivered from both the independent sector, funded 
by the NHS, and from NHS hospitals.  This division of services has worked well for many 
years, although as suggested by the responses to our survey, these services could co-exist in 
both the independent sector and in an NHS community SRH setting.  In Scotland the 
overwhelming majority of abortions are provided by hospitals, and whilst hospital services 
with surgical facilities and inpatient and daycase beds will still be required, assessment 
clinics and facilities for early medical or early surgical abortion could also exist in 
community SRH clinics.  
Clearly a potential drawback to our study is that most respondents from the scientific 
meeting were over 40 years old, and so may not necessarily have reflected the views of 
younger health professionals or those still in training, who are the potential future providers 
of abortion services.  There is currently a lack of recent qualitative research regarding 
attitudes towards abortion care of UK trainees in both obstetrics and gynaecology and sexual 
and reproductive health and a future study in this area would be valuable. Furthermore, there 
is the possibility of response bias, in that enthusiastic clinicians attending such a scientific 
meeting may be more inclined to respond more positively.  Nevertheless, our study showed 
that UK health professionals currently working in SRH are supportive of providing more 
106 
    
abortion services in a community SRH setting.  Clearly it will be important to evaluate 
service delivery from community SRH settings to determine if this model is indeed 
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CHAPTER 8: Conclusions and Future Research 
 
 
Rates of unintended pregnancy throughout the UK are high. In 2014 in England and Wales, 
184,571 induced abortions were performed, and in Scotland, the corresponding figure was 
11,475. [1,2] However, there are several possible strategies which could be employed with 
the aim of reducing unintended pregnancy, as demonstrated in the preceding chapters. 
 
Provision of accurate information about contraceptive methods 
Current use of intrauterine contraception (IUC), which has been shown to be amongst the 
most effective methods of contraception, [3] varies throughout the world. [4] It may have 
previously been thought possible that women are reluctant to use such methods due to 
misconceptions about them. However, chapter two demonstrates that at least amongst 
women attending for abortion, only a minority of hold such misconceptions. Chapter 2 also 
identified lack of knowledge about IUC to be an issue. Therefore, healthcare professionals 
can use consultations, such as at time of request for abortion, as an opportunity to inform 
women about the potential benefits of such effective methods of long acting contraception, 
with the hope of increasing uptake. One such strategy to provide good quality, standardised 
information about contraceptive methods, is in an audio-visual format through the use of a 
DVD. The use of DVD’s in sexual health service settings has previously been shown to be 
acceptable. [5,6] 
Chapter three considered the use of a DVD to inform women considering using a 
contraceptive implant for the first time about this method, and encouragingly, the DVD was 
shown to be acceptable to women as a means of imparting information. A DVD could be a 
useful adjunct to face to face contraceptive counselling from a clinician. A larger scale 
randomised study is required to determine if provision of accurate information about the 
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implant and other forms of LARC, including both the benefits of these methods and potential 
expected side effects, can result in both increased uptake and continuation of these methods. 
 
 
Pharmacy based strategies to increase contraceptive uptake after emergency 
contraception 
Chapter four confirmed that the majority of women who use EC do so following either 
unprotected sexual intercourse or an accident with a condom. More women now choose to 
obtain EC from a pharmacy as opposed to attending their GP or a sexual health service. [9] 
Therefore, there are a significant proportion of women who will remain at risk of unintended 
pregnancy following the use of EC from a pharmacy, if they do not commence an effective 
method of contraception following it. Whilst pharmacies can sell condoms, the majority in 
the UK are not routinely able to provide other more effective methods of on-going 
contraception. Chapters four through six considered the implementation of pharmacy based 
strategies which may lead to an increased uptake of effective methods of contraception 
following EC. Encouragingly women presenting for EC, clinicians in SRH and pharmacists 
all welcomed the idea of simple pharmacy based interventions, such as provision of a POP 
from the pharmacy to quickstart after EC, or rapid referral on to a sexual health service for 
on-going contraception. Furthermore, chapter five demonstrated that such interventions are 
feasible and may result in increased uptake of effective contraceptive methods. Larger scale 
studies are required to determine if such strategies can increase the uptake of LARC, and 
more importantly, as result can reduce rates of unintended pregnancy. 
 
Provision of LARC at time of abortion 
It is of vital importance at the time of consultation for request for abortion, and following the 
procedure, to consider counselling and provision of effective methods of contraception, 
particularly LARC methods. [10] A possible means to increase the uptake of LARC 
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following abortion is through provision of abortion services in a community sexual and 
reproductive healthcare setting. Reassuringly, chapter seven indicated that clinicians working 
in the field of SRH and in particular, those in a sexual health service where an abortion 
service was due to commence, where generally supportive of providing such services. 
Further research is required to determine if provision of abortion care from such settings 
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Patient Information Questionnaire - Patient Survey                                     
 
As part of our efforts to continuously improve women’s health, we would like to 
determine your views and knowledge about intrauterine methods of contraception. 
Doctors and nurses feel that the copper IUD and the mirena are both very good 
methods for contraception but many women are often reluctant to use either. We 
want to try and determine why this may be the case.   
 
This questionnaire is completely anonymous. Please read it carefully and take a few 
minutes to complete it. Place it in collection box when complete.  
 
Please circle your response(s) for each statement.  
 
1. The Intrauterine Device (the mirena or ‘coil’): 
 
a) Is painful to have inserted. 
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
b) Is only suitable for women who have had children.   
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
c) It is not suitable if you have had more than 3 childern. 
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
d) Can only be used by older women.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
e) There is a good chance it can make you infertile.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
f) There is a good chance it can damage the neck of my womb.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
g) There is a good chance it can damage the lining of my womb.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
h) It can get stuck inside your womb.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
i) It can rust inside of you. 




j) You or your partner can feel it during sex.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
 k) It can move during sex. 
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
l) It can move around inside your body.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
m) There is a high chance it might fall out.  
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
n) It can get stuck on the babies head if you become pregnant. 
   Strongly agree   Somewhat agree   Neither agree/disagree   Somewhat disagree   Disagree 
 
 
2. What age are you?........................years 
 
3. What is your postcode?.......................(e.g. EH1 37) 
This information is only used to find out what area you live in and how far you have 
had to travel here today.  
 
4. Are you a smoker? (Please tick) 
    ⁭   Yes               ⁭   Ex-smoker               ⁭   Never smoked 
 
5. Have you ever given birth? (Please tick)               ⁭   Yes         ⁭   No  
 
6. Have you ever had a miscarriage? (Please tick)           ⁭   Yes           ⁭   No 
 
7. Have you had an abortion before? (Please tick)         ⁭   Yes            ⁭   No  
 
8. Which of these contraceptive methods have you used before?  
    (Please tick any that apply) 
 
⁭  None      
⁭  Condoms    ⁭  Cap/diaphragm  
⁭  Oral contraceptive pill  ⁭  Hormonal injection (depoprovera) 
⁭  Implanon/Nexplanon  ⁭  Intrauterine device/coil  
⁭  Hormonal patch (Evra)  ⁭  Hormonal ring (NuvaRing) 
⁭  Sterilisation    ⁭  Other 
     
9. Which are you going to use after leaving today? (Please tick) 
 
⁭  None      
⁭  Condoms    ⁭  Cap/diaphragm  
⁭  Oral contraceptive pill  ⁭  Hormonal injection (depoprovera) 
⁭  Implanon/Nexplanon  ⁭  Intrauterine device/coil  
⁭  Hormonal patch (Evra)  ⁭  Hormonal ring (NuvaRing) 


























































Appendix 2    
 
SECTION A – Previous Contraception      
 
1. Which of the following methods of contraception have you used previously? 
(tick any that apply) 
 
 ⁭ None     
 ⁭ Diaphragm / Cap   ⁭ Condoms 
 ⁭ COCP     ⁭ POP 
 ⁭ Contraceptive patch  ⁭ Nuva Ring 
 ⁭ Depo-provera   ⁭ IUD 
 ⁭ IUS     ⁭ Other – specify……………………… 
 
2. Which of the following contraceptive methods are you currently using?  
 
⁭ None     
 ⁭ Diaphragm / Cap   ⁭ Condoms 
 ⁭ COCP     ⁭ POP 
 ⁭ Contraceptive patch  ⁭ Nuva Ring 
 ⁭ Depo-provera   ⁭ IUD 
 ⁭ IUS     ⁭ Other – specify……………………… 
 
SECTION B – Recall 
 
1. The contraceptive implant can be kept in for ...... years before it requires to 
be changed? (please circle) 
  
 1    3    5 
 
2. The contraceptive implant works by inhibiting ovulation – stopping an egg 
being produced. (please circle) 
 
 Correct  Uncertain   Incorrect 
 
3. The contraceptive implant can cause the following side effects. (please circle 
any that apply) 
 
 Significant weight gain 
 
 Altered bleeding pattern (irregular / longer lasting) 
 
 Your periods may stop when using it 
 







4. When the implant is removed your fertility can take weeks or months to 
return to normal. (please circle any that apply) 
 
 Correct  Uncertain  Incorrect 
   
SECTION C – Intention to have implant 
 
1. Do you intend to arrange to have an implant fitted? (please circle) 
  
 Yes  Uncertain  No 
 
2. If no, tick any of the following reasons for not choosing to have an implant. 
 
 ⁭  Scared of insertion / removal 
 ⁭  Due to possibility of problematic bleeding 
 ⁭  Concerned of other side effects (skin changes / mood changes) 
 ⁭  Don’t wish a foreign body in my arm 
 ⁭  Wish a shorter term contraception 
 ⁭  A friend told me it doesn’t work 
 ⁭  A friend told me it caused bad side effects 
 ⁭  I would prefer another option 
 ⁭ I have been advised another method would be more suitable 
 ⁭  Other (specify)……………………………………………………………. 
  
SECTION D – Acceptability (DVD group only) 
Please circle response to the following statements: 
 
1. I found the DVD to be helpful. 
 
strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree  
   
2. I found the DVD easy to understand.  
 
strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree 
 
3. I found the DVD to be confusing. 
 
strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree 
 
4. In comparison to a face to face consultation I found the DVD to be acceptable. 
 
strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree 
 
 
5. I would have preferred to have a face to face consultation instead of the DVD. 
 




6. Overall, on a scale out of 10, how useful would you rate the information you 
received about the contraceptive implant today? 
I rate the usefulness of the information I received as ………..out of 10.  
 













3. Smoking status (circle) 
 Never smoked  Ex-smoker  Smoker 
 








SECTION F – Contact Information  
 
Mobile phone number………………………… 
 
Home phone number…………………………. 
 

















Telephone interview       
 Verify that the person answering the telephone is the correct individual 
 Introduce oneself ; that you are a research nurse/doctor conducting the  
research project on using a DVD to provide information about the 
contraceptive implant.. Reminder of what project is about and that it is a 
short telephone interview (no more  than 15 mins) 
 Check that they are still willing to participate. 
 Remind them that they are under no obligation to answer any or all of the 
questions 
 Say that you are very grateful for their help.  
 Check that it is a convenient time for them to speak. If not rearrange a 
suitable date/time. (Re- scheduled for ……………………………. @     hrs) 
  
At END of interview: 
 Thank women for participation 
 Would they like a personal copy of results (12 months)- address or email 
 Or if copy on web site of Chalmers sufficient– give web address and email 
contact number  
 Ask how participant would like to receive £10 voucher  
 If by post then collect address that they wish voucher to be sent 
to.(address…………………………………………………………. 
 Care of ……………………………………………………) 
 Check if  participant would be willing to participate in IDI 
 
Name of interviewer…………………………………….. 
 




SECTION A – Contraception 
 
1. Which methods of contraception have you used since your initial attendance? 
 
⁭ None    ⁭ Condoms 
 
 ⁭ Diaphragm    ⁭ Cervical cap 
 
 ⁭ COCP     ⁭ POP 
 
 ⁭ Contraceptive patch  ⁭ Nuva Ring 
 
 ⁭ Depo-provera   ⁭ IUD 
 
 ⁭ IUS     ⁭ Nexplanon 
 
⁭ Other – specify……………………… 
 
2. Did you have a contraceptive implant fitted? (circle) 
 
 Yes   No  Not yet, I intend to 
 
3. If yes, when did you have it fitted? (please tick) 
 
 ⁭  Immediately following consultation ⁭  Within 7 days 
 
 ⁭  Within 2 weeks    ⁭  Within 1 month 
 
 ⁭  Between 1 month and now  
 
4. If no, give reason why. (tick any that apply) 
  
 ⁭  Scared of insertion / removal 
 ⁭  Due to possibility of problematic bleeding 
 ⁭  Concerned of other side effects (skin changes / mood changes) 
 ⁭  Didn’t wish a foreign body in my arm 
 ⁭  Wished a shorter term contraception 
 ⁭  A friend told me it doesn’t work 
 ⁭  A friend told me it caused bad side effects 
 ⁭  I wished to use another option 
 ⁭  I couldn’t arrange appointment for insertion 











SECTION B – Acceptability 
Please circle response to statements below.  
 
1. I was happy to have been involved in a randomised trial. 
 
strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree  
 
2. I would participate in a similar trial again in the future.  
 
strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree  
 




strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree 
 




strongly agree somewhat agree neither agree / disagree somewhat disagree      disagree  
 
 
SECTION C – Implant group only 
 
1. Are you happy with your implant so far? (circle) 
 
Yes, no problems  Uncertain  Some problems  No, not at all 
 
2. What problems are you having? (tick any that apply) 
 
 Local reaction to implant 
 Pain / discomfort at implant site 
 Bleeding side effects – persistent 
 Bleeding side effects – irregular 
 Bleeding side effects - amenorrhoea 
 Skin changes  
 Mood changes 
 Other (specify)………………………………………………………………… 
 
3. Did you expect these side effects from the information given to you at 
consultation? (circle) 
 









      Emergency contraception from the pharmacy poll 
 
 
We would be grateful if you could take the time to read and complete this short 
anonymous questionnaire. Once completed please place in the collection box. 
We hope that the information you provide will enable us to have a better 
understanding of the reasons that women use the emergency contraception, what 
contraception women choose to use following it and where they would choose to 
access it. 
Thank you for your time.  
 
1) What age are you?............   
 
2) Please state the first 4 characters of your current postcode (e.g. – EH14) 
…………. 
(This will let us know what areas of Edinburgh women answering this questionnaire live in.) 
 
3) Is this the first time you have taken the ‘morning after pill’? (tick box) 
  
⁭ Yes                
 
⁭ No  - please state number of times taken in last 12 months ………   ever……….. 
              
4) What contraception are you using just now? (tick box) 
  
⁭ None  ⁭ Condoms ⁭ Other (please state)……………………… 
 
5) What was the reason you required to use the ‘morning after pill’ today? (tick box) 
  
⁭ Unprotected sex (no condom)  ⁭ Condom failure (burst etc.) 
  
⁭ Forgot/ran out of contraceptive pills  
 
⁭ Forgot/unable to have Depo-provera injection or implant / coil changed when due 
 
6) Are you in an ongoing sexual relationship? (tick box) 
  
⁭ Yes  ⁭ No   ⁭ Uncertain 
 
7) Would you like to use a method of contraception other than condoms? (tick box) 
 
⁭ I Already do    ⁭ Yes 
  
⁭ No, not sexually active  ⁭ Uncertain 
   




 ⁭ No, happy not to use contraception (but use emergency contraception as back up)
  
PLEASE TURN OVER TO COMPLETE QUESTIONNAIRE 
 
8) If you answered yes to the previous question,  where would you choose to go first 
to obtain this contraception? (tick box)  
  
⁭ My own GP    ⁭ Family planning clinic / Chalmers Centre 
 
 ⁭ Caledonia Youth   ⁭ Uncertain 
 
 ⁭ Other – please 
state………………………………………………………………….. 
 
9) If at the pharmacy you could have been given a 1 month temporary supply of a 
contraceptive pill to start after taking the emergency contraceptive, to allow you the 
time to attend elsewhere for ongoing contraception– would you have found this 
helpful? (tick box) 
 











































S. Aziz Newington Pharmacy, 46-50 Clerk Street, Edinburgh, EH8 
9JB 
P. Tinkler Royal Mile Pharmacy, 67 High Street, Edinburgh, EH1 
1SR 
I. Kalka Boots the Chemist, 101-103 Princes Street, Edinburgh, 
EH2 3AA 
C. Barnes Lindsay and Gilmour, 11 Elm Row, Edinburgh, EH7 4AA 
G. Toohie / J. Dewart Boots the Chemist, 32 West Maitland Street, Edinburgh, 
EH12 5DX 
C. Cooney Boots the Chemist, 230-232 Gorgie Road, Edinburgh, 
EH11 2PN 
A. Wallace Boots the Chemist, 5-9 St James Centre, Edinburgh, EH1 
3SN 
C. Gallagher / F. 
Watson 
Boots the Chemist, 6 St Patrick Street, Edinburgh, EH8 
9HB 
M. Hamilton Bristo Square Pharmacy, 6 Bristo Square, Edinburgh, EH8 
9AL 
F. McKim Apple Pharmacy, 6 Eyre Place, Edinburgh, EH3 5EP 
L. Jack Boots the Chemist, Ocean Terminal, Ocean Drive, 























Survey of professionals in sexual and reproductive health in the United 
Kingdom, about attitudes towards provision of abortion care within SRH 
clinics.  
Increasingly in some areas in the UK, abortion services now run within community 
sexual and reproductive health services, either in addition or as an alternative to NHS 
hospital services or clinics run by private and charity based organisations. We wish 
to determine the attitudes of those working within this area towards participating in 
abortion and their views as to which settings are most appropriate for such services.  
We would be grateful if you could take the time to read and complete this short 
anonymous questionnaire. Once completed please place in the marked collection 
box. 
 
Thank you for your time.  
Dr Lucy Michie on behalf of the Clinical Studies Group  
 
SECTION 1 - Demographics 
 
1) Please indicate your gender? (please tick box) 
 Female ⁭   Male  ⁭ 
 
2) What age are you? (please tick box) 
20-30 years ⁭ 31-40 years ⁭ 
   
41-50 years ⁭ 51-60 years ⁭ 61 years and over ⁭ 
 
3) Which region do you work within? 
 England  ⁭ Wales  ⁭ Scotland  ⁭ 
 
Northern Ireland ⁭ Ireland  ⁭ Channel Islands ⁭ 
  
Other  (please specify) ……………………………………… 
 
4) What is your current role related to sexual and reproductive health (SRH)? 
Based mainly in community SRH 
 Consultant  ⁭  SAS grade ⁭ 




Based mainly in Genitourinary Medicine 
 Consultant  ⁭  SAS grade ⁭ 
 Medical Trainee ⁭  Nurse  ⁭ 
Based mainly in hospital - Obstetrics and Gynaecology  
Consultant  ⁭  SAS grade  ⁭ 
Medical Trainee  ⁭  Nurse   ⁭ 
 
General Practice 
  GP    ⁭     
Medical Trainee ⁭  Nurse  ⁭ 
Working within private / charity sector 
Doctor   ⁭  Nurse   ⁭ 
No longer working  ⁭ 
 




SECTION 2 - Current practice and attitude to abortion 
 
5) What involvement do you have in abortion care in your current practice? (please 
tick any that apply)  
None  ⁭  Refer patients on for abortion  ⁭  
 
Assessment / Provision of information to patient’s   ⁭  
 
Signing HSA 1 form       ⁭ 
 
Undertaking procedure / Administer medication   ⁭ 
 
 Other (please specify)……………………………………………………….. 
 
 
6) Please circle the response that best describes your view of abortion. 
    I consider myself to be:  
 
 
    Broadly       Undecided                    Anti-Abortion 
   Pro-Choice          
 
 
7) Please circle your response to the following statement. 
I believe women should have the right to choose to have an abortion in the 





Strongly Somewhat       Neither         Somewhat                Strongly  
  agree     agree              agree/disagree          disagree                 disagree 
 
 
SECTION 3 - Views on location of abortion services 
  
Please circle your response to the following statements. 
 
8) Abortion care services (for uncomplicated cases within the first trimester) 
would be best suited to community clinics as opposed to a hospital setting. 
 
Strongly Somewhat       Neither         Somewhat                Strongly  
  agree     agree              agree/disagree          disagree                 disagree 
 
 
9) Abortion care services are best provided within a hospital based setting in 
gynaecology. 
 
Strongly Somewhat       Neither         Somewhat                Strongly  
  agree     agree              agree/disagree          disagree                 disagree 
 
 
10) Abortion care services are best provided by separate non-NHS, private 
and/or charitable organisations. 
 
Strongly Somewhat       Neither         Somewhat                Strongly  
  agree     agree              agree/disagree          disagree                 disagree 
 
 
11) Abortion care services should be divided across these services. 
 
Strongly Somewhat       Neither         Somewhat                Strongly  
  agree     agree              agree/disagree          disagree                 disagree 
 
 
12) I am / would be willing to participate in abortion care for women, including 
completing relevant paperwork or administering medication / undertaking 
procedure where appropriate.  
 
Strongly Somewhat       Neither         Somewhat                Strongly  
  agree     agree              agree/disagree          disagree                 disagree 
 
 
13) I do not feel my role within sexual and reproductive health should have any  
involvement in abortion care services.  
 
Strongly Somewhat       Neither         Somewhat                Strongly  























































A survey of attitudes of staff working within an integrated  
sexual and reproductive health centre, towards undertaking  
early medical termination of pregnancy within the centre. 
 
It is planned that services to provide early medical termination of pregnancy up to 9 
weeks of gestation will begin at Chalmers Sexual Health Centre later in 2012, in 
addition to those already provided at The Royal Infirmary of Edinburgh. With this 
short questionnaire we hope to obtain information regarding staff attitudes towards 
both this change to services and about undertaking the procedure. We would 
therefore be grateful if you could read it carefully and complete it. 
 
1. Please indicate your gender: (please tick) 
 
 ⁭ Female    ⁭  Male 
 
2. Please indicate your role within Chalmers: (please tick) 
 
  ⁭ Consultant in SRH   ⁭ Consultant in GUM 
 
Medical ⁭ SAS grade doctor in SRH  ⁭ SAS grade doctor in GUM 
 
  ⁭  Junior doctor/Trainee in SRH ⁭ Junior doctor/Trainee in GUM 
 
 
  ⁭ANP nurse (based in SRH)  ⁭ ANP nurse (based in GUM) 
Nursing  
⁭ Nurse     ⁭ Clinical support worker 
 
  ⁭ Health Advisor   ⁭ Other 
 
3. How do you feel about the plan for early medical termination of pregnancy to 
take place at Chalmers? (please tick) 
 
⁭   This is a natural extension to services already offered at Chalmers. 
 
⁭   This is not an appropriate setting for termination of pregnancy. 
 
⁭   I am uncertain.    
 
⁭   I have no feelings either way. 
 
4. Would you be happy to work in such a clinic? (please tick) 
 ⁭ Yes 
 
 ⁭ No  – I conscientiously object to termination of pregnancy. 
   
18 
 
⁭ No - This is not an area that interests me. 
 
 ⁭ Other (please specify)………………………………………..………  
 
5. Which of the following do you feel could be advantages for women having the 
abortion service within Chalmers? (please tick all appropriate ) 
 
⁭   Better provision of contraception post procedure. 
 
⁭   More readily accessible site for patients. 
 
⁭   Opportunity to better manage STI’s. 
 
⁭   More holistic approach to patient care. 
 
⁭   Other(please specify)………………………………………………….  
 
6. Do you feel there will be any disadvantages for women seeking an abortion, to 
have their care delivered from Chalmers?   
 
⁭   Yes     In what way?………………………………………………… 
 
⁭   No 
 
⁭   Uncertain 
 
 
7. Do you feel the introduction of  the termination of pregnancy service will 
affect the running of other clinics? (please tick) 
 
⁭   Yes In what way?………………………………………………… 
 
⁭   No                      
 
⁭   Uncertain 
 
8. Would you wish further training in abortion care before this service begins at 
Chalmers? (please tick) 
 
⁭   Yes  
 
⁭   No  
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tive method.1 A study of women attend-
ing for abortion or for ante-natal care, at 
a large hospital in Edinburgh in 2005, es-
timated that 90% of pregnancies amongst 
women requesting abortion were unintend-
ed, and almost one third of the pregnancies 
amongst the women who were attending 
for antenatal care had also been unintend-
ed.2 In the United States (US) it is estimated 
that 49% of all pregnancies are unintend-
ed.3 In addition to the personal distress that 
some women may experience as a conse-
quence of this, unintended pregnancy re-
sults in substantial costs to health services.4, 
5 In the US, it is estimated that there are 3.11 
million unintended pregnancies annually, 
costing 4.6 billion dollars each year and 
that 53% of these costs were attributable to 
imperfect contraceptive adherence.5 Whilst 
a large proportion of unintended pregnan-
cies occur in those not using any method 
of contraception, a significant number re-
sult from incorrect or inconsistent use of 
a method. In almost half of all unintend-
ed pregnancies identified in a US study in 
2001, a method of contraception was be-
ing used during the month that conception 
1Department of Reproductive 
and Developmental Sciences 





L. MICHIE 1, 2, S. T. CAMERON 1, 2
Improving the uptake of long acting 
reversible contraception: 
a review
Across the world rates of unintended preg-
nancy are high. Unintended pregnancy not 
only results in substantial costs to health 
services, it can lead to personal distress for 
women experiencing this. Whilst a large 
number of unintended pregnancies occur in 
those not using any method of contracep-
tion, a proportion occur in women using a 
contraceptive method incorrectly or incon-
sistently. Long acting reversible methods of 
contraception such as the IUD, IUS, contra-
ceptive implant and contraceptive injectables 
are the most effective methods of contracep-
tion. In spite of this, they are under-utilized 
by women in developed countries. Educating 
women and health professionals, and dispel-
ling myths about these methods may improve 
their acceptability. Furthermore, facilitating 
uptake by ensuring that a range of contracep-
tive providers are trained and able to provide 
to women without undue delay, particularly 
in the immediate post abortion and postpar-
tum period, may also be effective strategies 
to improve uptake, and prevent more unin-
tended pregnancies.
Key words: Contraception - Contraception, bar-
rier - Pregnancy, unplanned.
Worldwide, estimations of rates of unin-tended pregnancy are high. Approxi-
mately 85 million unintended pregnancies 
occur annually and 33 million of them are 
thought to be in women using a contracep-
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took place.6 Although many contraceptive 
options are available to women, long act-
ing reversible methods are thought to be 
amongst the most effective as they require 
minimal patient adherence following initia-
tion. Reported rates of failure of contracep-
tion vary with perfect use and typical use, 
since methods that rely on user compliance 
are more likely to be used incorrectly or 
inconsistently. The percentage chance of a 
woman becoming pregnant within a year 
using either intrauterine contraception or a 
contraceptive implant, is the same with both 
perfect and imperfect use (0.2% and 0.05% 
chance of pregnancy, using Levonorgestrel 
intrauterine system (LNG-IUS) and the con-
traceptive implant respectively).7 Converse-
ly, with use of combined hormonal methods 
(pill, patch or ring), the chance of an unin-
tended pregnancy is 26 times greater with 
typical use compared to perfect use (0.3% 
and 8% chance of pregnancy, within a year 
with perfect and typical use respectively).7 
Furthermore, a large systematic review of 
studies reporting contraceptive efficacy 
from 1990 onwards, concluded that long-
acting hormonal contraceptives (LNG- IUS 
and implants) were as effective as female 
sterilisation and were closely followed in ef-
fectiveness by copper intrauterine devices 
with ≥300mm2 surface area.8
The term “Long Acting Reversible Con-
traception”, commonly referred to as LARC, 
has been defined in a United Kingdom (UK) 
National Guideline as “contraceptive meth-
ods that require administration less than 
once per cycle or month”.9 In the UK, LARC 
is taken to include; copper intrauterine de-
vices (IUD), progestogen-only intrauterine 
systems (IUS), progestogen-only injectable 
contraceptives, progestogen-only subder-
mal implants and combined vaginal rings.9 
Another term that has been used less com-
monly, to describe methods of contracep-
tion that don’t require any active interven-
tion before three years of use, is ‘forgettable 
contraception’. However, this additionally 
includes non-reversible sterilisation and ex-
cludes both progestogen-only injectables 
and the contraceptive vaginal ring.10 In the 
United States, LARC methods are described 
as those with a long duration of action and 
no need for active adherence following ini-
tiation. This takes into account both intrau-
terine devices and contraceptive implants.11 
For the purpose of this review, LARC meth-
ods will include IUD/IUS, contraceptive 
implants and progestogen-only injectables. 
This article will cover the barriers to uptake 
of these methods of contraception, and po-
tential strategies to overcome them in the 
developed world.
Rates of uptake
Comparison of rates of use of specific 
contraceptive methods between countries 
can be difficult, as a result of differences 
in design, methods and implementation of 
the population surveys used to obtain such 
data.12 Furthermore, some countries have 
data available that is more up to date than 
others. Nevertheless, uptake of LARC can 
be seen to vary across the world. In the 
UK, the most recent national data available 
from the Office for National Statistics sexual 
health survey, in 2008/2009, indicated that 
75% of women aged 16-49 yrs were cur-
rently using a method of contraception. 
However, in this survey the proportion of 
women using LARC methods were low, 
with 6% using an IUD or IUS, 3% using the 
progestogen-only injectable and only 1% 
using an implant.13 Estimations from the US, 
from a population survey in 2006/2008, are 
similarly low. Whilst 78.6% of women are 
using contraception, just 5.3% use an IUD 
or IUS, 1.4% use a contraceptive injectable 
and only 0.7% use an implant.12 Conversely, 
reported rates of use of intrauterine contra-
ception are as high as 40.6% in China (data 
from a 2006 population survey), 36.1% in 
Egypt (data from 2008) and 22.7% in France 
(data from 2004/2005) of women aged 16-
49 years of age who are either married or 
in a union.12 Likewise, in some countries 
the use of the contraceptive injectable is far 
higher at 28.4% in South Africa (data from 
2003/2004) and 31.8% in Indonesia (data 
from 2007).12 Across the world, reported use 
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uterine contraception was a drawback.15 
Whilst many doctors may perceive that a 
method of contraception that can be fitted 
and forgotten about, such as both intrauter-
ine methods and contraceptive implants, is 
beneficial, some women disagree. Women 
described feeling a loss of control of their 
contraception as they required it to be both 
fitted and removed by a health professional, 
and furthermore they expressed concerns 
that it felt less reliable as they could not 
see it once fitted.15 A survey undertaken 
in the US, specifically targeted adolescent 
and young women to determine their at-
titudes towards intrauterine contraception 
(IUC).16 In response to advice from the 
American College of Obstetrics and Gyne-
cology (ACOG) to consider IUC as first-line 
contraception in adolescents, the investiga-
tors sought to study the views of women 
aged 14-27 years to identify how realistic 
this might be. Of the 252 women surveyed, 
98% had previously had sex, although none 
of them had previously used an IUD/IUS. 
Less than half (45%) had heard of an IUD/
IUS, and following a brief description of 
an IUD/IUS, only 26% expressed some de-
gree of interest in using it in future. Similar 
negative perceptions were evident again, 
including fear of pain at insertion and the 
requirement for a health professional to fit 
and remove the device.16 Since several stud-
ies suggest that negative myths and miscon-
ceptions about intrauterine contraception 
are responsible for their poor uptake, a fur-
ther UK study sought to identify to what 
extent these beliefs are held.17 Over 100 
women requesting a termination of preg-
nancy at a hospital clinic in Scotland, UK, 
completed an anonymous questionnaire. 
The questionnaire contained 12 negative 
statements regarding IUD/IUSs and women 
were asked to indicate their level of agree-
ment with each. The statements women 
were most likely to agree with were that 
an IUD/IUS is painful to be inserted (34%), 
and that it could move around inside the 
body (24%). However, many women opt-
ed to neither agree nor disagree with the 
statements (ranging from 26-56%). A further 
25% indicated they were actually consider-
with Norway reporting the greatest use, at 
3.3% of women aged 16-49 who are married 
or in a union (data from 2005).12 Although 
many of the most recently available popula-
tion surveys reporting contraceptive use are 
now over 5 years old, and uptake of LARC 
methods may have increased in these coun-
tries since their publication, it is clear that 
more needs to be done to increase their use 
further in certain parts of the world.
Possible barriers to the use of LARC
Patient’s knowledge and attitudes towards 
LARC
There are several possible explanations 
for the low uptake of LARC methods in 
some countries. It has been shown that 
women lack accurate knowledge about 
the individual types of LARC and often 
hold negative attitudes towards them.14-16 
Qualitative research from the UK identified 
a common theme of women having little 
accurate knowledge about individual meth-
ods, instead relying on information relayed 
to them by friends and family.14 In this study 
conducted in Scotland in 2007 the views of 
55 women of varying ages, were sought 
during focus group discussions with regard 
to the acceptability of LARC (injectable/ 
IUD / IUS / Implant). In addition to limited 
knowledge, it was apparent that women 
were also concerned about the potential 
side effects of these methods, and in many 
cases these concerns were based upon the 
past negative experiences of friends. Even 
after providing women with accurate infor-
mation, concerns remained and only a mi-
nority (25%) expressed any interest in using 
LARC in the future.14 Similarly, in a separate 
qualitative study a lack of knowledge and 
fear of possible side effects, were amongst 
the common themes identified during inter-
views with ten women specifically about in-
trauterine contraception.15 Further concerns 
were anxiety about fitting of an IUD and 
of the risk of infection with an IUD. Addi-
tionally, this study highlighted that women 
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contraception with women, possess inaccu-
rate knowledge, or lack the skills to coun-
sel women about or administer LARC meth-
ods, then clearly an opportunity to increase 
their uptake via patient education is lost. 
A further survey of general practitioners in 
London, UK, concerning their knowledge 
and attitudes about the LNG-IUS, highlight-
ed again that misconceptions about this 
method are prevalent.19 In this survey, 17% 
of the 71 surveyed, incorrectly agreed the 
LNG-IUS would increase the risk of pelvic 
inflammatory disease (PID), whilst 23% be-
lieved it to increase the risk of an ectopic 
pregnancy. When asked regarding their first 
line choice of contraception for a young 
(<25 years of age) nulliparous women only 
8% stated a LARC method, none opted for 
LNG-IUS and the majority (92%) chose the 
pill.19 Amongst the Canadian counterpart 
to UK GPs, Family Physicians (FPs), it was 
also clear that many incorrectly believed 
misconceptions about IUDs.20 Over 60% of 
respondents incorrectly felt ectopic preg-
nancy and PID were major risks of using 
an IUD. Once again, the majority (>70%) 
would not recommend use of an IUD to 
nulliparous women.20
There is also evidence that gynaecologists 
may hold misconceptions about intrauter-
ine contraception.21-22 A 2002 survey of Fel-
lows of American College of Obstetricians 
and Gynecologists, regarding knowledge of 
and attitudes towards IUD, identified that 
nearly a third (29%) believed that the IUD 
increased the risk of PID by 10% or more.21 
It was also suggested that US gynecologists 
feared litigation from such grossly exagger-
ated beliefs about risks with use of an IUD, 
which in turn presented a barrier to uptake 
of the IUD.21 A more recent survey, showed 
that such misconceptions about the IUD 
still prevailed among gynaecologists in the 
US from 2008.22 Negative attitudes towards 
the IUD and other methods of LARC, might 
mean that health professionals are unlikely 
to promote these methods and may even 
perpetuate incorrect negative views of in-
trauterine contraception in patients. Beliefs 
that LARC methods such as the IUS/IUS 
are not suitable for young or nulliparous 
ing the use of an IUD/IUS following abor-
tion.17 This reinforces previous findings that 
women lack accurate knowledge about this 
method and suggests that negative views of 
intrauterine contraception may not be held 
as strongly as once thought. Health pro-
fessionals therefore have the opportunity 
to educate women, and dispel myths and 
misconceptions where they do exist, about 
both IUD/IUS and other LARC methods.
Health professionals’ knowledge and atti-
tudes towards LARC
Although health professionals may well 
have the opportunity to educate potential 
users of LARC about its benefits, it is also 
clear that lack of accurate knowledge and 
the skills required to provide these meth-
ods also exists among health profession-
als themslves.18-21 Following a recommen-
dation by the National Institute of Clinical 
Health and Excellence (NICE) in the UK, 
that increased use of LARC methods could 
decrease unintended pregnancy rates, the 
views of doctors and nurses working in 
general practice (main providers of con-
traception in the UK) were sought with 
regard to LARC.18 Respondents to this sur-
vey regarded LARC methods as safe, easy 
to use and rated them highly for efficacy 
compared to non-LARC methods. However, 
they ranked LARC lower than the combined 
pill, for acceptability. Misconceptions were 
prevalent in both doctors and nurses about 
side effects of these methods, with a sig-
nificant proportion of respondents incor-
rectly believing that the contraceptive im-
plant could cause weight gain and a delay 
in return to fertility. Disappointingly, 58% of 
male and 35% of female doctors stated they 
would not consider a contraceptive implant 
as a first line method for women in any age 
group, and 46% of male and female doctors 
would not consider the injectable as first 
line. This may in part be related to the high 
proportion of doctors in the survey (81% 
of male and 45% of female doctors) who 
felt they saw too few patients to maintain 
the skills to insert implants.18 If the health 
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as difficulty in travelling to a contraceptive 
provider, particularly for women who may 
live in remote or rural areas.27, 28 Difficulty 
with access to services or the requirement 
to travel a distance to attend, is a particular 
barrier to the use of the injectable method 
of contraception since it requires to be ad-
ministered by a health professional every 
ten (NET-EN) or twelve (DMPA) weeks. 
Even for those women where access to serv-
ices is not a particular problem, they may 
be less inclined to use it if they perceive 
regular 3 monthly visits to be an inconven-
ience. There is some evidence that the po-
tential ability to self -administer the inject-
able method could increase its acceptability 
and possibly uptake of this method.29 In a 
survey of women attending a family plan-
ning clinic in Scotland, 61% of women sur-
veyed stated they would prefer to attend a 
clinic less often for contraceptive supplies.29 
Two-thirds of the women who were current 
users of the injectable, expressed a theo-
retical preference to use a preparation that 
they could self-inject at home. In the same 
survey, a significant proportion of ex-users 
and never users of the method stated they 
would consider using it again, if it were 
available for self-administration.29
Contraceptive services in remote and/ 
or rural areas (even in developed nations) 
may also have difficulty in providing LARC 
to women, due to having fewer providers 
or lacking the provider training that is more 
easily available in urban areas.28 In a sur-
vey of both urban and rural family planning 
providers at Title X clinics (those providing 
free contraceptive services) in Texas, pro-
viders in urban areas were more likely to 
report that they were well trained in LARC 
methods (75%) compared to rural providers 
(57%).28
Strategies to increase the 
uptake of LARC
It is evident that barriers exist which may 
hinder efforts to increase the uptake of the 
most effective forms of contraception, al-
though there are various approaches which 
women are particularly worrisome, since 
these women are arguably at greatest risk 
of unintended pregnancy and would ben-
efit from the most effective method. It is 
possible therefore, that better training and 
knowledge about these methods among 
health professionals could increase uptake 
of LARC in women.
Accessibility and cost of LARC
There are national practice recommen-
dations, advising health professionals to 
provide counselling to all women about all 
contraceptive methods including LARC, in 
the UK and the US.9, 23 Additionally, World 
Health Organisation policy aims to elimi-
nate systemic barriers to contraceptive serv-
ices and increase access to modern con-
traception.24 Unfortunately, the uptake of 
LARC remains limited in some areas and in 
certain groups of women, as a result of dif-
ficultly accessing it and high costs. In the 
UK, contraception has been provided free 
of prescription charges as part of the Na-
tional Health Service since the 1970s. Fur-
thermore, women do not require to pay any 
consultation fees to receive contraception, 
and have the option of attending a range 
of providers, including their general practi-
tioner or community sexual health clinics.9 
In contrast, in the US and other parts of the 
world, women may be faced with high up-
front costs for LARC methods.23 The abil-
ity to provide these methods and the actual 
cost women may require to pay, can de-
pend upon the level of health insurance she 
has, if any, and the LARC methods available 
to her at the clinic she opts to attend. Some 
free or low-cost clinics may not be able to 
fund and therefore provide these methods 
to all women.25, 26 There is evidence in the 
US that women of low-income status, (im-
plied by virtue of receiving public health 
insurance), are significantly more likely to 
undergo sterilisation following a pregnancy 
rather than use LARC.27 This may not simply 
reflect higher upfront costs with LARC, but 
may also reflect other barriers to access that 
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the US, the ACOGs “LARC program” works 
to ensure health professionals have access 
to the most up to date information and re-
sources through provision of training and 
training materials and an E-newsletter.33 
The “LARC program” is a national strategy 
of the ACOG, and in addition to providing 
information and guidance on LARC meth-
ods to health providers via the college web-
site, it involves various activities nationally 
which aim to promote and increase the up-
take of LARC.33
A large prospective cohort study un-
dertaken in St Louis in the US, known as 
CHOICE, which has now been the sub-
ject of several publications, involved sev-
eral measures with the aim of promoting 
the use and increasing the uptake of LARC 
(which included intrauterine contraception 
and the contraceptive implant).25, 34-36 The 
Contraceptive CHOICE Project aimed to 
recruit a cohort of 10000 women aged 14-
45 yrs, of age, and provide them with any 
reversible contraceptive method of contra-
ception that the woman chose at no cost 
for a three year period. In addition to ob-
taining the method free of charge, all par-
ticipants read information about the safety 
and effectiveness of LARC and underwent 
in-depth, evidence based, contraceptive 
counselling by trained contraceptive pro-
viders before they chose their method. In 
addition to removing the barrier of cost 
and providing education about LARC to all 
women at enrolment, LARC was made more 
accessible to many women as the CHOICE 
project was widely available in many out-
patient facilities throughout the region. All 
participants were followed up by telephone 
at three months, six months and then six 
monthly intervals until three years.34 Over a 
four year period from 2007-2011, over 9000 
women were recruited, with a mean age of 
25 years. One third had only high school 
education or less, almost half were nullipa-
rous and almost two thirds reported a pre-
vious unintended pregnancy.35 The authors 
suggested that the demographics of this co-
hort of women indicated they were at high 
risk of unintended pregnancy. The major-
ity (75%) of participants recruited opted for 
could be taken to try to overcome them. 
Strategies to improve women’s knowl-
edge of LARC methods may result in a 
more positive attitude towards LARC. This 
was demonstrated in a study conducted in 
the US in 2006, where a team of investi-
gators devised a three minute educational 
intervention about the IUD for women at-
tending general obstetric and gynaecology 
clinics.30, 31 The intervention consisted of 
brief oral information about intrauterine 
contraception, including; its effectiveness, 
risks, benefits, effects on fertility and men-
struation, length of use and difference be-
tween the two different types and use of a 
plastic model IUD to explain the insertion 
procedure. The investigators showed that 
following the intervention, over half of all 
participants (54%) had a positive attitude 
towards IUDs compared to 15% before the 
intervention. Furthermore, even in women 
who had prior knowledge of the IUD, the 
proportion with a positive attitude towards 
them rose significantly from 38% to 64%.31 
The authors concluded that all sexually ac-
tive young women could benefit from brief 
education about the IUD.31 Previous quali-
tative research has identified that some of 
the factors that women take into account 
when choosing their method of contracep-
tion include; their perception of safety, effi-
cacy, reliability, ease of use, side effects and 
reversibility.14 Therefore the provision of 
accurate information about LARC, including 
reassurance of the safety, reliability, ease of 
use and reversibility of these methods, in 
addition to a clear explanation of side ef-
fects that are common and those that are 
not, may result in increased interest in the-
ses methods.
However, improving knowledge and atti-
tudes amongst patients will remain difficult 
if a poor knowledge or negative attitudes 
prevail amongst the health professionals 
who provide contraception. National prac-
tice guidelines, which recommend the use 
of LARC in women of all ages, and provide a 
clear guide for health professionals to refer 
to when considering their use, aim to elimi-
nate the misconceptions that exist amongst 
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ganisation defines youth friendly services as 
being equitable, accessible, acceptable, ap-
propriate and effective for young people.37 
Strategies to make services youth friendly 
include convenient locations and opening 
hours, age appropriate educational materi-
als and specific training of health profes-
sionals working within these services in 
adolescents and young adults. A team of in-
vestigators in the US aimed to identify youth 
friendly services within publicly funded fa-
cilities, and the relationship of LARC-related 
services in these settings versus non youth 
friendly services.38 Out of just over 600 serv-
ices that were surveyed, 78% were deemed 
as youth friendly sites. Respondents from 
these sites, were significantly more likely 
to indicate that LARC methods were typi-
cally discussed during a contraceptive visit 
with teens/young adults, and additionally 
that LARC provision had increased in their 
services, compared to sites that were not 
deemed as “youth friendly”.38 This study 
thus highlights that it is important to take 
account of the specific needs of teenagers 
and young adults when designing contra-
ceptive services as increased interest in and 
attendance at youth friendly services, will 
result in greater opportunities to educate 
them about LARC, and consequently in-
creased uptake of LARC.
The development of a subcutaneous form 
of Depo-Provera as an injectable method of 
contraception, lends the possibility of self-
administration, so removing the barrier of 
access for some women to this method.29, 
39, 40, 41 Three studies have investigated the 
feasibility of self-administration of subcuta-
neous DMPA.40, 41, 42 Continuation rates at 1 
year at 12 months were high (74% US and 
88% UK studies) and most women found 
the injections to be convenient (95%), 
easy (87%) and would recommend them 
to others (94%). The third study showed 
that self-administration of this subcutane-
ous injectable was feasible even in teenag-
ers after brief training.42 The possibility to 
self administer may not only be attractive 
to women but could potentially help to 
prevent unintended pregnancies for some 
women who might otherwise miss an injec-
an IUD/IUS or implant as their choice of 
contraception (46% chose LNG-IUS, 12% 
chose Cu-IUD, 17% chose contraceptive 
implant). If those choosing DMPA were in-
cluded in this total (7%), then 82% of par-
ticipants chose LARC as defined in this re-
view.35 This level of uptake for methods of 
LARC is significantly higher than both the 
most recent nationally reported US uptake 
rates, and reported uptake in many other 
parts of the world.12 This strongly suggests 
that when you remove potential barriers 
to these methods, uptake will increase. Of 
course, emulating this rise in use of LARC 
would obviously be more difficult in prac-
tice when it is not part of a large, regional, 
well organised and well funded research 
study. The CHOICE study also analyzed 12 
months of follow-up data in over 5000 par-
ticipants, to estimate continuation rates and 
satisfaction with intrauterine contraception 
and implants. It has been noted in previ-
ous research that some health professionals 
may have concerns about high discontinu-
ation rates with these methods.18 However, 
in this analysis, discontinuation rates were 
significantly higher among women not us-
ing a long acting method than in those us-
ing an IUD/IUS or implant (45% vs. 14% 
in IUD/IUS or implant users). Furthermore, 
those using LARC were significantly more 
likely to be satisfied with their method at 12 
months (84% satisfied vs. 53% satisfied on 
non-LARC users).36 This may help to allevi-
ate the concerns some health professionals 
may have about user dissatisfaction or dis-
continuation of LARC, and thus they may be 
more inclined to promote LARC use.
Unintended pregnancy is particularly 
high amongst teenagers and young adults 
(age 14-24 years).6 Specific measures to 
improve access to, increase awareness of 
and increase interest in LARC within this 
age group are therefore important. As al-
ready discussed, national guidelines and 
recommendations which reassure health 
professionals of the safety, benefits and 
acceptability of LARC in adolescents and 
young adults, go one step towards this.9, 23, 
32 Provision of youth friendly services may 
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ices on very few occasions, it may be the 
only opportunity to educate them about the 
benefits of LARC and dispel any miscon-
ceptions. In a survey of women requesting 
abortion in the US about their views on re-
ceiving contraceptive advice, two thirds of 
those surveyed expressed a desire to leave 
the abortion facility with a contraceptive 
method or supplies.48 Additionally, over 
60% of women expressed an interest in us-
ing a LARC (IUD/IUS/Implant) method in 
the future.48 In a study from the UK, of pro-
vision of specialist contraceptive advice to 
women at the time of abortion compared to 
standard care, enhanced advice and provi-
sion was associated with an increase in the 
uptake of LARC at this time.49 Similarly, in 
New Zealand, an intervention that involved 
updating medical staff about LARC, pro-
moting these methods to women and then 
providing them free of charge, significantly 
increased the uptake of LARC post-abortion 
from 44% to 61%.50 Insertion of intrauterine 
contraception is feasible at the time of sur-
gical abortion. However, it is not standard 
practice for insertion to occur at the time of 
medical abortion; particularly if the woman 
leaves the abortion facility after medication 
has been administered, going home to pass 
products of conception. In these circum-
stances, arrangements therefore require to 
be made for her to return for insertion of 
intrauterine contraception at a later date, 
if she opts for this. However, it has been 
shown that many women will not return 
for such appointments.51 One review of 
over 200 women referred following medical 
abortion, over a two and a half year period, 
indicated only 53% attended.51 Aiming for 
early insertion at one week post abortion, 
as opposed to delayed insertion, is one 
potential strategy to increase the propor-
tion of women who will attend. Insertion 
of intrauterine contraception at one week 
post medical abortion has been shown to 
be as safe as delayed insertion.52, 53 Moreo-
ver, in two separate studies where women 
were randomised to either early (1 week) 
or delayed (3-4 weeks) insertion follow-
ing medical abortion, significantly more 
women returned for insertion in the early 
tion because they unable to get to a sched-
uled clinic appointment. A further benefit 
of a subcutaneous form of Depo-Provera, 
aside from the option of self-administration, 
is the potential for it to be administered by 
a range of health professionals including 
community pharmacists.43 This was shown 
to be feasible in a pilot study in the US, 
whereby 50 women were randomised fol-
lowing an initial dose in clinic, to receive 
two subsequent doses of subcutaneous De-
po-Provera at either the same clinic or at 
a community pharmacy. Continuation rates 
with the second and third injections were 
similar in both settings and follow-up sur-
veys showed no significant differences in 
patient satisfaction with location, conven-
ience, privacy and respect from providers.43 
For those women who are not keen to self-
administer, attendance at a pharmacy in a 
location suitable for them would offer an-
other option.
The use of LARC following 
abortion and postpartum
Provision of counselling regarding con-
traceptive methods and access to a wide 
range of contraception immediately follow-
ing an abortion, is an important component 
of abortion care.1 Increasing evidence has 
emerged in recent years that immediate up-
take of LARC following an abortion, reduc-
es the incidence of repeat abortions.44-47 In 
one such study, of just under 1000 women 
attending for abortion in Scotland in 2008, 
the chance of a further abortion in the sub-
sequent two years was 20 times less with 
the use of intrauterine contraception post 
abortion, compared to the oral contracep-
tive pill. The risk of further abortion was 
16 times less with use of the contraceptive 
implant compared to the pill.44 Therefore, 
strategies to increase the uptake of LARC 
immediately following abortion care im-
portant. Furthermore, this is a time when 
women may be more motivated to use such 
methods and may welcome the opportunity 
to discuss LARC.48 For a small number of 
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with women, and service providers take 
these factors into account when organising 
their care, we may be more successful in 
initiating highly effective contraception in 
a group of women who would gain great 
benefit from it. Immediate insertion of con-
traceptive implants or intrauterine contra-
ception postpartum may avoid the problem 
of women failing to return for insertion in 
the weeks following delivery. In a study of 
adolescent mothers from the US, those who 
chose to have a progestogen only implant 
inserted soon after childbirth were shown 
to have good continuation rates with this 
method, and were significantly less likely to 
become pregnant again within 12 months 
compared to counterparts using other meth-
ods.58 A Cochrane Database Review, of nine 
randomised controlled trials of immediate 
postpartum insertion of IUDs, found this to 
be safe and effective.59 Although expulsion 
rates may be slightly higher than with inter-
val insertion, the added advantages of im-
mediate insertion include; highly motivated 
women at this point in time, assurance the 
women is not pregnant and convenience.59
Conclusions
Long acting reversible methods of con-
traception are amongst the most effective 
methods available to women, yet uptake 
rates are low. Aside from cost issues, improv-
ing knowledge and dispelling misconcep-
tions about LARC in women will be impor-
tant to increase demand for these methods. 
However, improved education and training 
for health providers regarding LARC is also 
necessary to ensure this occurs. Providing 
women with information promoting the 
benefits of LARC through social marketing 
can empower women to choose the most 
effective methods for themselves. Taking 
measures to ensure services meet the needs 
of specific groups, such as the provision 
of LARC in a youth friendly setting, may 
further enhance uptake. Similarly, offering 
LARC methods immediately or shortly fol-
lowing abortion and postpartum, targets 
women who may be highly motivated to 
group.52, 53 Therefore arranging for women 
to return for insertion of an IUD/IUS post 
medical abortion, sooner rather than later, 
is likely to have a greater impact on increas-
ing uptake.
It has been estimated that around 40% of 
women will have resumed vaginal sex by 6 
weeks post-partum, and there is some evi-
dence that this figure may be even higher 
amongst teenage mothers.54, 55 The post-
partum period is therefore an important 
time to initiate contraception and may be 
another opportunity within which the up-
take of LARC could be increased. Guid-
ance is available for health professionals 
regarding the timing of initiation of LARC 
postnatally, and to reassure them of their 
safety and benefits.9, 32. A recent survey of 
800 postpartum women in North Carolina, 
US, showed that a high proportion of moth-
ers (38%) were intending to use either an 
implant or an intrauterine device as contra-
ception;56 a figure that is much higher than 
most recent estimates of use of LARC na-
tionally in the US.12 Factors associated with 
intention to use LARC were if the index 
pregnancy had originally been unintended 
and if they had no desire for another baby 
within two years. Clearly however, there 
is no guarantee that intent to use these 
methods actually translates into increased 
use of them. One retrospective review of 
postpartum contraception in California, 
US, highlighted this. Although over 40% of 
women intended to use a highly effective 
method of contraception postpartum, of 
this group, only just over a third had actu-
ally established a LARC method by 8 weeks 
postpartum.57 Potential barriers to LARC 
uptake in the postpartum period include 
the same barriers as at other times, namely; 
lack of patient or provider knowledge, cost 
and access. In addition, significant change 
to a woman’s home life with the birth of 
a baby and possibly medical issues such 
as post-operative wound care, establishing 
breastfeeding and infant health concerns, 
may also supersede concerns about contra-
ception at this time.58 If health profession-
als bear these additional problems in mind 
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Riassunto
Migliorare la comprensione dei metodi contraccet-
tivi reversibili a lunga durata d’azione: una review
In tutto il mondo, i tassi di gravidanze non pro-
grammate sono elevati. Le gravidanze non pro-
grammate non solo comportano notevoli costi per 
i servizi sanitari, ma possono anche essere fonte di 
angoscia per le donne che le affrontano. Nonostante 
un gran numero di gravidanze non programmate si 
verifichi in donne che non utilizzano alcun metodo 
contraccettivo, parte di esse si verifica in donne che 
utilizzano un metodo contraccettivo in maniera sba-
gliata o irregolare. I metodi contraccettivi reversibili 
a lunga durata d’azione, come i dispositivi intrau-
terini (IUD), i sistemi intrauterini (IUS), gli impianti 
contraccettivi e le sostanze iniettabili, rappresentano 
i metodi contraccettivi più efficaci. Nonostante ciò, 
essi sono sottoutilizzati dalle donne nei paesi svilup-
pati. Educare le donne e gli operatori sanitari, eli-
minando le leggende su tali metodi può migliorare 
la loro accettabilità. Inoltre, agevolare la compren-
sione, garantendo che una serie di operatori siano 
addestrati e capaci di fornire assistenza alle donne 
senza eccessivo ritardo, in particolare subito dopo 
l’aborto e il parto, può anche essere una valida stra-
tegia per migliorare la comprensione e prevenire un 
maggior numero di gravidanze non programmate.
Parole chiave: Contraccezione - Contraccezione, 
barriera - Gravidanza non programmata.
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ABSTRACT
Background Immediate initiation of an
intrauterine device (IUD) or intrauterine system
(IUS) following termination of pregnancy (TOP) is
associated with a significant reduction in the risk
of another TOP. In spite of its high efficacy,
uptake of intrauterine contraception in the UK is
low. Myths and misconceptions about the
method may contribute to the low uptake.
Study design Anonymous, self-administered
questionnaire among women requesting a TOP
in a hospital abortion service in Scotland, UK.
Methods Misconceptions about intrauterine
contraception were extracted from an online
social networking and micro-blogging service,
and from existing research to develop a
questionnaire containing 12 negative statements
about intrauterine contraception. Respondents
indicated their level of agreement with each
statement.
Results A total of 106/125 (85%) women
requesting a TOP completed the questionnaire.
The two commonest negative statements that
respondents agreed with were that the IUD/IUS
‘Is painful to have inserted’ (n=36; 34%) and
that ‘It can move around inside your body’
(n=25; 23.6%). The range of women who
neither agreed nor disagreed with negative
statements was 26.4–56.0%. Twenty-seven
(25%) women indicated that the IUD/IUS was
their planned method of post-TOP
contraception.
Conclusions Although myths about
intrauterine contraception persist among a small
proportion of women requesting a TOP, lack of
knowledge about the method is also evident.
The consultation prior to TOP is an important
opportunity to provide accurate and quality
information to women about the IUD/IUS that
may serve to increase uptake and prevent repeat
abortions.
Key message points
▸ Only a minority of women requesting a
termination of pregnancy (TOP) hold
misconceptions about intrauterine
contraception, although knowledge of
the method is lacking.
▸ The consultation prior to TOP is an
important opportunity to provide
accurate and quality information to
women about intrauterine contracep-
tion that may serve to increase uptake
of this method and protect women
from a further TOP.
INTRODUCTION
The use of intrauterine contraception,
either as an intrauterine device (IUD) or
hormone-releasing intrauterine system
(IUS), varies significantly across the world.
Worldwide use was most recently esti-
mated to be 14%, although this rises in
some countries with rates as high as 37%
in Eastern Asia.1 2 The UK, however, has
much lower rates of use of intrauterine
contraception (6% using an IUD and 2%
using an IUS in 2010).3 Intrauterine
contraception is considerably less popular
in the UK than either oral contraception
or condoms.3 A systematic review of the
literature regarding contraceptive efficacy
found the IUS to be as effective as female
sterilisation, and the IUD was rated
second to the IUS for effectiveness.4
In 2011, the rate of abortion per 1000
women aged 15–44 years was 12.0 in
Scotland and 17.5 in England and
Wales.5 6 National guidance from the UK
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recommends that increasing uptake of intrauterine
contraception has the potential to reduce the number
of termination of pregnancies (TOP).7 There is also
global evidence that immediate initiation of intrauter-
ine contraception at the time of TOP is associated
with a significant reduction in the likelihood of subse-
quent TOP.8–10 In 2011, 29% of women having an
abortion in Scotland and 35% in England and Wales
had at least one previous TOP.5 6 Increased uptake of
intrauterine contraception among women having a
TOP could therefore play an important role in redu-
cing this repeat abortion rate. Unfortunately, myths
and misconceptions about intrauterine contraception
may account for the low uptake of this method in the
UK.11 12
In order to determine what proportion of women
seeking TOP hold misconceptions about the IUD/IUS
we conducted a survey among women requesting
TOP at a hospital abortion service at the Royal
Infirmary of Edinburgh (RIE), Edinburgh, Scotland,
UK. The RIE is the main provider (80%) of abortion
services in Lothian (Edinburgh and surrounding area).
In 2011, 2416 induced abortions were conducted in
Lothian.5 The purpose of the study was to provide
information to help guide health professionals in
developing effective educational strategies that may
increase positive attitudes towards intrauterine contra-
ception, so that more women may consider this as a
method of ongoing contraception after a TOP.
METHODS
In order to help to develop a short questionnaire for
women to complete regarding their beliefs about intra-
uterine contraception, two separate sources were used
to identify common misconceptions women may have.
First, statements about intrauterine contraceptives
were taken from unpublished transcripts of interviews
undertaken with young people aged 13–21 years
during 2000–2004 as part of an evaluation of a
national teenage pregnancy strategy.13 Second, we
extracted negative statements about the IUD/IUS from
an online social networking and micro-blogging
service (Twitter) by conducting two searches 10 days
apart in December 2011. The search terms used were
‘IUD’, ‘intrauterine device’, ‘IUS’, ‘mirena’, ‘coil’ and
‘paragard’. Statements were identified that discussed
the IUD, although those that used the term in an unre-
lated meaning were not included. By reviewing these
sources common themes were identified regarding
women’s views towards, and concerns about, the IUD/
IUS. This allowed us to create a questionnaire compris-
ing a short introductory paragraph followed by 12
negative statements about the IUD/IUS. During
January and February 2012, women attending the RIE
clinics requesting a TOP were given the questionnaire
by one of the clinic nurses and invited to complete it
and place it in an opaque sealed envelope in a collec-
tion box. The questionnaires were completed by
women prior to either ultrasound scan or consultation
with medical staff in the clinic, and they therefore were
not aware of what method of TOP they could have (if
at all), and had not discussed contraception with any
medical staff in the clinic at that point. The question-
naire was anonymous and self-completed and required
a response to each statement on a five-point Likert
scale ranging from ‘strongly agree’ to ‘strongly dis-
agree’. Further questions sought demographic informa-
tion including age, postcode area of residence (used to
obtain a Carstairs deprivation category score)14 and
previous and intended contraceptive use.
Statistics
All the data were coded and entered onto a database
using Microsoft Excel™. Data were entered into the
database by a research nurse and the data were
checked and coded by one of the authors (LM).
Responses to each statement were combined such that
‘strongly agree’ and ‘somewhat agree’ were grouped as
‘agree’, while ‘strongly disagree’ and ‘somewhat dis-
agree’ were grouped as ‘disagree’. The remaining
group of responses were ‘neither agree nor disagree’.
Data analysis was performed using IBM Statistical
Package for Social Sciences (SPSS) software V.18 (IBM
Corporation, New York, NY, USA). Demographic data
were obtained including means and standard devia-
tions. To allow statistical comparison between age
groups, four age groups were defined: 0–19, 20–24,
25–34 and 35+ years. Comparisons were made using
Fisher’s exact test as counts within the individual cells
of the contingency table fell below 5. Statistical sig-
nificance was deemed to be p<0.05.
Ethical approval
The questionnaire was reviewed by the chair of a local
research ethics committee who confirmed that ethical
approval was not required for this study.
RESULTS
A total of 106 completed questionnaires were obtained
from 125 distributed (an 85% response rate). The age
of respondents ranged from 15 to 42 years and their
demographics are shown in Table 1. Seventy-eight per
cent of women (n=83) had used more than one method
of contraception previously, and eight (8%) women had
previously used an IUD or IUS in the past (Table 1).
Regarding future planned use of contraception, three
(3%) women intended to use no contraception and two
(2%) were uncertain. Of those respondents (n=101)
who were intending to use contraception, the methods
planned included oral contraceptive pill (n=33; 31%),
IUD or IUS (n=27; 25%), progestogen-only implant
(n=26; 24%), barrier methods (n=26, 24%),
progestogen-only injectable (n=13; 12%), combined
hormonal contraceptive patch (n=3, 3%) and sterilisa-
tion (n=2, 2%). Parous women were significantly more
likely to indicate that they planned to use an IUD/IUS
Article
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for future contraception compared to nulliparous
women (p=0.009). Women who had previously had a
TOP were also significantly more likely to choose the
IUD/IUS as a future method when compared to women
with no history of TOP (p=0.039). Women who had
used an IUD/IUS as a contraceptive method previously
were significantly more likely to choose this as future
contraception (p=0.003).
The 12 statements presented to the women and the
responses to each statement are shown in Table 2.
Agreement with negative statements ranged from 2.8%
to 34.0%. The range in percentage of women who
neither agreed nor disagreed with each negative state-
ment was 26.4–56.0%. The statements that most
women agreed with were that ‘It is painful to have
inserted’ (34.0%) and that ‘It can move around inside
your body’ (23.6%). Responses were compared
between women who had previously used an IUD or
IUS and those who had never used these methods.
Women who had used previously used intrauterine
contraception were significantly more likely to disagree
with Statement 5 (‘There is a good chance it can make
you infertile’) than those who had not (p=0.03).
There was no significant difference in responses
between these groups for all other statements. Women
aged 19 years and under (n=24) were significantly
more likely to agree with Statement 1 (‘It is painful to
have inserted’) compared to women in any other age
group (p=0.037). There were no significant associa-
tions between any demographic factors tested (i.e. age
group, deprivation category score, reproductive
history) and agreement with any other statements.
DISCUSSION
Our study showed that only a small percentage of
women requesting a TOP agreed with the negative
statements about intrauterine contraception, suggest-
ing that only a minority of these women held major
misconceptions about this method. Our study did,
however, show that approximately one-third of
women ‘neither agreed nor disagreed’ with the state-
ments, which may suggest a lack of knowledge about
intrauterine contraception amongst this group. Thus
the TOP consultation does offer a good opportunity
to provide information about this most effective
method of contraception that has been shown to
reduce the risk of a subsequent TOP.8–10 Some health
professionals may worry that women requesting a
TOP may not wish to discuss contraception at this




Mean (SD) 25 (6.4)
Range 15–42
Deprivation Category score*
1–2 Affluent 15 (14.2)
3–5 Moderate 77 (72.6)




Previous abortion 36 (34.0)
Previous methods of contraception ever used
Condom 98 (92)
Oral contraceptive pill 74 (74)
Progestogen-only implant 16 (15)
Progestogen-only injectable 12 (11)
Intrauterine device/system 8 (8)
Combined hormonal patch 5 (3)
None 4 (4)
*Deprivation Category is a marker of deprivation in Scotland based upon
postcode area of residence.
SD, standard deviation.





1 It is painful to have inserted 36 (34.0) 59 (56.0) 11 (10.0)
2 It is only suitable for women who have had children 8 (7.5) 40 (37.8) 58 (54.7)
3 It is not suitable if you have had more than three children 3 (2.8) 53 (50.0) 50 (47.2)
4 Can only be used in older women 4 (3.8) 38 (35.8) 64 (60.4)
5 There is a good chance it can make you infertile 3 (2.8) 45 (42.5) 58 (54.7)
6 There is a good chance it can damage the womb 17 (16.0) 36 (34.0) 53 (50.0)
7 There is a good chance it can damage the ovaries 6 (5.7) 44 (41.5) 56 (52.8)
8 It can rust inside you 8 (7.5) 36 (34.0) 62 (58.5)
9 It can move around inside your body 25 (23.6) 28 (26.4) 53 (50.0)
10 There is a high chance it might fall out 16 (15.1) 40 (37.7) 50 (47.2)
11 It can get stuck on the baby’s head if you become pregnant 6 (5.6) 36 (34.0) 64 (60.4)
12 It is a breeding ground for infection 17 (16.0) 47 (44.4) 42 (39.6)
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time, or that they may feel under pressure to accept
contraception in order to obtain agreement to have an
abortion. However, there is good evidence that
women value the opportunity to discuss contraception
at this visit and do no feel coerced into accepting a
method of contraception.15 Although the consulta-
tions to discuss TOP may be lengthy and the time
available to discuss contraception is short, there is evi-
dence from the USA that even brief (3 minutes) oral
educational interventions about the IUD/IUS can
improve knowledge and positivity about this
method.16–18 Furthermore, women seeking a TOP
find that information about contraception imparted
from viewing a digital video disk (DVD), rather than a
face-to-face consultation with a health professional, is
highly acceptable at this time.15
In our study the most common misconceptions
about intrauterine contraception that women agreed
with were that the IUD/IUS is painful to have inserted
and that it can move around inside your body. This
may indicate that health professionals need to concen-
trate on providing accurate information and reassur-
ance to women about these issues. In particular, oral
analgesia or local anaesthesia for insertion can be dis-
cussed with women, as is recommended by the
Faculty of Sexual & Reproductive Healthcare guid-
ance.19 Women can also be reassured that the likeli-
hood of an IUD/IUS perforating the uterus is rare.19
The demographic characteristics of women partici-
pating in our survey were similar to that of previous
studies of women attending for TOP in our region.10
In addition, our finding of 8% of women having pre-
viously used an IUD/IUS is in keeping with rates of
uptake of intrauterine contraception in the UK.3
More surprising was the finding that 25% of respon-
dents were considering using an IUD/IUS following a
TOP. A study of ongoing contraception post-TOP
from our service in 2008 showed that 9.5% of
women had an IUD/IUS inserted immediately follow-
ing a TOP.10 It is possible that this apparent increase
in ‘interest’ in intrauterine contraception in our
current study may reflect the impact of a Scottish
Government sexual health strategy that used social
marketing to promote awareness of the most effective
long-acting methods of contraception.20 Our surveys
were anonymous, so it is unlikely that women felt
compelled to indicate interest in this method of
contraception. It does, however, suggest that the con-
sultation prior to a TOP is a good opportunity for
health professionals to provide accurate information
to women about the IUD/IUS, since motivation to use
this method may be high and its uptake may protect
women from a subsequent TOP. Although clearly our
study was limited by sample size, the findings do add
weight to the importance of abortion care providers
being trained and funded to be able to provide the
IUD/IUS to women at the time of abortion, if they
wish this and if it is appropriate to do so.10
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Background To provide standardised
information about the contraceptive implant
(Nexplanon®), a digital video disc (DVD) was
developed for use within a sexual and
reproductive health (SRH) service in Edinburgh.
The aim was to determine if the accuracy of
information recalled after watching a DVD was
comparable to that following a face-to-face
consultation, and if patients found the use of a
DVD acceptable.
Methods Fifty women attending an SRH service
abortion clinic considering using Nexplanon for
the first time agreed to be randomised to receive
information about the implant either by (a) a
DVD (n=35) developed using information taken
from Faculty of Sexual & Reproductive Healthcare
guidance or (b) a face-to-face consultation
(n=15). A structured interview was conducted
immediately following the DVD/face-to-face
consultation and by telephone 3 months later.
A small number of participants from each group
attended for in-depth interview.
Results Knowledge recall (e.g. expected side
effects) immediately following each intervention
was similar in both groups. Most of the women
who watched the DVD felt it was helpful (89%),
easy to understand (94%) and acceptable (69%).
Subsequently 76% of participants were
contacted successfully at 3 months. The majority
of those who had watched the DVD agreed that
it had been informative (93%) and would be
happy to receive contraceptive information via a
DVD in future (93%).
Conclusions The use of a DVD to provide
patient information on Nexplanon is acceptable
and informative, and may enhance patient
consultations. A large randomised controlled trial
may determine if provision of quality
standardised information via DVD can improve
uptake or continuation rates of long-acting
reversible methods of contraception.
INTRODUCTION
Unintended pregnancy is common. In
Scotland in 2013 there were 11 777
therapeutic abortions1 and around 30%
of pregnancies are unplanned.2 Most
could have been prevented by use of
effective contraception. Unlike other
medical treatments (e.g. antihypertensive
drugs, antibiotics) it is the individual user
who chooses their contraceptive method.
This choice is likely to be based on infor-
mation received from friends, family or
the media, just as much as from health
professionals.3 The effectiveness of a
contraceptive method is contingent upon
its correct and continued use, and this is
vitally dependent on its acceptability to
the user. It seems logical that the provi-
sion of good-quality information about a
contraceptive method and what might be
expected during its use should improve
both correct use and continuation rates;
however, there is little evidence for this,
and none from the UK.4
Providing detailed information about a
contraceptive method takes time to do
well, but for many health care providers
Key message points
▸ The use of an audio-visual digital video
disc (DVD) to provide patient informa-
tion on the contraceptive implant is
acceptable and informative and may
enhance patient consultations.
▸ Women who watched the DVD felt it
was helpful and easy to understand,
and they would be happy to watch a
DVD for information provision again.
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consultation times are short. Health care providers
have different levels of training and education and
may place emphasis on different aspects of a contra-
ceptive method. Furthermore, the content of the con-
sultation may vary depending upon organisational
factors such as whether the patient is the first or last
to be seen that day. Consequently the quality of infor-
mation women receive about a contraceptive method
may be of variable quality, may sometimes be inaccur-
ate, and may reflect the bias of the provider.
In NHS Lothian, the sexual and reproductive health
service (SRH) has used digital video discs (DVDs) in
the clinic for several years to provide information
about vasectomy, intrauterine contraception and abor-
tion. This ensures that patients receive accurate and
standardised information in an audio-visual format. In
a questionnaire survey of women requesting abortion
who received information via DVD, women rated
highly the content of the DVD and the acceptability
of receiving information in this way.5 However, the
effectiveness of a DVD for information giving, nor
how it compares to a traditional face-to-face consult-
ation for information provision, has not been formally
evaluated.
To provide standardised, quality information about
the contraceptive implant (Nexplanon®), a DVD was
developed for use at Chalmers Sexual Health Centre
SRH service, NHS Lothian. The information included
on the DVD was taken from the Faculty of Sexual &
Reproductive Healthcare Clinical Effectiveness Unit
Guidance on contraceptive implants,6 and covered
mode of action, insertion, removal, contraindications,
risks and side effects. The DVD’s content was agreed
by clinicians working in the service and the DVD
was made with technical assistance from the Medical
Photographic Department, NHS Lothian. The DVD
was piloted among stakeholders and minor modifica-
tions were made. The final version lasted 9 minutes.
We conducted a pilot study that was designed to
determine whether women found receiving informa-
tion about Nexplanon via the DVD acceptable and
informative. We wished to ascertain how the amount
and accuracy of information recalled after watching a
DVD compared to that following a face-to-face con-
sultation with a clinician, and if the information given




All women aged ≥16 years, attending Chalmers
Sexual Health Centre from January to June 2013 for
medical abortion, and considering using Nexplanon,
were invited to participate. Following a routine con-
sultation and after arrangements had been made for
the abortion procedure, the clinician determined eligi-
bility for Nexplanon, according to UK Medical
Eligibility Criteria for Contraceptive Use.7 Exclusion
criteria included previous use of the contraceptive
implant and the need for an interpreter during the
consultation. A member of the research team provided
further written and verbal information about the
study before written consent was obtained from
women agreeing to participate. Fifty women consider-
ing starting Nexplanon for the first time were
recruited.
Interventions and randomisation
Participants were randomised to be given information
about Nexplanon, either by DVD (35 women) or in
a traditional one-to-one face-to-face consultation
(15 women) with either a doctor or nurse (control
group). Because this was a pilot study, a randomisation
scheme allocating more participants to the interven-
tion than the control group was chosen to improve
the power in the intervention group without seriously
affecting the power for between-group comparisons.
A clinician provided women in the control group with
information about Nexplanon according to their
routine practice. Women randomised to the DVD
watched it in the consultation room. When the DVD
had finished, the clinician returned to the consulting
room, thus providing an opportunity for women to
ask any questions, and women wishing to undergo
implant insertion were scheduled for this procedure
following the abortion. Randomisation was done at
the time of recruitment using sequentially numbered
opaque sealed envelopes produced by a computer-
generated randomisation sequence. Due to the nature
of the intervention it was not possible to blind either
the research team or the participant to the allocated
intervention. Women were offered a £10 voucher if
they were successfully contacted 3 months later for
telephone interview.
Follow-up
Immediately following the consultation all women
underwent a structured interview with a single
researcher. A standard proforma was used to record
demographic information, previous contraceptive
use and what information the subject had gleaned
from the consultation and its accuracy. The overall
acceptability of the consultation was determined
using a Likert8 scale to quantify descriptors including
‘helpful’, ‘easy to understand’ and ‘confusing’.
Three months following the initial intervention all
the study participants were contacted about participat-
ing in a short standardised telephone interview, lasting
≤5 minutes, conducted by the same member of the
research team (LM), Three attempts at contact were
made using the telephone numbers provided, at
varying times of the day. Women were asked which
contraceptive method they had chosen following the
intervention. Women who had Nexplanon inserted
were asked if the implant matched their expectations,
particularly with respect to side effects and bleeding
Article
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patterns. All the women were asked about their
experience of taking part in a randomised trial, and
those in the DVD group were additionally asked
about their experience of using a DVD as a means of
receiving information.
Qualitative methods
At the time of the telephone interview all the women
were invited to attend for a further in-depth interview
with a member of the research team (LM or AJ), which
was designed to explore in more detail their feelings
about participating in a research study and the use of a
DVD for information provision compared with a trad-
itional consultation. Four women who watched the
DVD and four who did not watch the DVD agreed to
attend. A topic guide was used to structure each inter-
view, based on the key areas described above. Women
were offered a £20 voucher if they attended for in-depth
interview. Interviews were conducted between May and
August 2013 at Chalmers Sexual Health Centre, and
lasted approximately 30 minutes. Interviews were audio-
recorded and transcribed verbatim. Data were organised
by cross-sectional indexing. After all the interviews had
been conducted the data were analysed using thematic
analysis.9
Statistics
A sample size of 35 subjects was allocated to the DVD
group to allow estimation of percentage rates of
acceptability and recall to within a standard error of
around 8%. The power for the randomised compari-
son to 15 controls is low, but sufficient to give a high
chance of detecting a statistically significant major dif-
ference between the two groups of the order of 40%.
The allocation of unequal numbers of participants to
the two groups was to improve the power for estima-
tion within the DVD group without greatly decreasing
the power for the between-group comparisons. All the
data, including demographic data recorded at recruit-
ment and at telephone follow-up, were coded and
entered onto a Microsoft Excel™ database by LM and
checked by AJ. Descriptive statistics were obtained
including means and standard deviations (SDs). Rates
of acceptability and recall in both groups were calcu-
lated. Comparisons were made using Chi square (χ2)
tests or Fisher’s exact test where appropriate counts
within individual cells of the contingency table fell
below a value of five. Statistical significance was
deemed to be p<0.05.
Ethical approval
The Scotland A Research Ethics Committee (12/SS/
0075) approved the study in May 2012.
RESULTS
Only 8/58 women asked to participate declined,
giving a recruitment rate of 86%. Seven women had
no time to participate, while one declined as she did
not wish to be randomised to watch the DVD. The
mean age of participants was 24 (SD 5.5) years.
Thirty-five women were recruited to the DVD arm
of the study and 15 to the control arm. There were
no statistically significant demographic differences
between the two groups (Table 1).
Immediately following either the DVD viewing or
the face-to-face consultation all the women were
asked four multiple-choice questions to test informa-
tion recall. Recall was similar in both groups in
response to three of the questions (Table 2); however,
respondents in the control group incorrectly expected
mood and/or skin changes to be common side effects
with Nexplanon compared to respondents in the
DVD group.
All the participants were asked if they intended to
proceed to implant insertion after the abortion pro-
cedure; 43 (86%) women stated that they did [30
(86%) and 13 (87%) in the DVD and control groups,
respectively]. The remainder was uncertain, and no
woman definitely decided not to have Nexplanon
inserted. DVD participants were asked to respond to a
series of statements relating to the DVD itself.
Thirty-one (89%) women agreed it was helpful, 33
(94%) agreed it was easy to understand and 24 (69%)
felt it was an acceptable way in which to receive infor-
mation compared to a face-to-face consultation.
Thirty-four (97%) women disagreed that the DVD
was confusing, and only one felt neutral. Asked to







Mean (SD) 24 (5.3) 23 (5.9)
Range 16–36 17–34
DepCat Score* [n (%)]
1–2 (Affluent) 3 (9) 1 (7)
3–5 (Moderate) 25 (71) 13 (87)
6–7 (Deprived) 7 (20) 1 (7)
Smoker [n (%)]
No 19 (54) 10 (67)
Current 13 (37) 4 (27)
Ex 3 (9) 1 (7)
Previous birth [n (%)] 12 (34) 5 (33)
Previous abortion [n (%)] 11 (31) 3 (20)
Previous contraception use [n (%)]
None 2 (6) 0
Condoms 32 (91) 14 (93)
Combined (pills/patch) 26 (74) 14 (93)
Progestogen-only pill 11 (31) 0
Contraceptive injection 3 (9) 1 (7)
Intrauterine method 2 (6) 1 (7)
*The DepCat Score is a marker of deprivation in Scotland based upon
postcode area of residence, scoring from 1 (least deprived) to 7 (most
deprived).15
DVD, digital video disc; SD, standard deviation.
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rate the usefulness of the information that they had
received via the DVD on a scale from 0 (least useful)
to 10 (most useful), responses ranged from 5 to 10,
with a mean score of 9 out of 10.
Thirty-eight (76%) women were successfully con-
tacted and interviewed 3 months later, 27 (77%) from
the DVD group and 11 (73%) from the control
group. There were no statistically significant demo-
graphic differences between the women interviewed
and those not. Of those women with no completed
follow-up at 3 months, one no longer lived in the UK,
two had an incorrect number documented on their
contact sheet, two answered but declined to proceed
with the interview and seven had no answer after
three attempts. The mean time to telephone interview
from recruitment was 92 (SD 3.9, range 88–104) days
(i.e. 13 weeks). Of those women completing tele-
phone follow-up, 34 (89%) had an implant inserted,
25 (93%) and nine (82%) in the DVD and control
groups, respectively. A further two women in the
DVD group stated they still intended to get the
implant fitted at a later date, and two in the control
group stated they had changed their mind due to con-
cerns about using a ‘foreign object’ (n=1) or concern
about possible bleeding patterns (n=2). While nine
(26%) women remained happy with their implant, 10
(29%) were uncertain about it, eight (26%) were
having some problems and seven (21%) were
unhappy (Table 3). Women who experienced side
effects were asked if the information received had led
them to expect these side effects. Over 60% of those
experiencing side effects in the DVD group stated that
they did not expect to experience side effects to this
extent, while the majority (83%) of women in the
control group did, although this difference did not
reach statistical significance (Table 3). Side effects
described included bleeding problems (15), mood
changes (8), concern about amenorrhoea (1), pain/irri-
tation at the site of implant insertion (2) and skin
changes (1). By 3 months’ follow-up, five (20%)
women in the DVD group who had Nexplanon fitted
had already had the implant removed, while all nine
women in the control group continued to use
Nexplanon. This difference was not statistically sig-
nificant (p=0.29). Women in the DVD group were
again asked about their experience; 27 (93%) agreed
that the DVD was informative and that they would be
happy to use a DVD for information provision again.
Two (7%) women disagreed with these statements.
In-depth interviews
One of the four women in the control group failed
to attend; consequently three in-depth interviews
were conducted in the control group, and four in the
intervention group. All seven respondents still had
Nexplanon in situ at the time of the interview.






Q1: Length of licence limit
of implant?
1 year 0 0
3 years 33 (94) 15 (100) 1.0
5 years 2 (6) 0
Q2: The implant works by
inhibiting ovulation?
Yes 28 (80) 11 (73)
No 1 (3) 0 0.63
Uncertain 6 (17) 4 (27)
Q3: Common side effects to
expect with implant?
Weight gain 6 (17) 5 (33) 0.27
Irregular bleeding 29 (83) 15 (100) 0.16
Amenorrhoea 28 (80) 14 (93) 0.41
Mood or skin changes 2 (6) 8 (53) 0.0004
Q4: There can be a delay
in return to fertility?
Yes 14 (40) 2 (13)
No 15 (43) 10 (67) 0.17
Uncertain 6 (17) 3 (20)
Bold figure denotes significance.
DVD, digital video disc; Q, question.






Happy with implant 6 (24) 3 (33)
Uncertain about implant 6 (24) 4 (44)
Having some problems with implant 6 (24) 2 (22)
Not happy at all with implant 7 (28) 0
If side effects experienced, do they meet expectations from information provided?
Yes 7 (37) 5 (83) 0.09
Not to the extent I have experienced 9 (47) 0
No, not at all (n=women in whom side effects present) 3 (16) (n=19) 1 (17) (n=6)
DVD, digital video disc.
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The respondents in both groups generally viewed
the information provided to them, either by DVD or
via face-to-face consultation, as sufficient. All four
respondents who watched the DVD thought it was
useful and helpful as a means of information provi-
sion (Box 1). However, there also seemed to be con-
sensus that a DVD could not entirely replace a
traditional consultation, as women also valued the
opportunity to ask questions of someone face-to-face
(Box 2). Some suggestions were made about improv-
ing the DVD, including the inclusion of endorsements
from women who have already used an implant and
the use of graphics to demonstrate insertion and
mechanism of action. All the respondents felt that
having the DVD available to watch via a website
would be useful (Box 3).
All the respondents expressed positive views about
participating in clinical research and all would agree
to do so again if asked. Respondents appeared to have
no concerns with the concept of being randomised
and understood the purpose of it.
DISCUSSION
This pilot study demonstrates that using a DVD to
provide information about the contraceptive implant
is both acceptable and informative. The majority of
participants who watched it felt that the DVD was
both helpful and easy to understand, and rated it
highly with a mean score of 9 out of 10 points for
usefulness. Although information recall was similar
for both the DVD and control groups, more women
in the control group incorrectly thought that side
effects comprising mood/skin changes were common.
This highlights the variation in counselling that can
occur in face-to-face consultations. The majority of
respondents in the DVD group, when asked at
follow-up 3 months later, stated that they would be
happy to watch a DVD for information provision
again. Participants from both groups who returned for
in-depth interview were happy with the quality of
information provided to them at their initial consult-
ation, and those who watched the DVD felt it was
useful and helpful. Previous research on the use of a
DVD to provide information about abortion to
women had similar findings, namely that women
rated receiving information via DVD highly.5 Some
sexual health services have adopted the use of DVDs
routinely, and have reported that men find this prefer-
able to attending an outpatient appointment for vasec-
tomy pre-operation counselling.10
While research relating to the use of a DVD in
contraceptive counselling is limited, the use of ‘apps’
providing information about contraception, including
long-acting reversible contraception (LARC), that
patients can access via a smartphone or tablet com-
puter prior to a consultation, have proved acceptable
for information provision, and may increase knowl-
edge and interest in effective forms of contracep-
tion.11 12 Similarly, a computer-based contraceptive
assessment module, with the use of additional specif-
ically tailored health materials, may positively influ-
ence contraceptive choice and potentially improve
contraceptive continuation and adherence.13 14
Our qualitative research revealed some possible
factors to consider if producing DVDs for patient
information provision. The inclusion of endorsements
from women who have previously used the contracep-
tive method may aid decision-making. The use of case
studies showing other patients’ experiences was well
liked by men who used a DVD for vasectomy counsel-
ling.10 The use of animated graphics demonstrating
the mode of action of contraceptive methods and,
where relevant, insertion and removal procedures,
Box 2 In-depth interview quotes: possible disad-
vantages to digital video disc (DVD) use
“I thought it was quite good. I have to say I don’t
think I was taking it all in. Some information to
take away would be ideal; something to think
about later if you had questions because the DVD
doesn’t give you the opportunity to ask questions
there and then.” [DVD group]
“You don’t have the option to ask someone
face-to-face if you have any questions.” [Control
group]
Box 1 In-depth interview quotes: positive feed-
back from digital video disc (DVD) group
“I think it covered everything and it was good
because it mentioned loads of other things.”
“I was happy with the DVD. I would say it covered
everything so I am quite happy with it.”
Box 3 In-depth interview quotes: suggestions for
further development
“Maybe getting some other people’s comments
instead of just showing the demonstration and
talking about it. To get some different ages of
women and girls commenting on how it’s affected
them personally and how it’s benefited them.”
[DVD group]
“I think it would be a great idea. It would make it
really accessible and people could go back time and
time again if they had something else they wanted
to know or if they wanted to double check some-
thing.” [DVD group – regarding use of a DVD on a
website]
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may also be helpful (but expensive to produce). It was
clear that women appreciate having the opportunity to
ask questions of health professionals, and to have
information provided to them to take away to read, or
possibly watch, later. It is not our intention that DVDs
should replace face-to-face consultations completely,
rather they could enhance these. A health provider
will always be required to issue the chosen method of
contraception thus allowing questions to be asked, but
after watching a DVD or similar technology the result-
ant questions should be better informed and more
focused. The concept of having DVDs available to
watch on a relevant website, either before or after a
consultation, was welcomed by women in our study.
There are limitations to this pilot study, namely the
select population that we recruited from and the small
number of participants. We chose to recruit women
attending a clinic for abortion, as this is a time when
counselling about contraceptive use, and particularly
encouraging the use of LARC methods, is vitally
important. Although the sample was small, we did
achieve a high recruitment rate, and our aim in this
small pilot study was to determine if using a DVD for
information provision was feasible and acceptable,
with a view to considering initiating a larger multicen-
tre study at a later date. Neither the research team nor
the study participants were blinded to the intervention
to which they were randomised. Women requiring an
interpreter were excluded from participation, which
did of course eliminate a segment of the population.
In any further larger-scale studies it would be import-
ant to consider producing DVDs in languages other
than English, although this would be expensive.
This pilot study has shown that the use of audio-
visual DVDs to provide patient information about the
contraceptive implant is acceptable and informative,
and can be used to enhance face-to-face patient
consultations rather than replace them altogether.
A large-scale randomised controlled trial is now
needed to determine if provision of quality standar-
dised information via DVD can improve uptake and/
or continuation rates of LARC and save time during
consultations, a factor that we did not evaluate.
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Objectives Most women who use emergency
contraception (EC) do so because of
unprotected sexual intercourse or condom failure
and so remain at risk of pregnancy unless they
commence an effective method of
contraception. In Great Britain, increasingly
women now choose to obtain EC from a
pharmacy; however, pharmacists do not
currently provide effective ongoing
contraception. We sought to determine the
views of women obtaining EC from pharmacies
and clinicians working in sexual and
reproductive health care (SRH) about the
possibility of pharmacists providing a temporary
supply of a progestogen-only pill (POP)
together with EC.
Methods Self-administered, anonymous
questionnaires of (1) women requesting EC from
pharmacies in Edinburgh, Scotland and (2) SRH
clinicians attending a major UK scientific
meeting.
Results A total of 211/232 women completed
questionnaires in pharmacies (a 91% response
rate). Of those women not using a hormonal
method of contraception at the time of EC
(n=166; 79%), almost half (44%) wished to use
an effective method. Most women (64%) agreed
that the option of a pharmacist being able to
supply a POP would have been helpful. Among
the SRH clinicians, 110 completed questionnaires
out of 150 distributed (a 73% response rate).
The majority of respondents (92%) were positive
about a pharmacist supplying a POP at the time
of EC.
Conclusions A reasonable proportion of women
requesting EC would like to start using an
effective contraceptive method. Both the women
and the SRH clinicians we surveyed are positive
about the option of a short supply of a POP
being provided by the pharmacy in the UK
together with EC.
INTRODUCTION
The majority of women who require
emergency contraception (EC) do so fol-
lowing unprotected sexual intercourse
(UPSI) or an accident when using a
condom.1 2 A smaller proportion of
women may have had a mishap with a
hormonal method of contraception (e.g.
missed pills).1 2 Increasingly, women in
Great Britain prefer to attend a pharmacy
for EC rather than a sexual and repro-
ductive health (SRH) service or general
practitioner (GP).3 Levonorgestrel EC has
been available free of charge without a
prescription from pharmacies since 2008
in Scotland4 and 2011 in Wales.5 In a
recent trial comparing two oral emer-
gency contraceptives fewer than 3% of
women became pregnant, and so the vast
majority of women remain at risk of
pregnancy after they have used EC.6
Key message points
▸ Only a minority of women presenting
for emergency contraception (EC) are
using an effective method of contra-
ception at the time.
▸ Many women presenting for EC wish
to use effective ongoing contraception
and welcome the possibility of a
supply of the progestogen-only pill
(POP) from the pharmacist following
EC.
▸ The majority of clinicians working in
sexual and reproductive health care are
positive about the possibility of phar-
macists providing a limited supply of
the POP at the time of EC.
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A few women get pregnant in the same menstrual
cycle from sexual intercourse after taking EC. In a
meta-analysis that included 11 trials of just under
5000 women who had sexual intercourse after using
EC but before the return of menses (i.e. in the same
cycle) the relative risk of pregnancy was 2.67 (2.11–
3.39) when compared with women who did not have
sex after using EC.7 Starting an effective ongoing
method of contraception after EC use is clearly
important if women are to avoid unintended preg-
nancy. Community pharmacists in the UK and most
other industrialised countries are usually unable to
provide any ongoing contraception except condoms,
which are available for purchase. Two mystery
shopper studies have shown that while pharmacists
are good at adhering to protocols for providing EC,
only a minority of them provide women with advice
about ongoing contraception.8 9
Little is known about the views of women who
present for EC on the use of regular, effective
methods of contraception. In order to determine such
views, and estimate the proportion of women using
EC that may wish to start a method of effective
contraception, we designed a questionnaire for
women to complete when they attended a pharmacy
for EC. We also sought to determine the views of
women attending for EC, and clinicians working in
sexual and reproductive health care (SRH), on the
possibility of a pharmacist being able to provide
women with a limited supply of progestogen-only oral
contraceptives at the time of EC, allowing the women
time to arrange an appointment to obtain a long-term
contraception method.
METHODS
Two separate one-page, self-completed questionnaires
were designed: (1) a questionnaire offered to women
presenting to any of nine community pharmacies with
a request for EC in January 2013 and (2) a question-
naire distributed to delegates (SRH clinicians) at the
Faculty of Sexual and Reproductive Healthcare
(FSRH) UK scientific meeting in May 2011. A short
introductory paragraph explained the purpose and
anonymous nature of both questionnaires. Selected
community pharmacies in the City of Edinburgh and
Lothian region (in Scotland) had participated in a clin-
ical study aimed at increasing the uptake of regular
contraception after EC in 2012.10 Nine pharmacists
participating in that study, who dispensed EC to more
than 10 women per month, agreed to participate in
the questionnaire study. Pharmacists in Scotland can
prescribe and dispense EC to women free of charge
under a preapproved patient group direction (PGD),
although they are required to complete additional
training related to sexual health and contraception to
enable them to do so.11 Women were offered the
questionnaire by the pharmacist at the time of EC
consultation, and once completed placed it in a sealed
collection box before leaving the pharmacy. All ques-
tionnaires were numbered to allow us determine the
response rate. At the FSRH scientific meeting ques-
tionnaires were distributed during a plenary session
and collected from delegates at the end of the session.
Both questionnaires, which included limited demo-
graphic data, required simple tick box responses,
however additional space was provided for free text
comments in response to certain questions. Delegates
were asked to indicate how they felt about a limited
supply of a progestogen-only oral contraceptive pill
(POP) being offered to women presenting for EC.
Responses included extremely positive, positive,
neutral, negative and extremely negative. For the pur-
poses of analysis, extremely positive and positive
results were combined, as were negative responses.
Statistics
All the data were coded and entered onto two separ-
ate databases using Microsoft Excel™. Data analysis
was performed using the IBM Statistical Package for
Social Sciences (SPSS) software V.18 (SPSS Inc.,
Chicago, IL, USA). Demographic data were obtained
including means and standard deviations (SDs) where
appropriate. To allow statistical comparison between
age groups in the questionnaire conducted in the
pharmacies four age groups were defined: 14–19, 20–
24, 25–34 and 35 years and over. Comparisons were
made using Chi square (χ2) test or Fisher’s exact test
where appropriate if counts within the individual cells
of the contingency table fell below 5. Statistical sig-
nificance was deemed to be p<0.05.
Ethical approval
The questionnaire for women attending pharmacies
for EC was reviewed by the scientific officer of the
local research ethics committee, who confirmed that
ethical approval was not required as the questionnaire
was an opinion survey seeking views of patients on a
health care issue. Ethical approval was not required
for the questionnaire distributed at the scientific
meeting as the responses were anonymous.
RESULTS
Pharmacy questionnaire
A total of 211 completed questionnaires were
obtained from 232 distributed to women attending
pharmacies for EC (a 91% response rate). The mean
age of respondents was 23 (range 14–48; SD 5.6)
years. For 59 women (28%) this was the first time
they had taken EC; 151 (72%) had used it before and
one person (0.5%) did not answer the question.
Significantly more women aged 14–19 years were
using EC for the first time compared to women aged
35 years and over (Table 1). The mean number of epi-
sodes of ever-use of EC was 2 (range 1–7) and for use
in the past 12 months was 1 (range 1–4).
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The majority of women (n=140; 66%) were using
condoms as their contraceptive method at the time of
requesting EC, whilst 45 (21%) were using a hormo-
nal method and 26 (12%) were using no contracep-
tion (Figure 1). The majority of respondents (n=163;
77%) stated they were currently in a sexual relation-
ship at the time of using EC. Almost one-third of
respondents (n=66; 31%) required EC on this occa-
sion because of UPSI, whilst almost half of them
(n=99; 47%) reported a condom failure (Table 2).
There were no significant associations between
respondents’ age and method of contraception used,
reason for use of EC or relationship status.
All the women were asked if they would like to
start using a regular method of contraception other
than condoms and, if so, from where they would
choose to obtain it. Of the 166 women who were not
already using a hormonal method of contraception at
time of EC, 73 (44%) women would like to do so
(Figure 1). Most commonly women would choose to
Table 1 Previous use of emergency contraception (EC) by women attending a pharmacy for EC provision
First ever use [n (%)] Use in past 12 months [n (%)]
Age (years) n (%) Yes No Missing data Yes No Missing data
14–19 59 (28) 27 (46)* 32 (54) 0 24 (41) 32 (54) 3 (5)
20–24 83 (39) 20 (24) 62 (75) 1 (1) 23 (28) 50 (60) 10 (12)
25–34 58 (27) 11 (19) 47 (81) 0 20 (34) 33 (57) 5 (9)
≥35 11 (5) 1 (9)* 10 (91) 0 3 (27) 8 (73) 0
Total 211 (99) 60 (28) 151 (72) 1 (0.5) 70 (33) 123 (58) 18 (9)
*p=0.006.
Figure 1 Flowchart of contraceptive use on presentation at a pharmacy for emergency contraception (EC) provision and interest in
the use of a regular method of contraception.
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obtain contraception from their GP (family doctor)
(n=80; 48%), while 12 (7%) would attend a family
planning clinic; four (2%) did not state a preference;
seven (4%) would attend a sexual health service for
young people and seven (4%) were unsure where they
would go. One-third (n=52; 31%) of the women
chose not to answer this question. Three women
stated they would choose to obtain contraception
from a pharmacy, while one woman stated she wished
to go “somewhere no one knows her” to obtain
contraception.
Women were asked if it would have been helpful
for the pharmacist to provide a 1-month supply of a
POP to allow them time to attend elsewhere for
ongoing contraception. The majority of respondents
(n=135; 64%) agreed that this would have been
helpful, 25 (12%) women felt it would not be, 38
(18%) were unsure and 13 (6%) did not respond.
Significantly more young women (aged 14–19 years)
felt a supply of a POP would have been helpful, com-
pared to women aged 35 years and over (80% vs
18%; p=0.002). Fifteen women added free text com-
ments to their response to this question. Five women
made positive comments stating that this was a good
idea, and three women commented that it would be
helpful as it was difficult to obtain an appointment
with their GP to discuss contraception. The reasons
given by the seven women who stated that it may not
be helpful included problems using the POP in the
past (n=2); a wish to avoid a hormonal method
(n=1); concern about possible side effects (n=2); a
preference to discuss contraceptive methods with a
doctor (n=1) and concern that a medical condition
they had might contraindicate use of the POP (n=1).
Scientific meeting questionnaire
A total of 110 questionnaires were completed from
150 distributed at the FSRH scientific meeting (a
73% response rate). The majority of respondents were
female (88%) and 90% were doctors (Table 3). When
asked how they felt about the concept of a pharmacist
being able to provide a 28-day supply of a POP at the
time of EC the majority (n=101; 92%) felt positively
about this, whilst six (5%) were neutral and three
(3%) were negative. There were no statistically
significant differences in views about this concept so
far as gender, age group and work roles were con-
cerned. Respondents were invited to provide add-
itional free comments about this concept. Six made
comments reaffirming their view that this is a good
idea with benefits for women. Concerns expressed
included that this may lead to a decrease in the use of
long-acting reversible methods of contraception
(LARCs) (n=2) or an increase in the use of EC (n=2),
and two delegates stated that they would still prefer
women to be reviewed by a medical professional in
order to discuss all available methods of contraception
and undergo testing for sexually transmitted infections
where appropriate. Concern was also expressed that
pharmacists would require adequate training to enable
them to dispense the POP and advise women correctly
(n=4).
DISCUSSION
Our study confirmed previous findings that the major-
ity of women presenting for EC do so either following
UPSI or as a result of condom failure.1 2 Given the
small number of women using effective contraception
at the time of EC, and the fact that more than 75% of
the survey respondents were in an ongoing sexual
relationship, we can assume that the majority of them
remained at risk of unintended pregnancy.
Reassuringly, however, our study did identify that
Table 2 Relationship status and reason for emergency contraception (EC) use by women attending a pharmacy for EC provision
In a sexual relationship [n (%)] Reason for EC use [n (%)]
Age (years) n (%) Yes No Unsure UPSI Condom failure Forgot regular method Missing data
14–19 59 (28) 43 (73) 11 (19) 5 (8) 23 (39) 25 (42) 11 (19) 0
20–24 83 (39) 64 (77) 17 (20) 2 (2) 26 (31) 37 (45) 19 (23) 1 (1)
25–34 58 (27) 48 (83) 7 (12) 3 (5) 15 (26) 29 (50) 13 (22) 1 (2)
≥35 11 (5) 8 (73) 2 (18) 1 (9) 2 (18) 8 (73) 1 (9) 0
Total 211 (99) 163 (77) 37 (18) 11 (5) 66 (31) 99 (47) 44 (21) 2 (1)
UPSI, unprotected sexual intercourse.
Table 3 Demographics of respondents at a Faculty of Sexual
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almost half of the women not already doing so would
wish to use an ongoing method of contraception, sug-
gesting that there is potential to target this sizeable
group of women to increase contraceptive use follow-
ing EC. Our results suggest that significantly more
young women (<20 years of age) were using EC for
the first time compared to older women (>35 years
of age), and that significantly more women welcomed
the option of a supply of a POP at the time of EC.
Although the number of women aged 35 years or over
was small and there is the possibility this may have
resulted by chance, it suggests that younger and poten-
tially more vulnerable women may be receptive to
simple interventions to increase contraceptive uptake.
Research has shown that pharmacists are good at
supplying EC, and that women rate community phar-
macy EC services highly.9 12 However, research has
also identified that pharmacists are not particularly
good at providing advice about ongoing contracep-
tion, and some women have expressed concerns about
receiving advice in the pharmacy about future contra-
ception.9 12 13 A recent study in London, UK con-
cluded that when pharmacists were trained to provide
oral contraception by means of an approved PGD
they were competent in doing so and women were
satisfied with this additional service.14 Simple inter-
ventions within the pharmacy that may encourage and
help women to start effective contraception after EC
have also been the subject of recent research.15 We
considered the possibility of a pharmacist providing a
limited supply of a POP, allowing women time to
arrange an appointment with a health care profes-
sional to discuss contraception further. We suggested
offering a POP rather than a supply of the combined
oral contraceptive pill (COC) since the list of contra-
indications to a POP is very small, making it more
suitable for pharmacy provision.16 The concept was
welcomed by the majority of women presenting for
EC and also by the SRH clinicians. Women commen-
ted on the difficulty in obtaining an appointment with
their GP, and that this could serve as interim measure
in such situations.
Obviously not all women who use EC wish to com-
mence a regular method of contraception. A propor-
tion of women will inevitably make an informed
choice to use condoms or no contraception, and inter-
ventions like this are unlikely to impact on this group
of women.1 15 17 As with other studies, some women
had concerns about obtaining a limited supply of a
POP from the pharmacist;12 however, providing
reassurance to women may allay some of these con-
cerns. Women can be reassured of the very small daily
dose of progestogen in a POP compared to the dose
in EC, and its safety compared with the COC. A small
number of health professionals expressed concern that
such interventions may decrease the use of the most
effective LARC methods and thus preferred that
women attended a clinic to discuss such methods.
However, we know that a large number of women
now seek EC from community pharmacies3 and that
they rate such services highly.12 Moreover, even when
women attend specialist services for EC, almost three-
quarters of them leave without effective contracep-
tion, let alone a long-acting method.1 Therefore, we
need to establish ways in which we can help women
access ongoing contraception after obtaining EC from
a pharmacy.
A limitation to our study is the lack of demographic
data available from both our study populations. Short,
anonymous questionnaires were used in order to
encourage a high response rate and we chose to limit
the amount of demographic data sought. However,
the survey was conducted in several large pharmacies
located within a large city, with a response rate close
to 100%, so we would hope that our study population
is close to being representative of most women pre-
senting for EC in Scotland.
Encouragingly, many women presenting for EC
would wish to use effective ongoing contraception if
they do not already do so, and would welcome a
simple intervention in the pharmacy to help them do
so. SRH clinicians, who are experts in contraception,
are also positive about such an intervention. By
helping women to obtain ongoing methods of effect-
ive contraception at time of using EC we may succeed
in preventing more unintended pregnancies for more
women.
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Pharmacy-based interventions for initiating effective contraception
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Objectives: In Scotland most women get emergency contraception (EC) from pharmacies. Pharmacists currently cannot provide effective
ongoing contraception after EC. In this pilot study, we aimed to determine the feasibility of a larger study designed to ascertain if pharmacy-
based interventions can increase the uptake of effective contraception after EC.
Study design: This is a pilot study of women presenting for levonorgestrel EC to community pharmacies in Edinburgh, UK, in 2012.
Pharmacies were cluster randomized to provide either standard care or one of two interventions: (a) one packet of progestogen-only pills
(POPs), giving women 1 month to arrange ongoing contraception; (b) invitation to present the empty EC packet to a family planning clinic
(FPC) for contraceptive advice (rapid access).
Results: One hundred sixty-eight women were recruited from 11 pharmacies to POP (n=56), rapid access (n=58) and standard care (N=54)
groups, respectively. Telephone follow-up was conducted successfully in 102 women (61%) 6–8 weeks later to determine current
contraceptive use. In the POP arm, 35/39 (90%) women used the pills provided, and 9/28 women (32%) in the rapid access arm attended the
FPC. The proportion of women using effective contraception at follow-up was significantly greater in both POP [56% (22/39), p=b0.001]
and rapid access [52% (13/25), p=0.006] groups compared to standard care [16% (5/31)]. The relative probability of a woman using an
effective method of contraception versus barrier/no method, after use of EC, was 3.13 [95% confidence interval (CI), 1.90–5.13] in the POP
group and 2.57 (95% CI, 1.55–4.27) in the rapid access group.
Conclusions: This promising pilot study suggests that simple pharmacy-based interventions may increase the uptake of effective
contraception after EC. A larger study is required to provide further validation of these findings.
Implications statement: For women obtaining EC from a pharmacy, simple interventions such as supplying 1 month of a POP, or offering
rapid access to a FPC, hold promise as strategies to increase the uptake of effective contraception after EC.
© 2014 Elsevier Inc. All rights reserved.Keywords: Morning-after pill; Levonelle; Quick-start; LARC; POP☆ Funding: The Edinburgh & Lothians Health Foundation provided
funding for this study. In addition, a research grant was provided by HRA
Pharma which enabled LM to be funded as a clinical research fellow at The
University of Edinburgh. This grant was independent and unrestricted; not
specified to fund any particular research projects.
☆☆ Conflict of interests: Both STC and AG, currently and in the past,
have received research support from and undertaken consultancies for
pharmaceutical companies working to develop emergency contraception.
★ Clinical Trial Registration Number: NCT01738971
⁎ Corresponding author at: Chalmers Sexual Health Centre, 2A
Chalmers Street, Edinburgh, EH3 9ES, United Kingdom. Tel.: +44 131
536 1070; fax: +44 131 536 1609.
E-mail address: michieluc@yahoo.co.uk (L. Michie).
http://dx.doi.org/10.1016/j.contraception.2014.05.004
0010-7824/© 2014 Elsevier Inc. All rights reserved.1. Introduction
Since hormonal emergency contraception (EC) became
available without prescription from UK pharmacies, increas-
ingly, women prefer to attend a pharmacy for EC rather than
a doctor [1]. From late 2008, levonorgestrel-EC (LNG-EC)
became available from pharmacies throughout Scotland free
of charge [2]. Fewer than 5% of women get pregnant after
EC, so the vast majority remain at risk [3]. In a meta-analysis
of 11 trials among almost 5000 women having sexual
intercourse after using EC but in the same cycle, the relative
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women who abstained from sex [4]. UK guidelines
recommend that women using EC should be provided with
an effective contraceptive to start either with the onset of
their next period or immediately if they will not abstain from
sex [5]. This may be an interim “bridging” method that
women can use until they can initiate their chosen
contraceptive [5]. In an audit of almost 500 women attending
a specialist family planning clinic (FPC) for EC in 2007/08,
only 24% were provided with effective contraception
(excluding condoms) to start immediately [6]. This figure
may be even lower when EC is obtained from nonspecialist
services. Community pharmacists in the UK (as elsewhere in
the industrialised world) are unable to provide any ongoing
contraception (except condoms, which can be purchased).
Two mystery shopper studies show that while UK
pharmacists provide EC appropriately, only a minority
give women advice about ongoing contraception which
mostly comprises advising them to consult a doctor [7,8]. So
while in the UK EC is much easier to obtain and, by making
it free of charge in pharmacies, use has almost certainly
increased [8], we have created a situation where EC is
provided almost solely from settings where other more
effective methods of contraception cannot be immediately
provided. We need urgently to explore ways to ensure that
women attending pharmacies for EC have easy and rapid
access to an ongoing contraceptive method which they start
as soon as possible.
Within the Edinburgh region community pharmacists
dispense an average of 1300 courses of EC every month. We
wished to test two interventions designed to increase the uptake
of effective ongoing contraception (all methods other than
barriermethods) after use of ECobtained from a pharmacy.As a
pilot study, the primary outcomewas to determine the feasibility
of a larger study, investigating whether either intervention
resulted in an increased proportion of women self-reporting use
of effective ongoing contraception at 6–8 weeks after EC use,
compared to standard care.2. Materials and methods
2.1. Interventions
2.1.1. Intervention 1
A packet of 35 progestogen-only pills (POPs: 35-mcg LNG;
Norgeston®, Bayer, UK)was provided by the pharmacist [using
a locally approved patient group directive (PGD)] at no cost to
women as a bridging method of contraception, giving them 1
month to attend their usual healthcare provider for ongoing
contraception. A PGD allows pharmacists to dispense certain
approved medications without a prescription. Outwith this
study, pharmacists in Scotland are not currently able to dispense
the POP without a prescription. Pharmacists were not
specifically trained to provide information regarding where to
attend for further ongoing contraception, although they could
provide their usual verbal/written information similar to thosepharmacists in standard care groups. The very few absolute
contraindications to the POP [9] make it easier to argue the case
for pharmacy provision compared with the combined oral
contraceptive pill. Pharmacists were trained in POP counselling
and provision before the study started and given nationally
available written information leaflets about the POP to issue
with the supply of pills. Women were advised to start the POP
immediately or within 24 h of EC use and to abstain from sexual
intercourse or use condoms for 48 h, before relying upon the
POP for contraceptive protection.
2.1.2. Intervention 2
Participants in the “rapid access” arm were instructed by
the pharmacist to take their empty packet of EC to the local
specialist FPC (a single large clinic in Edinburgh city centre)
to discuss contraception, as soon as possible. Women
attending the FPC were seen on the day that they presented
as a drop-in client, without requiring a booked appointment,
and were offered all methods of contraception, including
long-acting reversible methods of contraception (LARC) to
start immediately. This differed from standard practice, as
women not participating in the study who present as a drop-
in for ongoing regular contraception may be asked to return
on another day, if the clinic is already at capacity. The EC
boxes were clearly labelled, alerting FPC staff to study
participants. The boxes were returned to the study coordi-
nator. Pharmacists provided written information about the
location and opening hours of the FPC.
2.1.3. Standard care
Pharmacists dispensed EC in the usual manner, which
included the option to provide their usual verbal and/or
written information (if available) regarding the importance of
establishing an effective ongoing method of contraception.
All pharmacies within the region have leaflets detailing the
location and services available at local FPCs, should they
wish to use them.
Participants were advised that they would be contacted 6–8
weeks later to complete a short telephone interview. At
interview completion, a £10 voucher to redeem in the pharmacy
was mailed to participants.
2.2. Randomisation
A cluster randomised design was chosen since it was
deemed impractical to randomise individual women in
pharmacies. Each pharmacy (cluster) agreeing to participate
was randomised (by NL) to provide one of the interventions
or standard care. Restricted randomisation was used to
ensure balance between study arms with respect to EC-
dispensing figures and the deprivation category [10] that is
based on deprivation category scores derived from postcode
area in which the pharmacy is situated.
2.3. Pharmacist and subject recruitment
Pharmacists who had previous experience of undertaking
research [11,12] or dispensed 10 or more courses of EC
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the study team. Eleven pharmacists from 11 different
pharmacies agreed to participate. A small incentive (£10
per subject recruited) was offered. Four pharmacies were
randomised to the POP intervention arm of the study; four to
the rapid access arm and three to standard care.
At the start of the study, a pharmacist randomised to the
POP arm of the study was relocated out of Edinburgh, so this
pharmacy was removed from the study, and the remaining
three pharmacies in the POP arm were each allocated a
greater recruitment target. Four months into the study, a
participating pharmacist in the standard care arm retired, so
the pharmacy was replaced by another pharmacy. All
participating pharmacists underwent prestudy training with
two members of the research team. This consisted of a
detailed explanation of the study and their allocated study
arm, inclusion and exclusion criteria, the requirements to
complete study paperwork (including demographic infor-
mation from participants) and consent forms.
Between April 23, 2012 and December 21, 2012, the 11
study pharmacies were asked to invite all women aged 16
years and older, presenting for EC, who had been using
either no contraception or a barrier method, to participate.
Further eligibility criteria included woman eligible for EC
according to the PGD criteria with no medical contraindi-
cations, resident in the United Kingdom and not requiring
language interpreting services. Contraindications which
prevent a pharmacist from dispensing LNG-EC via a PGD
include unexplained vaginal bleeding, pregnancy, severe
hepatic dysfunction, severe malabsorption syndrome, previ-
ous unprotected sexual intercourse in the same menstrual
cycle or unprotected sex over 72 h earlier. Although women
were excluded if they were already using a hormonal method
of contraception, it became apparent later that a small
number of such women were recruited and they were
subsequently excluded from statistical analysis of the
primary outcome.
After EC was dispensed by the pharmacist, a short verbal
description of the study and a written patient information leaflet
were provided to eligible women, and written consent was
obtained by the pharmacist. Demographic data including date of
birth, postcode area of residence and contact details (mobile/
landline telephone numbers and email addresses) were also
recorded. Pharmacists were asked to record the number of
women declining to participate and the number of eligible
women not invited to participate (e.g., when the pharmacy was
particularly busy or when the pharmacist consulting was
unfamiliar with the study, e.g., locum/relief staff).
2.4. Telephone follow-up
Two members of the research team conducted all follow-up,
which consisted of a short telephone interview lasting
approximately 5 min at 6–8 weeks after attendance for EC
when women who had received a packet of POP should have
finished it. In an attempt to maximise follow-up rates, at leastthree attempts at contact were made to both landline and mobile
telephone numbers, at varying times of the day. Furthermore, if
no telephone contact was possible, for those participants who
had provided an e-mail address, an e-mail was sent to them to
ensure that the telephone contact number documented was
correct and to identify if therewas amore suitable time to call the
participant. Women were asked what method of contraception
they were currently using, about their experience of obtaining
EC from the pharmacy and of the care that they received. All
women were asked if they felt that a small supply of POP had
been or would, in theory, have been “helpful”.
2.5. Statistical analysis
Nopublished datawere available onwhich to base a sample
size. There are no data on how many women who use EC then
visit their general practitioner (GP) or FPC for ongoing
contraception. Less than 50% of pharmacists providing EC
aroundEdinburgh [8] give advice about contraception after EC
use. We assumed that the proportion of women starting
ongoing contraception following EC from a pharmacy would
be far less than that in the specialist FPC clinic (24%) [6]. For
this pilot studywe aimed to recruit 180women (60 to each arm
of the study) from 10–12 pharmacies, as we considered this
to be a reasonable number of women to recruit within our
8-month timescale, while still providing an adequate
number for follow-up. Based on previous research in sexual
health, among reproductive age women [12], we estimated
that 50% of women attending for EC would agree to
participate and we anticipated loss to follow-up of at most
50%. From these assumptions we calculated that pharmacists
would need to see 360 women for EC, in order to recruit 180
and collect follow-up data on at least 90 women.
All data, including demographic data recorded at
recruitment and at telephone follow-up, were coded and
entered onto a Microsoft Excel database by LM and checked
by AJ. Analysis was performed using IBM Statistical
Package for Social Sciences (SPSS) software Version 18
(SPSS Inc. Chicago, IL, USA). Descriptive statistics were
obtained including means and standard deviations (SDs). To
take account of the cluster randomisation, it was necessary to
carry out an analysis at cluster rather than individual subject
level, and the proportions in each cluster using effective
contraception were compared between groups by two-
sample t tests [13], weighted by the different number of
patients in each cluster. This approach was preferred to
random-effects modelling, including variation at both
individual and cluster level because of the small number of
clusters, since it explicitly recognises this through the
degrees of freedom rather than requiring a normal approx-
imation to generate p values. Confidence limits for relative
probabilities were derived from t tests based on the
logarithms of the effective proportions. Statistical signifi-
cance was deemed to be pb0.05.
The South East Scotland Research Ethics Committee 03
(11/ss/0045) approved the study in September 2011.
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During the 8-month recruitment period, a total of 168
subjects were recruited, with a mean age of 23 years (SD,
5.2), to the POP (n=56), rapid access (n=58) and standard
care (N=54) groups, respectively. The commonest reason for
requesting EC was a condom accident [n=62 (61%)]. Of
those recruited, 132 (78%) were subsequently contactable by
telephone 6–8 weeks later. Of those contacted, 102 women
(61% of all subjects recruited) completed the telephone
interview; the remaining 30 women withdrew consent to
continue in the study (Fig. 1). The demographics of those
women completing telephone follow-up in each of the three
study arms are shown in Table 1. For subjects who were not
contactable, only data on age were available, and there was
no significant difference in age between women contacted
and those not contacted [mean age of 23 years (SD, 5.2) and
22 years (SD, 4.9), respectively].
In the POP arm, 35/39 (90%) women reported using the
pills provided. Two women chose not to use the pills as theyAssessed fo
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Fig. 1. CONSORT (modified) flow diagram showing recruitwere “not currently sexually active;” one woman stated, “she
did not get round to using it,” and one was concerned about
side effects. Most women, 26/35 (74%), who took the pill
reported completing the packet; 5 used between 7 and 14
pills; 3 delayed starting and had not finished the packet at the
time of interview; the information was not documented for 1
woman. Three of the five women who stopped taking the
pills did so because of side effects, and two stated they had
difficulty remembering to take it. Asked if they felt that the
option of a 1-month supply of POP being available from the
pharmacy following EC was helpful; 33 (84%) agreed that it
was, 3 (8%) felt it was not and 3 (8%) were unsure.
In the rapid access arm, 9/28 (32%) women attended the
FPC, three on the day they obtained EC and six, 2 days to 1
month later. Attendance at the FPC after EC use was
confirmed by collection of the marked EC boxes. The
commonest reason given for not attending for rapid access
contraception was “pressure of time” [n=10 (53%)].
Additional reasons included “prefer to see GP” (n=1), “still
considering contraceptive options” (n=1), “FPC too farr eligibility*
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ment and follow-up of participants (see separate file).
Table 1
Demographics of women completing telephone interview
POP, n=39 Rapid access, n=28 Standard care, n=35
Age (years) Mean (SD) 22 (5.2) 25 (5.6) 23 (4.5)
Range 16–44 18–40 18–36
DepCat⁎ 1–2 (Affluent) 4 (10%) 9 (32%) 3 (9%)
n (%) 3–5 (Moderate) 33 (90%) 18 (64%) 31 (89%)
6–7 (Deprived) 0 1 (4%) 0
Previous birth n (%) 2 (5%) 1 (4%) 1 (3%)
Previous abortion n (%) 4 (10%) 3 (11%) 3 (9%)
Contraception at time of EC
n (%) None 13 (33%) 8 (28%) 12 (34%)
Condoms 26 (67%) 17 (61%) 19 (54%)
Other (e.g., cocp) 3 (11%) 4 (12%)
⁎ DepCat Score is a marker of deprivation in Scotland based upon postcode area of residence scoring from 1 least deprived, to 7 most deprived [10].
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two women stated that “the option was not clearly explained
to them.” A 1-month supply of POP being available from the
pharmacy following EC would have been helpful to 15
women (54%); however, 10 (36%) felt it would not help, and
3 women (10%) were unsure.
Women in the standard care arm were asked if they had
received information from the pharmacists about the range of
methods of contraception available or where they could
obtain contraception. Eight (23%) women stated they
received no information about methods available, and six
(17%) had not received any information about where they
could get contraception. A 1-month supply of POP from the
pharmacy following EC would have been helpful to 16
women (46%), but 13 (37%) felt it would not have helped,
and six (17%) women were unsure.
3.1. Effective method of contraception use at 6–8 weeks
post-EC
Seven women were excluded from further analysis as
they were using hormonal contraception at the time of
presenting for EC and continued to use it at follow-up (three
in the rapid access and four in the standard care arms of the
study). Only 16% of women receiving standard care reported
using an effective method of contraception 6–8 weeks after
EC. When compared to standard care, the relative probabilityTable 2
Method of contraception used at 6–8 weeks post-EC study arm
POP
Effective contraception All effective methods, n (%) 22 (5
LARC methods, n (%) 3 (8
No/Barrier method, n (%) 17 (4
Effective=all contraceptive methods aside barrier or natural methods.
LARC (intrauterine method, contraceptive implant, contraceptive injection).




⁎⁎⁎⁎ p=0.07.of a woman using an effective method of contraception
versus barrier method/no method after use of EC was 3.13
(95% CI, 1.90–5.13) in the POP group and 2.57 (95% CI,
1.55–4.27) in the rapid access group. Compared to standard
care, the use of a LARC 6–8 weeks after EC was
significantly greater in the rapid access group (20% vs.
0%, p=0.004) (Table 2.)4. Discussion
This pilot study demonstrates that a simple intervention
may increase the uptake of effective contraception after the
use of EC obtained from pharmacies. The relative probability
of using an effective method of contraception 6–8 weeks
after using EC was three times (among women in the POP
group) and more than twice (among women in the rapid
access group) than among women in the standard care group.
This was a pilot study, and loss to follow-up (including lack
of willingness to be interviewed after successful contact) was
relatively high. However, even if we assume that all the
women who did not complete telephone follow-up in each
arm of the study were not using an effective method of
contraception, there would still be a significant increase
in the use of an effective method in the intervention [POP
group 39% vs. 9% (p=0.005); rapid access groups 22% vs.
9% (p=0.043)].(n=39) Rapid access (n=25) Standard care (n=31)
6%)⁎ 13 (52%)⁎⁎⁎ 5 (16%)
%)⁎⁎⁎⁎ 5 (20%)⁎⁎ 0
4%) 12 (48%) 26 (84%)
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although any rapid access arrangement would need to be
agreed with local services. While this may be more difficult
in places without large specialist FPC services it should not
be impossible for GPs to agree that women who have used
EC should be seen urgently. There is only one other study of
a pharmacy-based intervention after EC that we know of
[14]. In this Jamaican study women were offered a voucher
for a discount on the cost of oral contraceptive pills. This
study did not increase the uptake of effective contraception
after EC, and at follow-up 6 months later, most women
continued to use condoms or no method.
For the endpoint of this feasibility study we chose
contraceptive use after EC at a time when women receiving
the POP should have finished the packet. Increasing the
uptake of effective contraception after EC is not a surrogate
for reducing unintended pregnancies or abortions, and
discontinuation rates of oral contraceptives are high [15].
Moreover, both oral and injectable contraceptives have
proven no better than condoms in preventing repeat abortion
[16,17]. However, the rapid access intervention also resulted
in a statistically significant increase in the uptake of LARC
which has been shown to decrease both repeat abortion and
teenage pregnancy [18]. Not all women attending for EC will
want to start effective contraception. In an anonymous
questionnaire of women attending for EC conducted in the
same pharmacies in Edinburgh, 53% wished to continue
using condoms [19].
There are inevitable limitations to our study. Contracep-
tive use 6–8 weeks after EC was self-reported. It is unlikely
that inaccurate reporting alone could account for the
significant differences in use of effective contraception
between both intervention groups and standard care. We also
lack robust data on those women who were not recruited to
the study and cannot rule out selective recruitment.
Pharmacists said that they either did not have time to
document these demographics during busy working periods
or they simply forgot. This illustrates the difficulties
encountered when conducting clinical research in pharmacy
settings [20]. Finally, we fell short recruiting the intended
target sample size during the 8-month recruitment period,
and completed telephone follow-up occurred in only 61% of
subjects, and we were therefore unable to determine
contraceptive use in the remaining 40%. Prior to conducting
a larger scale study, further qualitative research with both
pharmacists and EC users may help determine what
incentives they feel might enhance both recruitment and
study continuation and follow-up.
This pilot study has shown that while conducting research
within a pharmacy setting poses certain challenges, it is
feasible. Despite the small number of participants, the results
suggest that the use of simple pharmacy-based interventions
may increase the uptake of effective contraception after EC.
More robust evidence from a larger study is required to
demonstrate that the interventions really do increase use of
effective contraception and that this leads to reductions inunintended pregnancies. Frequently interventions which
look promising at a pilot stage are shown to be ineffective
when scaled-up in a larger study or rolled out to routine
care [21,22].
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of the pilot study, using a standardised topic guide. Pre- and post-study interviews were
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options available. They also identified possible advantages and disadvantages of each
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Community pharmacies in the UK are well placed to provide
sexual and reproductive health (SRH) services, with many
already providing emergency contraception (EC). Women rate
these services highly, perceived benefits including anonymity
and ease of access.1,2 Although a small number of pharmacies
currently provide enhanced SRH services, such as provision of
oral contraception, there is scope for more to do so and for
even greater development.3,4 Research exploring pharmacy
based provision of such services is important to determine
whether it really is advantageous for patients. An evaluation
of community pharmacy provision of oral contraception
demonstrated that pharmacists were competent to provide
the service and clients were satisfied with it.5 Several studies
have sought the views of pharmacists regarding the provision
of chlamydia screening in the pharmacy. While pharmacists
are willing to provide screening there are difficulties, such as
pharmacists feeling uneasy about offering screening to all
women in all circumstances and tending to select groups for
screening, such as those presenting for EC, or those under 16
years of age.6e8
As SRH services develop within the pharmacy setting,
there are increased opportunities to undertake SRH research
within this setting. Whilst SRH research, including a pilot of
expedited partner therapy for chlamydia, has previously been
conducted effectively from the pharmacy setting,9 research
undertaken in this setting is not without challenges. Some of
the challenges documented by previous SRH researchers in
the pharmacy included; difficulty in calculating a response
rate as no record of those declining participation in the study
was kept; slow recruitment; and problems ensuring patient
confidentiality.10
UK guidelines recommend that women using EC should be
provided with an effective contraceptive to start either with
the onset of their next period, or immediately if they will not
abstain from sex.11 In a meta-analysis of 11 trials among
almost 5000 women having sexual intercourse after using EC
but in the same cycle, the relative risk of pregnancy was more
than two times that of women who abstained from sex.12 We
conducted a pilot study of pharmacy based interventions for
initiating effective contraception after EC, in community
pharmacies in Edinburgh, UK in 2012.13 Pharmacies were
cluster randomized to provide either standard care or one of
two interventions: (a) one packet of progestogen-only pills
(POPs), giving women 1 month to arrange ongoing contra-
ception; (b) invitation to present the empty EC packet to a
family planning clinic (FPC) for contraceptive advice (rapid
access (RA)). Pharmacists who had previous experience ofL, et al., Provision of con
r providing sexual and repundertaking research9,14 or who dispensed at least ten courses
of ECmonthly, were invited to participate. Eleven pharmacists
from eleven different pharmacies agreed to take part. Four
pharmacies were randomised to the POP intervention arm of
the study, four to the rapid access arm and three to standard
care. All participating pharmacists underwent pre-study
training with two members of the research team.
Between 23rd April 2012 and 21st December 2012, the 11
study pharmacies were asked to invite all women aged 16
years and over, presenting for EC, who had been using either
no contraception or a barrier method, to participate. After EC
was dispensed by the pharmacist a short verbal description of
the study and a written patient information leaflet were pro-
vided to eligible women, and written consent obtained by the
pharmacist. Demographic data and contact details (mobile/
landline telephone numbers and email addresses) were
recorded.13 Pharmacists were asked to note the number of
women declining to participate and the number of eligible
women who were not invited to participate (e.g. when the
pharmacy was particularly busy). Womenwere contacted 6e8
weeks later for a telephone interview, during which they were
asked what method of contraception they were using, and
about their experience of obtaining EC from the pharmacy.
The aim of the study was to determine the feasibility of a
larger study to ascertain if pharmacy based interventions can
increase the uptake of effective contraception after EC.13
Recruitment to and follow-up of participants in that study,
and the methodology of this study is described fully else-
where.13 In this paper we report the views of both the women
and the pharmacists regarding the provision of these in-
terventions from the pharmacy setting. Using these findings
our primary aim was to identify possible barriers and facili-
tators to providing such interventions from the pharmacy in
practice. In addition, during the study we documented any
operational problems that arose with research in the phar-
macies, to help inform the development of larger scale studies
of such interventions from the pharmacy.Methods
Semi-structured interviews with women
In the pilot study, women were contacted for a telephone
interview at 6e8 weeks post EC, to determine contraceptive
use at that time. A purposive sample of 12 women (four from
each study arm), were recruited at time of telephone follow-
up to undergo a face-to-face interview to allow further eval-
uation of the intervention (or lack of it in standard care arm).traception after emergency contraception from the pharmacy:
roductive health services, Public Health (2015), http://dx.doi.org/
p u b l i c h e a l t h x x x ( 2 0 1 5 ) 1e7 3The face-to-face interviews were semi-structured and con-
ducted by a qualitative researcher (ZEC) at a time/venue
chosen by the women. The interviews were carried out be-
tween August and November 2012.
Given that this is a novel intervention, a semi-structured
interview using a standardised topic guide was chosen as a
flexible researchmethod. This was to facilitate the generation
of data that could be easily compared and thematically ana-
lysed, whilst also enabling women to raise issues that are
important to them and could inform future development of
the research and clinical implementation of interventions.
Women were asked to briefly recount their contraceptive
history and describe the circumstances leading to the index
episode of obtaining EC from the pharmacy. They were also
asked to share their experience of obtaining EC from the
pharmacist and being invited to participate in the study.
Women were asked to reflect on their experience of the
intervention (if assigned POP or RA appointments) and also
their thoughts about these interventions being offered as
routine practice. Finally, women were asked about their
motivation to participate in the research and whether
providing a financial incentive influenced their decision to
participate. Interviews were audio-recorded and transcribed
verbatim. Data were organised by cross-sectional indexing
and thematically analysed and presented.15Structured interviews with pharmacists
All study pharmacists agree to participate in a telephone
interview before and after the study. These interviews were
conducted by telephone and were arranged at a time of day
convenient for the pharmacists in order to minimise disrup-
tion to working practice. Nine pharmacists were interviewed
pre-study and ten post-study (some remained unavailable).
None of the pharmacists simply declined to undergo the
interview. The structured telephone interviews were con-
ducted by two public health practitioners (DM and SW) who
had prior experience with this approach and methodology. A
standardised topic questionnaire was used to enable
comparability of data collected. In the pre-study interviews
pharmacists were asked; whether they anticipated any bar-
riers or issues to arise, any specific training required, and
their views on the provision of vouchers as incentive for the
women. In the post-study interviews they were asked toTable 1 e Comparison of demographics of women completing
face-to-face interview.
Telephone interview






n(%) 3e5 (Moderate) 82 (80%)
6e7 (Deprived) 1 (1%)
Previous birth n (%) 4 (4%)
Previous abortion n (%) 10 (10%)
a DepCat Score is a marker of deprivation in Scotland based upon postco
deprived.18
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the research or the interventions. Data were organised by
cross-sectional indexing and thematically analysed and
presented.15Observations from the research team
Throughout the study, a research log was utilised by the
research team to record any operational issues arising as a
result of conducting a research study from this setting.Results
Semi-structured interviews with respondents
49 womenwere asked to participate in a further interview and
26 agreed (53%). Once the desired sample of 12 women had
successfully attended for interview, no further women were
asked to participate, hence only 12 women were interviewed;
all chose to be interviewed at the city centre SRH service,
rather than their home or another venue.
The interviews each lasted about 1 h and covered all the
questions prepared in the topic guide. The demographics of
women interviewed (n ¼ 12), compared to those of all women
who were successfully contacted for telephone interview
(n¼ 102) in the pilot study, are shown in Table 1. The three key
themes that were discussed during the interview include
accessing effective contraception, provision of POP or Rapid
Access (RA) appointments, and recruitment at the pharmacy
and participation in the study.
Accessing effective contraception
Women's description of their experience highlighted chal-
lenges they faced in accessing effective contraception which
had led to their need for EC. Most womenwere using condoms
as their regular contraceptive method with EC used as a ‘back
up’ when they felt they had put themselves at risk of preg-
nancy. All of the women interviewed indicated that they did
not view EC as a routine method of contraception and
all expressed the wish to be using effective, ongoing
contraception.
Difficulties getting an appointment to discuss contracep-
tion with their General Practitioner (GP) or at family planningtelephone interview (in pilot study) and attending for








de area of residence scoring from one least deprived, to seven most
traception after emergency contraception from the pharmacy:
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p u b l i c h e a l t h x x x ( 2 0 1 5 ) 1e74services were noted by women. The limited availability of
appointments after work coupledwith having to be ‘organised
and plan ahead’ weeks in advance had been suggested as
reasons for putting off accessing more contraception. A
couple of respondents said they felt contraception would not
be a priority for the GP service, hence their reluctance to raise
it with their GP.
I am very busy and work irregular hours which makes it very
difficult for me to get appointments with my current GP. I don’t
want to trouble my GP for minor health concerns so I prefer to
self-medicate or go to the pharmacy across from where I live
where they operate a drop-in system to suits me better. (standard
care group)Provision of POP or rapid access (RA) appointments
All women interviewed welcomed both interventions noting
that it would be good to have different options available to
support women in accessing effective contraception.
Provision of a month supply of POP
The women had mixed views on being offered the POP when
presenting for EC at the pharmacy. Discussions centred
around two themes: the amount of POP provided and the
setting of the provision (at the pharmacy, when presenting for
EC).While somewomen said that amonth supplywas enough
for a woman to make a follow-up appointment to access
further supply or to discuss other methods, several women
felt that one month supply could be a ‘waste of time’ or put
women off using hormonal methods altogether.
I think it will be useful for other women… but for myself and
other women, it will take a while for the pill to settle, so a month
supply may not be worth it as it may not be able to give a good
indication of the side effects on the body. This might put some
women off thinking it is not working for them. (standard care
group)
Some women felt that being offered the POP at the phar-
macy was a good alternative to accessing it only at the GPs or
the FPCs.
It is quite good to do this because some people can be quite hes-
itant going on it and asking about it from their GP. So if they are
offered, they can try it. It is easier to ask GP for more rather than
to start on it. A month supply should be enough to make an
appointment with their GP. (POP group)
However, others had reservations about starting a
woman on a new hormonal method at the time of pre-
senting for EC. A few women questioned whether it was
the role of the pharmacist to undertake contraception
consultations. One woman who attended her GP to discuss
contraception said that her GP was shocked that she was
offered the POP.
I think for women like me who have never tried hormones before,
it is not a good idea. I want to speak to someone about different
options and the health implications of hormones before I takePlease cite this article in press as: Michie L, et al., Provision of con
evaluating the acceptability of pharmacy for providing sexual and rep
10.1016/j.puhe.2015.11.017them. My GP was surprised when I mentioned that I was given
the pills at the pharmacy, it was not a good method for me.
(POP group)
All four women from the POP arm of the study recalled
being provided with information by the pharmacist and
given the opportunity to ask questions about the POP.
However three women said they felt they went away hav-
ing questions about POP which they did not feel able to ask
at the time.
Provision of a rapid access (RA) appointment
All womenwelcomed the idea of awomanpresenting for EC to
be provided with a RA appointment, as it enabled quicker
access to consultations and potentially more specialist sup-
port that can help match women to suitable and effective
methods of contraception.
Getting the emergency contraception can kick start your brain to
think about wanting to get on the pill or something… having an
appointment to see someone quickly to discuss more will be really
helpful. (standard care group)
Moreover, a few respondents suggested that an appoint-
ment several days after presenting at the pharmacy for EC
could give a woman time to reflect on her experience and seek
appropriate clinical as well as emotional support during
follow-up.
For women getting the morning after pill, it can be quite a
stressful time for them. With the appointment, they can speak
to someone about what happened especially if it had been a
bad situation. The appointment will give them a little bit
longer to think things through and then they have someone to
confide in. If it's within a week that is not too long to wait.
(POP group)
There was some discussion about the option of services
where the RA appointment can be accessed. A few women
noted that being offered a RA appointment at a FPC would
be welcomed especially by younger women who may not
feel comfortable using their own GP for EC and contracep-
tion. A few women said they would like the RA appoint-
ment to be available from their own GPs. These women
mentioned that they would be unlikely to use a RA
appointment if it were available only from the FPC as they
preferred to see their own GP with whom they already have
a good relationship and who knows about their medical
histories.
I have a good relationship with my GP who knows me well and
my problems with finding a suitable method. I am aware that
they have specialist here in the centre but I really don’t want to go
throughmy history againwith another person. I rather go back to
my own GP. (RA Group)Recruitment at the pharmacy and participation in the study
Discussions with women about their experience at the phar-
macy suggested that they felt the information given to themtraception after emergency contraception from the pharmacy:
roductive health services, Public Health (2015), http://dx.doi.org/
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clear. When asked whether they felt it was appropriate to
recruit women when they presented for EC at the pharmacy
most women replied that it was as they were able to make an
informed choice and did not feel pressured into participating.
The pharmacist was very nice, it was all very relaxed and very
human. It didn't feel like I was being sold anything… I didn’t feel
any pressure to be involved. I think women just need to be
assured there is not a lot involved and that they can help other
women, feel like they are part of something useful. (standard care
group)
A couple of women noted however, even though they were
happy to participate, they were keen to be ‘in and out’ of the
pharmacy as soon as possible and would have liked to be able
to directly contact the research team to discuss being involved
rather than having to decide whilst at the pharmacy.
I'm not entirely sure I knew exactly what she was talking about
although I was given the information to take away. I think the
pharmacist could have asked me a bit more question. But to be
honest, I didn’t ask her much because I just wanted to get out of
there. (POP group)
After prompting, one woman revealed that she had felt
‘obliged’ to agree to participate despite being assured by the
pharmacist that participation was voluntary and would have
no impact on the service she would receive. When asked
about their motivation to participate in the study, most
women said they wanted to ‘help other women’ through the
study and to ‘give back’ to the excellent services they received.
When asked if the incentive voucher (£10 value to spend in the
pharmacy) was a motivation, most women said it helped to
remunerate the time they had given to take part, although
they would have participated without the voucher.Pre- and post-study interviews with pharmacists
Pre-study interviews
Interviews were conducted with nine pharmacists. The ma-
jority perceived no potential problems with the study
although two expressed concern that the time taken to recruit
women, within a busy commercial setting, may potentially
present a problem. The small incentives offered to pharma-
cies to recruit women (£10 per woman recruited) and those
offered to women to participate (£10 voucher to spend in
pharmacy) were seen as helpful. They felt the option of rapid
access to a FPC was a good idea to help build on the women's
motivation to use ongoing contraception at presentation for
EC.
Post-study interviews
Post-study telephone interviews were conducted with ten
pharmacists. All were positive about their involvement and
felt that pharmacies could offer a wider range of sexual and
reproductive health services. Concerns were expressed by
some that recruitment had been slower than they expected.
They felt that pressure on consultation time had not been aPlease cite this article in press as: Michie L, et al., Provision of con
evaluating the acceptability of pharmacy for providing sexual and rep
10.1016/j.puhe.2015.11.017significant issue, although there were some occasions when
the pharmacy was too busy to allow recruitment.
Methodological issues identified from research team
observations
Operational issues were documented throughout the study
and reviewed, with the following key themes identified:
Retention/continuity of pharmacist
There was the difficulty in retaining within the study the
pharmacists who had agreed to participate and underwent
pre-study training. One pharmacist randomised to the POP
arm was relocated to another pharmacy out of Edinburgh, so
this pharmacy was removed from the study and the remain-
ing three pharmacies in the POP arm were each allocated a
greater recruitment target. Four months into the study, a
pharmacist participating in the standard care arm retired
without informing the research team, and the replacement
did not wish to participate. Recruitment within this pharmacy
therefore stopped and was replaced by another pharmacy.
Recruitment of women
Recruitment of women to the study, within all of the phar-
macies, slowed towards the end of the study. In one of the
larger pharmacies, which is a branch of a large pharmacy
conglomerate within the UK, recruitment slowed over the
months of June and July, as the travel vaccination service
offered by the pharmacy became the priority. The number of
women recruited overall during the study fell short of inten-
ded recruitment numbers of 180 by 12.
Adherence to study protocol
There were problems related to pharmacists adhering to
guidance given to them during pre-study training about in-
clusion and exclusion criteria for recruitment, maintaining
records of the numbers of eligiblewomenwhowere dispensed
EC but not recruited, and documenting the reasons for this.
Exclusion criteria included women who were already using a
hormonal method of contraception at time of recruitment.
However, seven women were recruited whilst already using a
hormonal method. They were subsequently excluded from
statistical analysis of the primary outcome of the study. All
pharmacists failed to keep accurate records of the numbers of
women to whom ECwas dispensed and whowould have been
eligible to participate, but either declined or were not
approached to by the pharmacist. Thus there was no way to
determine an accurate response rate, or to ascertain the rea-
sons the pharmacists chose not to recruit, or why women
decided not to participate.
A further concern was the occasional difficulty the phar-
macists had in maintaining accurate documentation. On two
occasions the form documenting consent to participate was
not signed by the woman, and without consent they could not
be contacted for follow-up. Some pharmacists did not docu-
ment women's date of birth on every occasion resulting in
time spent trying to determine this information from phar-
macy records. Additionally, the contact information recorded
at time of recruitment was inaccurate for 14 women providing
no way of conducting follow-up with them.traception after emergency contraception from the pharmacy:
roductive health services, Public Health (2015), http://dx.doi.org/
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Enhanced sexual health services provided in pharmacies have
been shown to be effective and viewed favourably by
women.1,2,5,9 Our pilot study demonstrated that the provision
of simple interventions from the pharmacy after EC may in-
crease the uptake of contraception.13 Overall, women
welcomed both interventions and felt they offered solutions
to the barriers they faced in obtaining regular contraception,
leading to the use of EC, in terms ofmaking appointments and
being supported to find acceptable and effective contracep-
tion. Some concerns were highlighted relating to ‘easy access’
to hormonal methods at pharmacies and the preference some
women have for visiting their own GP rather than a family
planning clinic. None of the pharmacists felt that pressure on
consultation time was an issue in providing the intervention.
However, as this paper demonstrates, there are barriers to
providing such a service in practice. Reassuring women about
the safety of POPs, and provision of information to General
Practitioners (GPs) about a service providing POP after EC, may
help alleviate some of the concernswe identified fromwomen
in our study. Consideration could also be given to extending
the provision of rapid access to contraception to GPs, rather
than FPCs alone.
A barrier to rolling out such findings from a pilot study into
clinical practice is the ability to conduct high quality research
in this setting. The difficulties we encountered in conducting
the study may impinge on the quality of evidence obtained
and therefore the ability to translate it to clinical practice.
Although limited evidence would suggest pharmacists are
interested in participating in research,16,17 we had some
problems in retention of pharmacists during the study.Whilst
pharmacists felt recruitment to the study and provision of
interventions did not significantly affect their consultation
time, recruitment slowed in all pharmacies at points
throughout the study. Community pharmacies, which are
commercial businesses, may have to prioritise more lucrative
services above clinical research at certain times. Reassuringly
women found the notion of being recruited to clinical research
within a pharmacy acceptable. However, as with recruitment
to research in any setting, care should be taken (by pharmacist
and research team) to ensure women do not feel obliged to
participate at a time when they may be feeling anxious and
vulnerable.
Although the depth of detail provided from face-to-face
interviews, and similar responses from women across the
groups, provides strength to the methodology and suggests
reliability of results, there are obvious limitations in this
study. This was a small study, with a small sample of
women from a single urban site, as the interviews were
intended to explore possible facilitators and barriers. The
results may not be applicable in other settings, such as
rural pharmacies.
Conducting a pilot study and undertaking the follow-up
interviews with women, provided an opportunity to gain
valuable feedback. Women welcomed both participation in
research and the interventions offered. Pharmacists viewed
their participation in the study positively. The problems
encountered provide valuable feedback to inform furtherPlease cite this article in press as: Michie L, et al., Provision of con
evaluating the acceptability of pharmacy for providing sexual and rep
10.1016/j.puhe.2015.11.017development of research methods in the pharmacy setting,
and larger scale studies of such interventions.Author statements
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ABSTRACT
Background Abortion services should provide
high-quality contraceptive care. The community
sexual and reproductive health (SRH) services
may be well placed to deliver more abortion care
in the UK. We wished to determine the views of
health professionals working in SRH regarding
their attitudes towards providing more abortion
services and also the views of staff within one
community SRH centre in Scotland where a
service providing early medical abortion (EMA)
was due to commence.
Methods An anonymous questionnaire
distributed to attendees at a UK SRH scientific
meeting collected data on demographics, current
practice of and attitude to abortion, and views
on delivery of abortion services. An internet
questionnaire distributed by e-mail to staff at a
community SRH clinic in Scotland sought
demographics, views regarding the planned
introduction of an EMA service and willingness
to participate in it.
Results 165 questionnaires were completed out
of 200 distributed at the scientific meeting (an
82% response rate). 128 (78%) respondents felt
that abortion services were suited to community
clinics and 115 (70%) stated that they would be
willing to participate in them. 62/90 (69%) staff
from the SRH clinic responded to the internet
questionnaire. 44 (71%) felt the plan to
introduce abortion services was a natural
extension to services already offered and the
same number would be willing to be involved in
such a service.
Conclusion There is clear support amongst
health professionals in community SRH in the UK
towards greater participation in the provision of
abortion care services.
INTRODUCTION
Delivery of abortion care services
throughout the UK is changing. In
England and Wales in 2011, 61% of all
abortions were carried out in the inde-
pendent sector, funded by the National
Health Service (NHS), whilst 35% were
carried out in NHS hospitals.1 In contrast,
in Scotland 98% of abortions are pro-
vided through the NHS and most of these
are delivered from hospital-based depart-
ments of obstetrics and gynaecology.2 A
key component of the care of women
requesting an abortion, as directed in UK
guidelines, is the provision of comprehen-
sive counselling and immediate access fol-
lowing abortion to all available forms of
contraception, in particular the long-
acting reversible methods.3 Indeed there
is growing evidence that uptake of these
effective methods of contraception,
notably the intrauterine device (IUD) and
intrauterine system (IUS) and the
progestogen-only implant, is associated
with a significantly reduced risk of repeat
abortion.4–8 In some hospital settings the
care of women requesting an abortion
may be delegated to the more junior
KEY MESSAGE POINTS
▸ UK health professionals in sexual and
reproductive health (SRH) are generally
supportive of providing abortion ser-
vices from a community SRH setting.
▸ SRH staff consider abortion care to be
a natural extension of existing services.
▸ Delivery of abortion services from a
community SRH service would afford
high-quality contraceptive provision
and comprehensive management of
sexually transmitted infections to
women following abortion.
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members of the medical staff, who often lack knowl-
edge about contraception and the training to insert
implants or intrauterine methods. While there is a lack
of recent evidence regarding the attitudes of UK obste-
trics and gynaecology trainees towards provision of
abortion care, there are anecdotal reports that increas-
ing numbers of them are choosing to opt out of abor-
tion care for reasons of personal belief or because they
find the work repetitive. A questionnaire of a propor-
tion of both consultants and trainees in obstetrics and
gynaecology in the UK in 1998 acknowledged similar
concerns. The results identified that around one-third
of trainees in obstetrics and gynaecology had not had
any training in abortion procedures, a similar number
stated a conscientious objection to abortion, and a
number of consultants expressed views that some trai-
nees also opted out of abortion for other reasons.9
It has been suggested that abortion services would
be better provided in the community sexual and
reproductive health (SRH) setting, since staff working
within this area may be better placed to provide for
women’s ongoing contraceptive needs and have
expertise in the insertion of IUDs and contraceptive
implants.4 Additionally, SRH services may well be
better for screening and testing for sexually transmit-
ted infections (STIs) and may have more robust
systems for partner notification.
Increasing numbers of women in Great Britain are
undergoing early abortion, 78% of abortions in
England and Wales having been performed at under
10 weeks’ gestation and 65.5% in Scotland at under
9 weeks in 2011,1 2 and increasing numbers of this
group are opting for the medical method and choos-
ing to go home soon after treatment to pass the preg-
nancy at home.10 11 There is good evidence that early
medical abortion (EMA) is highly amenable to deliv-
ery from a community setting and highly acceptable
to women.12
The attitude of general practitioners, gynaecologists
and medical students in the UK towards their involve-
ment in provision of abortion has been the subject of
previous research.13–16 However, no previous studies
have focused on the views of those working within
the field of SRH. In this study we aimed to determine
the views of health professionals working in SRH
regarding their attitudes towards a future role for spe-
cialists in SRH in providing more abortion care ser-
vices by surveying delegates at the Annual Scientific
Meeting of the Faculty of Sexual & Reproductive
Healthcare (FSRH) in the UK. In addition, we wished
to determine the views of staff working within a com-
munity SRH centre in Edinburgh, Scotland, UK about
the planned provision within the following 6 months
of EMAwithin their integrated SRH service.
METHODS
To obtain the views and attitudes of a large number of
health care workers, either working within or with an
interest in SRH, we designed a questionnaire to dis-
tribute to all attendees at a large UK SRH scientific
meeting (that of the FSRH) in April 2012. An intro-
ductory paragraph on the questionnaire explained its
purpose and anonymity. Completed questionnaires
were placed in sealed collection boxes. The question-
naire collected demographic data of the respondents
including gender, age, current working role and geo-
graphical region of work, information on their
current practice of and attitude to abortion, and their
views on location of abortion care services. Responses
in the sections relating to views on abortion and atti-
tude and willingness to participate in, and location of,
abortion care services were recorded by the partici-
pants on five-point Likert scales, the options ranging
from ‘strongly disagree’ to ‘strongly agree’.17
For the survey of staff within the community SRH
service in Edinburgh, an anonymous internet question-
naire was distributed to all staff named on an up-to-date
staff mailing list between January and March 2012. The
questionnaire sought demographics including gender
and role within the service, in addition to views regard-
ing the planned introduction of the EMA service and
willingness to participate in it. Responses consisted
mostly of drop-down list options with additional free-
text responses to selected questions.
Statistics
Data from both questionnaires were coded and entered
onto separate databases using Microsoft Excel™. In
the questionnaire of attendees at the SRH scientific
meeting, responses relating to views on abortion, will-
ingness to participate and location of services were
combined such that ‘strongly agree’ and ‘somewhat
agree’ were grouped as ‘agree’ whilst ‘strongly disagree’
and ‘somewhat disagree’ were grouped as ‘disagree’.
The remaining group of responses was ‘neither agree
nor disagree’. Data analysis was performed using IBM
Statistical Package for Social Sciences (SPSS) software
V.18 (IBM Corporation, New York, NY, USA). Groups
were compared by Chi square (χ2) test or Fisher’s exact
test, where counts within any individual cell of the
contingency table fell below five. Statistical significance
was deemed to be p<0.05.
Ethical approval
Both questionnaires were reviewed by the chair of a
local research ethics committee who confirmed that
ethical approval was not required as they constituted
health services research.
RESULTS
A total of 165 questionnaires were returned out of
200 distributed at the UK SRH scientific meeting (an
82% response rate). Almost all respondents were
female (88%) and over two-thirds (73%) were aged
between 41 and 60 years. Over half of the respon-
dents worked in England (54%) and the majority
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were doctors (95%). Demographics of the respon-
dents are shown in Table 1. Regarding any current
involvement in abortion, only five (3%) respondents
stated they had no involvement in any aspect of abor-
tion care; 129 (78%) currently referred women for
abortion, 106 (64%) counselled and assessed women
for consideration for abortion and 103 (62%) signed
the required legal paperwork for abortion. Only 24
(14%) respondents stated that they either performed
surgical abortion or administered the medications
required for medical abortion.
Most respondents (149; 90%) considered them-
selves to be ‘broadly pro-choice’; six (4%) were
undecided and 10 (6%) stated they were broadly anti-
abortion. There was no statistically significant differ-
ence between gender, age groups, region of work or
current working role and personal view of abortion.
Statements were put forward to respondents regard-
ing their view on location of abortion services, their
willingness to participate, and views as to whether
there is a role within SRH for abortion care. The
responses are shown in Table 2. The majority of
respondents (128; 78%) attending the UK SRH
scientific meeting felt that abortion services were better
suited to community clinics than hospital services.
Eighty-three (50%) respondents felt that services
should be divided across community, hospital and
non-NHS charitable and private organisations.
Respondents working in England were statistically
more likely to agree that abortion services were best
suited to non-NHS charitable and private organisations
compared to respondents working in other regions
(p=0.001). In addition, female respondents were statis-
tically more likely to agree that abortion services were
best suited to non-NHS charitable and private organi-
sations compared to male respondents (p=0.017).
There were no other statistically significant differences
in the responses to statements regarding location of ser-
vices between gender, age groups, region of work or
working role. Some 115 (70%) respondents agreed
that they would be willing in the future to participate
in abortion services; 35 (21%) disagreed while 13 (8%)
were undecided. The majority (143; 87%) disagreed
that there was no role in SRH for abortion services;
eight (5%) neither agreed nor disagreed and 11 (7%)
agreed there was no role. Significantly more women
disagreed with this statement than men (p=0.006).
Respondents who considered themselves to be broadly
anti-abortion were statistically more likely to disagree
to participate in abortion services (p=0.001) and statis-
tically more likely to agree that there is no role in SRH
for abortion services (p=0.004).
The questionnaire of staff working within an SRH
service in Edinburgh was distributed to 90 people, of
whom 62 (69%) responded. The majority (56; 90%)
of respondents were female. Twenty-four (39%)
respondents were nursing staff, 22 (35%) doctors and
16 (26%) administrative and clerical staff.
All were asked ‘How do you feel about the plan for
early medical abortion to take place in your service?’
Forty-four (71%) stated they felt this was a natural
extension to the services already offered, four (6%)
were neutral and nine (15%) were uncertain. Only
five (8%) respondents felt it was not an appropriate
setting. There was no significant difference in
responses to this question with gender and different
working roles. In response to the question ‘Would you
be happy to be involved in such a clinic?’, 44 (71%)
stated ‘yes’, seven (11%) stated ‘no’ due to conscien-
tious objection to abortion and 11 (18%) were either
uncertain or stated that this would not be of interest
to them. Neither gender nor working role was asso-
ciated with response to this question.
Respondents were asked, from a list of potential
advantages, to select those that they felt would apply
to women as a result of providing EMA within the
service. Responses are shown in Table 3. One-third
(21; 34%) of respondents felt all were possible advan-
tages to women.
Respondents were asked ‘Do you feel there will be
any potential disadvantages to women seeking an
Table 1 Demographics of respondents to the questionnaire
distributed at the Faculty of Sexual & Reproductive Healthcare
















England and Wales 1 (1)
Northern Ireland 2 (1)
Ireland 1 (1)
Channel Islands 3 (2)
Working role
Consultant 35 (21)
General practitioner 51 (31)
Staff grade/associate specialist grade doctor 53 (32)
Trainee doctor 16 (10)
Unspecified doctor 2 (1)
Nurse 6 (3)
No longer working 1 (1)
Missing data 1 (1)
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abortion, in having their care delivered from the com-
munity SRH setting?’ and were invited to specify
what they considered the disadvantages to be.
Thirty-two (52%) felt there would be no disadvan-
tages, 14 (22%) thought there would and 16 (26%)
were uncertain. A total of eight possible disadvantages
suggested by the respondents were: possible lack of
anonymity within the community setting (n=4);
concern that the new abortion service would place
undue additional workload on the existing services
(n=2); concern that some women may not wish to
attend an SRH clinic for abortion due to possible
stigma associated with sexual health clinics (n=1);
and that women may not wish to return to the SRH
service in the future as it may remind them of having
had an abortion (n=1).
DISCUSSION
This study showed that most of the health profes-
sionals in SRH who were surveyed were generally sup-
portive of providing abortion services from a
community SRH setting. This is reassuring for future
workforce provision of abortion services in the UK.
Currently, those abortion services that are provided
from hospital departments of obstetrics and gynaecol-
ogy often compete for staffing with acute areas such
as the labour ward, with the result that staffing of the
abortion clinic may be delegated to junior, inexperi-
enced members of the team. There is also evidence
that trainees in obstetrics and gynaecology may lack
interest in abortion management since a survey of
senior trainees in 2008 showed that only 2.8% had
opted to undertake the advanced training module in
abortion care.18 Our study confirms that doctors
working within community SRH may be more willing
to participate in abortion services. Additionally, abor-
tion care is included as a mandatory module within
the new training curriculum for UK specialist trainees
in community SRH, ensuring that all doctors training
in this new specialty gain knowledge and exposure of
this integral part of SRH.19
Increasing numbers of women in Great Britain who
request an abortion are at early gestation (≤9 weeks),
and increasing numbers are choosing to have an EMA
method that enables them to leave the abortion
service soon after treatment to pass the pregnancy at
home.10 11 There is evidence that this method is
highly amenable to provision in a community setting
and that it is safe to do so, and furthermore it is
acceptable to women.12 Our results show that the
overwhelming majority of delegates at the SRH scien-
tific meeting surveyed agreed that abortion services
would be suited to a community SRH setting.
Additionally, the majority of staff working in a com-
munity SRH clinic where abortion services were
about to be introduced felt that this was a natural
extension to the services already offered.
There are other reasons why it may be advanta-
geous for more abortion care to be provided from
community SRH clinics. First, it is possible that
uptake of the most effective long-acting reversible
methods of contraception (LARC) would be greater in
a specialist contraceptive setting compared to a hos-
pital setting, where hospital staff may lack specialist
contraceptive knowledge or the ability to insert intra-
uterine contraception or progestogen-only implants.
In our study, 7/10 staff surveyed at the community
SRH clinic agreed that better contraceptive provision
would be an advantage of providing abortion care
through the SRH clinic. Immediate post-abortal provi-
sion of LARC is important as there is increasing evi-
dence that insertion of an IUD/IUS or an implant is
associated with a significantly reduced risk of having a
further abortion.4–8 In a Scottish study of a hospital-
based abortion service, women who chose to have an





nor disagree Disagree Missing
Abortion services would be best suited to community clinics as opposed to a hospital setting 128 (78) 24 (14) 12 (7) 1 (1)
Abortion services are best provided within a hospital-based setting in gynaecology 31 (19) 44 (27) 88 (53) 2 (1)
Abortion services are best provided by separate non-NHS, private and/or charitable organisations 18 (11) 53 (32) 93 (56) 1 (1)
Abortion services should be divided across these services 83 (50) 49 (30) 29 (18) 4 (2)
I would be willing to participate in abortion care for women, including relevant paperwork or
administering medication/undertaking procedure where appropriate
115 (70) 13 (8) 35 (21) 2 (1)
I do not feel my role within SRH should have any involvement in abortion services 11 (7) 8 (5) 143 (87) 3 (2)
NHS, National Health Service; SRH, sexual and reproductive health.
Table 3 Possible advantages for women of an abortion service
located in Chalmers Sexual Health Centre, Edinburgh, UK
Possible advantages* n (%)
Better provision of contraception post-procedure 44 (71)
More holistic approach to patient care 42 (68)
Opportunity to better manage sexually transmitted infections 33 (53)
More readily accessible site for patients 32 (52)
No response 10 (16)
*Multiple advantages could be selected by each respondent.
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IUD/IUS fitted were almost 18 times less likely, and
women who chose to have a contraceptive implant
inserted were 16 times less likely, to return for
another abortion within the next 2 years, compared to
those choosing to use an oral contraceptive pill.4
It would also seem only logical that an integrated
community SRH service would also be better placed
to manage STIs in women requesting abortion.
Indeed, over half (53%) of the respondents working
within the community SRH clinic agreed that better
management of STIs would be an advantage to offer-
ing abortion care within their setting. It has previously
been shown that women who test positive for
Chlamydia trachomatis at a hospital abortion service
have poorer partner treatment rates than their coun-
terparts who test positive at either a genitourinary
medicine clinic or family planning clinics.20 This sug-
gests that management of STIs amongst women
requesting abortion may be particularly challenging
for hospital services.
Of course it is possible that there may be some dis-
advantages to providing abortion care services from a
community setting. Only a small number of staff from
the SRH clinic reported possible disadvantages and
these tended to be related to perceived increasing
workload for themselves, or concerns that women
may have less anonymity than in a hospital clinic.
Clearly any abortion service must be able to provide
guarantees of privacy and anonymity for women, and
sexual health services are surely particularly sensitive
to users’ needs in this respect. A concern that was
expressed by a minority of staff was that women
might be reluctant to attend an SRH setting due to
perceived stigma attached to a sexual health service.
However, currently many women actually choose to
attend SRH clinics to request a referral for abortion.
Clearly, future qualitative research on the views
and experiences of women attending abortion services
in both hospital and community settings will be
important to determine the location of services that
women would consider most convenient and
acceptable.
Although more than three-quarters of respondents
from the scientific meeting felt that abortion services
were suited to a community SRH setting, half also
agreed that services should be divided across commu-
nity, hospital and non-NHS organisations. Currently
in England and Wales, abortion services are delivered
from both the independent sector, funded by the
NHS, and from NHS hospitals. This division of ser-
vices has worked well for many years, although as
suggested by the responses to our survey, these ser-
vices could co-exist in both the independent sector
and in an NHS community SRH setting. In Scotland
the overwhelming majority of abortions are provided
by hospitals, and while hospital services with surgical
facilities and inpatient and day case beds will still be
required, assessment clinics and facilities for EMA or
early surgical abortion could also exist in community
SRH clinics.
Clearly a potential drawback to our study is that
most respondents from the scientific meeting were
aged over 40 years, and so may not necessarily have
reflected the views of younger health professionals or
those still in training, who are the potential future
providers of abortion services. There is currently a
lack of recent qualitative research regarding attitudes
towards abortion care of UK trainees in both obste-
trics and gynaecology and SRH, and a future study in
this area would be valuable. Nevertheless, our study
showed that UK health professionals currently
working in SRH are supportive of providing more
abortion services in a community SRH setting. Clearly
it will be important to evaluate service delivery
from community SRH settings to determine if this
model is indeed associated with the anticipated bene-
fits for women and what, if any, the disadvantages
may be.
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